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A b str a c t
Aims: The aim was to identify at least 250 cases of LCIS via the NHSBSP to 
ascertain if LCIS can be screen detected as well as identifying its prognostic factors 
and to establish recommendations for its treatment.
Methods: LCIS cases were identified from screening centre databases. Mammograms 
and pathology were reviewed and correlated to identify which cases were truly screen 
detected. Subsequent breast cancers were identified.
Results: 366 cases of LCIS were identified. Pathology blocks were available on 205. 
On review we were unable to confirm a diagnosis of LCIS in 22, 19 were reclassified 
as DCIS and 164 were confirmed as LCIS. Of these 164 LCIS cases, 99 presented 
with mammographie calcifications, 28 with a mass and 50 with distortion. 88 cases 
presented with calcification alone, 28 were associated solely with the LCIS and were 
large enough to be visible on mammography fulfilling our definition for screen 
detected LCIS. 60 cases were incidental with 9 cases of calcification within both 
LCIS and benign changes and 51 in benign changes only. With a total of 701.3 
women years of follow up, 7 women with screen detected (7/28) and 10 with 
incidental LCIS (10/135) developed breast cancer. With event rates of 49.1/1000 
women years in the screen detected group and 17.9/1000 in the incidental group 
(relative risk of 2.66, 95% Cl 1.03-6.86; p=0.04). There was no difference in the 
mammographie features of the two groups.
Conclusions: LCIS can be detected on mammography. Screen detected LCIS is 
associated with a higher subsequent cancer risk than incidental LCIS.
S co pe  o f  th e  T h esis
This thesis describes the diagnosis and management of women diagnosed with 
Lobular carcinoma in situ (LCIS) of the breast identified through the National Health 
Service Breast Screening Programme in the United Kingdom. The women were 
diagnosed between 1988 and 2003 and all aspects of their patient pathway have been 
studied.
The first chapter introduces the classification of breast cancer and how LCIS fits into 
this. It describes the history of LCIS since it was first described in 1941 and addresses 
the controversial issues that surround the disease. It concludes with the reasons for 
embarking on this study.
The literature review in the second chapter sets out to describe the studies in the 
scientific literature that have considered LCIS and its features. It discusses the 
pathology, epidemiology, risk factors and consequences of a diagnosis of LCIS, as 
well as reviewing the imaging features of LCIS and the past and present methods of 
management of the disease. It finishes with a summary of the current literature.
The aims of the study describe the key objectives set out following the literature 
review that we hope to answer in this thesis.
In the chapter regarding methods our study population is defined and the process by 
which women in England with LCIS were identified is described. The information 
collected along with the methods and reasons behind which information was recorded 
is discussed in this chapter. We describe the statistical analysis performed and the
11
crucial debate around patient confidentiality. The conclusion of this chapter describes 
the ethical issues and problems that we encountered during set up and data collection.
Our results chapter details all the results obtained both in the collection of data of 
women diagnosed with LCIS, the review of the mammographie features and the 
pathological review. We describe the differences between those cases identified as 
screen detected LCIS and those deemed to be incidental. We assess disease free 
survival in both groups.
Like other studies we try to identify those features in initial cases of LCIS, which can 
identify women who develop a subsequent breast cancer.
The discussion relates our findings, described in the results section to those detailed in 
the literature review. We describe the strengths and the weaknesses of our data. 
Finally we detail further work that we feel would enhance this thesis, our conclusions 
and recommendations derived fi*om this comprehensive review of cases of LCIS from 
the NHSBSP.
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CHAPTER ONE
THE INTRODUCTION:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Study for Wing-Like Arms - Francine Van Hove
B reast  C a nc er
Breast cancer has an enormous impact on the Western world with significant medical, 
social, political and economic implications. According to the United Kingdom breast 
cancer registries, in 2004 40,710 women were diagnosed with breast cancer and 13,000 
died of the disease (Toms 2004). British women have a 1 in 9 chance of developing the 
disease within their lifetime. It is the commonest malignancy in both Caucasian women 
and in Ethnic minority groups within the UK. In women, it is a more common cause of 
death than ischaemic heart disease and is the commonest cause of death among women 
aged 40-50 (Toms 2004). With improvements in treatment and screening the survival 
from breast cancer has improved over the last two decades and now an average of 74% of 
women will be alive, 5 years after their diagnosis (Toms 2004).
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Figure 1: European age standardised incidence and mortality, female breast cancer EU 1998 (Toms JR 2004).
Despite this improvement the United Kingdom has one of the highest age standardised 
incidence and mortality rates from breast cancer in the world; this is illustrated in Figure 
1. America has a similar burden. The American Cancer Society predicted that in 2004, 
215,990 women would be diagnosed and nearly 40,110 women would die of the disease 
in the United States (Toms 2004). Breast cancer is the leading cancer in whites and
African American women. The lifetime risk of breast cancer in America has increased 
from 1 in 20 women in 1960 to 1 in 8 women today.
A n a t o m y
The adult female breast is comprised of ducts and acini, which are lined by epithelial eells 
and set in a connective tissue stroma. There are two epithelial cell types, the luminal or 
secretory cells and an incomplete myoepithelial layer that lines the duct-lobular system of 
the breast. Almost all of the benign and malignant pathology seen in the breast is a result 
of changes in the luminal cells. Malignant disease of the breast can be divided into 
invasive and in situ disease. Invasive disease implies breach of the basement membrane of 
malignant epithelial cells whereas with in situ disease these cells are contained within an 
intact membrane and can be of either ductal or lobular origin, although there is also a 
group o f ‘special type’ invasive breast cancers. This is illustrated in Figure 2.
Invasive lobular
cancer
Invasive duct
Intraduct cancer
Lobular carcinoma 
in situ
Figure 2; Schematic o f the female breast
Carcinoma in situ was first described in 1932 (Broders et al 1932) and occurs in many 
organs and cell types. The definition of in situ is that of cytologically malignant epithelial
cells confined by the basement membrane of the original structure. It was believed then 
that these malignant cells would eventually breach the basement membrane to invade 
surrounding tissues and that all in situ lesions would, in time, develop into invasive 
disease. Treatment was based on the belief that as long as there was no invasion there was 
no risk of metastasis and that this provided a good argument that all in situ disease should 
be removed before cells developed a potential for spread.
In  S itu Cancers
In situ carcinoma of the breast is classified into two cell types. Ductal Carcinoma in Situ 
(DCIS) and Lobular Carcinoma in Situ (LCIS). In 1931 Joseph Bloodgood, a surgeon at 
John Hopkins Hospital described the earliest forms of DCIS, which he termed as 
‘borderline breast tumours’ (Bloodgood 1931) and in 1941 Foote and Stewart (1941) 
described the first cases of LCIS, thus they are relatively recently described breast lesions 
compared with invasive disease. LCIS and DCIS are classically described as having 
differing behaviour and potential for subsequent development of invasive disease and this 
is reflected in the differences in their management.
DCIS
DCIS is a heterogenous disease which ranges from high to low grade and is recognized as 
having varying architectural patterns including comedo, solid, cribriform and 
micropapillary types. DCIS, especially of the high-grade comedo type, is recognized to be 
a pre-cancerous lesion and women with DCIS are at a significantly increased risk of 
subsequent development of an invasive ductal carcinoma at the same site (i.e. in the same 
quadrant of the ipsilateral breast).
Prior to the publication of the Forrest Report (London et al 1986) and the set up of the 
National Health Service Breast Screening Programme (NHSBSP), DCIS accounted for 
approximately 4% of all breast cancers (Rosen 1980). Since the introduction of screening 
in 1989 the detection of DCIS has risen dramatically. DCIS now accounts for 21% of 
screen detected breast cancers in women 50 -  65 years of age (BASO Breast Audit Group 
2003). DCIS is usually detected mammographically, commonly as calcification or rarely 
as a mass or distortion. DCIS is almost always unilateral although it can be multifocal.
LCIS
LCIS is, in contrast, an enigmatic and controversial lesion. LCIS typically involves 
intralobular and extralobular, or terminal ductules, as well as the acinar units of the lobule 
as seen in Figure 3. It is essentially a rare a-symptomatic finding in apparently healthy 
individuals. The true incidence of LCIS is unknown because it is a microscopic lesion that 
does not form a palpable tumour. Classically and historically LCIS has been an incidental 
finding at surgical biopsy. LCIS is typically discovered in breast tissue removed for 
proliferative lesions that cause a mass, or in apparently normal tissue surrounding a 
benign lesion, such as a fibroadenoma. It usually detected in women under the age of 50.
Preoperative diagnosis of LCIS is extremely difficult, since there are no associated 
symptoms. Even at gross examination, the lesion cannot be seen and it is only identified at 
the microscopic level (Muir 1941).
Multifocality (multicentricity) and bilaterality are inter-related characteristics of breast 
cancer. Certain types of carcinoma that are associated with a high frequency of bilaterality 
are more likely to occur as multiple foci in the affected breast. LCIS is one of these cancer 
types, which makes it difficult to determine the extent of the disease at the time of 
diagnosis and makes treatment more complex.
Mammographically, unlike its DCIS counterpart, LCIS is thought not to have any 
significant distinctive features. Calcifications are thought to be infrequently formed in 
LCIS, but they occur commonly in coexisting benign lesions such as sclerosing adenosis. 
Therefore it is currently believed that mammography is not an effective way of detecting 
LCIS and is inaccurate at assessing the extent of the disease and its multicentricity or 
bilaterality.
V
Classical LCIS
Pleomorphic LCIS
a
Figure 3: Classical and Pleomorphic LCIS on H & E stain.
M a n a g e m e n t  o f  In  S itu  D isea se
The main consideration with management of in situ disease is the risk of subsequent 
development of invasive cancer. DCIS is more likely to progress than LCIS and this 
explains why their treatments differ. Historical papers have suggested that less than 20% 
of patients with LCIS ^vill develop invasive disease in the future (Haagensen et al 1978), a 
sharp contrast with more than 50% of cases of DCIS (Page et al 1982). It was also found 
that in LCIS, unlike DCIS, this risk was bilateral and not specific to the type of invasive 
breast cancer that may occur. Thus the subsequent invasion could be ductal or lobular in 
type. This led to the belief that LCIS was more a marker for risk than a direct precursor 
lesion like DCIS. However, recent research has questioned this concept and some authors 
now believe again that it is a true precursor lesion (Lakhani 2001 and Page et al 2003).
Proven cancer precursors in various other parts of the body share three determinant 
features: a high likelihood of later invasion; cancer development in the same area or site; 
and similar cytological findings as the subsequent invasive cancer. LCIS is thought to 
have a low rate of subsequent development of invasive disease in areas distant to the 
initial site of LCIS and this invasive disease can be ductal as well as lobular in origin, thus 
not fulfilling the criteria of a precursor lesion.
Management of LCIS has changed dramatically since it was first described. Initially it 
was believed that mastectomy, usually unilateral although sometimes bilateral, was 
necessary to prevent the development of invasive disease but 60 years on this is deemed 
to be excessive. The treatment has changed to surgical excision for diagnostic purposes 
combined with surveillance, as such radical surgery was felt to be over treatment when a 
large majority of the patients would not go on to develop invasive disease. In contrast
unilateral surgery was believed by some to be an inadequate response to a potentially 
bilateral condition (Wheeler 1974).
T h e  P a t h o l o g i c a l  H is t o r y  o f  LCIS
Initial Recognition bv Foote & Stewart
When Frank W. Foote and Fred W. Stewart wrote their article entitled ‘Lobular 
Carcinoma in Situ -  ‘a rare form of mammary cancer’ in 1941 (Foote et al 1941) from the 
Pathological Laboratories of the Memorial Hospital, New York they probably could not 
have anticipated that over 60 years later controversies would remain around its description 
and treatment.
They predicted that with the emphasis on the early diagnosis of cancer pathologists would 
observe increasing numbers of early histological manifestations of this disease. Although 
carcinoma in situ of the breast had been recognised for many years, Foote and Stewart 
were the first to describe a relatively rare in situ disease of the small lobular ducts and 
lobules rather than the commoner disease of the larger duct system. When they presented 
a case of LCIS to a clinical-pathological symposium, they found that the malignant 
process of the disease was not recognised by a number of pathologists. Following that 
presentation they wrote an article (Foote 1941) describing a review of 300 breast cancers 
from the Memorial Hospital, New York in which they had identified 12 cases of this 
separate pathological entity that had previously not been documented.
Foote and Stewart believed that because of this lack of knowledge amongst their peers, a 
review of the features of the disease would be desirable. In almost all the subsequent 
papers written about LCIS the resulting article is quoted at least once. They stated in this 
seminal paper that there was ‘no way in which a clinical diagnosis could be made since in
this non-infiltrative state, the breast reveals none of the classic clinical signs of cancer’, in 
fact the diagnosis in their initial 12 cases remained wholly unsuspected until the 
pathology sections were made.
Gross Pathologv
In addition Foote and Stewart claimed that there was no way LCIS could be recognised in 
gross pathology specimens although subsequent literature suggests that the tissue that 
harbours LCIS often appears abnormal as a result of coexisting proliferative lesions. It is 
these lesions such as fibrocystic disease, fibroadenomas and cysts that prompt the surgeon 
to biopsy a breast in the first place. However, in patients with florid and extensive LCIS, 
the cut surface of the breast tissue may have a faintly granular appearance when viewed at 
an angle, because the affected lobules are sufficiently enlarged to be visible. With the 
development of infiltration, the gross morphology may become that of usual type breast 
cancer.
Microscopic Pathologv
Foote and Stewart suggested that all types and sizes of lobules can show LCIS changes, 
including large, small, lobules with mucoid stroma, metaplastic lobules, and hyalinised 
ones. Occasionally only part of the lobule is involved and a sharp line of division is seen 
between the normal epithelium and carcinoma in situ. They noted the following features 
of the disease process:
1) Large cells within lobules of normal or small size (often twice the size of those 
in normal lobules and their nuclei are in proportion).
2) Clear nuclei and opaque cytoplasm that is sometimes vacuolated.
3) Loss of cohesion of the normally ordered epithelium, the cells being individual 
and pushed towards the lumen in a disorderly fashion.
4) Rare mitoses.
5) Cells lose polarity, varying in shape while maintaining a uniform size.
Some of these features are demonstrated in Figure 4.
Large eells, loss of cohesion and 
rare mitosis
Figure 4: LCIS demonstrating the features noted by Foote & Stewart.
They predicted that the disease was more common than their initial results suggested and 
noted that it could be associated with all other types of breast carcinoma.
Foote and Stewart (1941) also emphasised that the lesion occurred in multiple lobules that
if there was even a small amount it constituted ‘an extreme hazard’ and that it was always
a disease of multiple foci. They stated that ‘it is never safe to leave the breast with local
. □
excision only, even i f  the entire palpable lesion has been removed’. They had found in 
their 12 cases that whenever the process was found by local excision, subsequent 
mastectomy alwavs showed additional foci of disease and they believed that simple 
mastectomy was essential.
They also noted that the mode of infiltration from these lobular cancers was peculiar with 
evidence of sudden, often explosive liberation of cells from their natural boundaries. The 
resultant picture was that of a terminal duct containing the non-infiltrative phase of the 
tumour surrounded by large numbers of isolated, loose cells of uniform size but of 
varying shape, which might readily be confused with mast cells. This comprehensive 
description of this newly identified disease process put them at the forefront of their 
speciality and their term Tobular carcinoma in situ’ has been employed ever since. They 
believed that the term ‘acinar’ carcinoma was not appropriate, as they could not identify 
distinct differences between the terminal ducts and acini themselves.
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Robert Muir
Robert Muir from the Pathology Department of Glasgow University and Glasgow 
Western Infirmary published his seminal paper (Muir 1941) on in situ disease in the 
Journal of Pathology in 1941 titled ‘The Evolution of Carcinoma of the Mamma’, which 
complemented Foote and Stewarts’ paper described previously.
In his paper he described a study of the evolution of intraduct and intra-acinous carcinoma 
of the breast. He also pondered the possible association of hyperplasia and malignancy to 
both hormonal and viral influences, and the reasons why only part of the breast is affected 
while other adjacent parts remain normal. He postulated that the irregularity or varying 
distribution may be due to a varying ‘receptibility or reactivity ’ of different parts of the 
epithelial elements (Muir 1941).
In this paper, as well as describing three cases in detail, Muir postulated several theories 
covering the cause of this malignant change and the way in which this change occurred. 
He recognized that intra-acinous carcinoma of the breast can be seen merely as a result of 
the spread of cancer cells from terminal ducts in which the malignant process has started. 
This is what we now refer to as cancérisation of the lobules in DCIS.
Muir’s description of LCIS, or ‘intra -  acinous’ carcinoma as he called it, was based on 
cases that he had seen at the Glasgow Royal Infirmary. He noted that initially the cells 
became larger, more prominent and often of the more columnar type. He believed, that a 
hyperplastic proliferation occurred later, which was associated with increasing de­
differentiation. He recognized that this proliferation could occur in different ways. 
However, he suggested budding in a centrifugal direction was most common resulting in 
the formation of many closely applied acini of approximately normal size. During these
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changes the intervening stroma may become scantier. He stated ‘it was impossible to state 
when malignancy actually occurs, but a stage is reached when it can be definitely 
recognized to have affected masses o f cells still within the acini’ (Muir 1941). This 
reflects today’s diagnostic problem of identifying the difference between Atypical 
Lobular Hyperplasia (ALH) and Lobular Carcinoma in Situ at its early stage.
Ultimately he believed that there may be a break-through at one or more points and an 
infiltrating carcinoma would then result. Within his case series he noted the multifocality 
of the disease, and he described ‘that the malignancy had developed in a somewhat diffuse 
manner in situ’ (Muir 1941). He also commented on the bilaterality of some of his cases 
ofLClS.
These two seminal papers, both published in 1941, established LCIS as a distinct 
morphological entity, which changed the views and opinions of many working within the 
field of malignant breast disease. We still recognize the statements of these three eminent 
pathologists today and have added to these through the collection of many more cases and 
the collaboration of pathologists. As LCIS became more widely recognized, pathologists 
agreed on the diagnostic criteria, although several aspects of these are still debated and 
these are discussed below.
M ak in g  A  P a th o l o g ic a l  D iag no sis  o f  L C IS
One of the largest dilemmas in the pathology of LCIS is the question as to how much 
lobular involvement is necessary in order to make the diagnosis of LCIS, something that 
Muir alluded to in his paper (Muir 1941). There have been several papers on the subject 
of these quantitative factors but the question remains largely unanswered. Some authors 
have required there to be at least two lobules exhibiting the diagnostic features (Rosen et
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al 1978 and Ludwig et al 1973) whereas others have concluded that one fully affected 
lobule is enough evidence for the diagnosis (Haagensen 1978). Arbitrarily in other studies 
it has been suggested that at least 50% (Hutter et al 1969) or 75% (Page 1991) of one 
lobule should be involved to establish a diagnosis of LCIS and that specimens with fewer 
lesions should be included in the category of Atypical Lobular Hyperplasia (ALH). The 
number of affected lobules at the time of mastectomy was investigated in two studies and 
were not found to be related to the subsequent risk of developing an invasive cancer 
(Rosen 1978 and Fisher et al 1996).
Loss of cohesion, which was recognized by Foote and Stewart, remains a characteristic of 
neoplastic cells in LCIS although this can be difficult to recognise when the acini are 
filled and expanded by the malignant process. Sometimes the spaces between these cells 
are so large that they are mistaken for glandular lumina.
The cells in LCIS are typically described as having scant cytoplasm and small, round, 
cytologically bland nuclei that lack nucleoli. This is the cytological pattern that was 
described by Haagensen and associates (1978) as Type A or classical LCIS, see Figure 5.
. #  *  .4* *
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Figure 5; Classical LCIS
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Later a variant of LCIS was described, the pleomorphic or Type B variety, seen below in 
Figure 6.
Abundant 
cytoplasm and 
large
pleomorphic
nuclei
Figure 6: Pleomorphic LCIS
Table 1 outlines the differences between the two described types of LCIS
CLASSICAL LCIS -  Type A PLEOMORPHIC LCIS -  Type B
Scant cytoplasm Abundant cytoplasm
Small, round cytologically bland nuclei Larger pleomorphic nuclei
Lack of nucleoli Sometimes have nucleoli
Diploid DNA content Hyperdiploid
Table I: Pathological differences between Classical & Pleomorphic LCIS
When the abnormality comprises Type B cells only, the distinction between LCIS and 
intra-lobular extension of DCIS can be difficult to establish. When there is 
intracytoplasmic mucin secretion, a diagnosis of LCIS is favoured. Mucinous secretions 
are almost always present in at least some of the cells in LCIS but this is often an 
inconspicuous feature that needs to be highlighted by stains such as Alcain blue-PAS or
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mucicarmine (Andersen et al 1981). In the combined AbPASD stain, acid mucin stains 
blue whereas neutral mucin stains pink. These intracytoplasmic vacuoles are very 
important, even though they are not a necessary criterion for the diagnosis of LCIS, 
because they are less common in cases of DCIS and are virtually absent in hyperplastic 
lesions of the ductal or lobular epithelium.
There are several uncommon cytological features that can be associated with LCIS such 
as clear cell change and apocrine metaplasia. There are also rare forms of myoid and 
goblet cell (signet ring) LCIS.
LCIS typically involves intralobular and extralobular, or terminal ductules, as well as the 
acinar units of the lobule. This involvement of the epithelium of the ducts and ductules 
occurs in 65-75% of the patients. In postmenopausal patients where the lobules are 
atrophic this may be the only manifestation of LCIS (Haagensen et al 1972). The highly 
irregular formation of these involved ductules is described as a saw-toothed or cloverleaf 
pattern.
LCIS cells cluster under the normal ductal epithelium forming buds around the periphery 
of the duct protruding outwards with the cells either being distributed continuously or 
discontinuously along the duct system, ultimately displacing the normal ductal epithelium. 
Sometimes the normal epithelium persists but it is elevated and pushed inwards towards 
the lumen of the duct. The myoepithelial layer is preserved to a variable extent and may 
require an immunostain, for example actin to confirm its presence, this is paramount to 
exclude and differentiate fi*om invasive disease. All these various growth patterns are 
referred to as pagetoid spread of the LCIS.
15
Although LCIS usually arises in lobules not affected by other conditions we know that it 
can be encountered within tissue previously altered by various benign proliferative 
processes such as fibroadenomas, hamartomas, sclerosing adenosis and radial sclerosing 
lesions. Often this can make diagnosis even more difficult and the pathologist relies on 
identifying specific cytological features such as intracytoplasmic mucin. When LCIS is 
associated with these other lesions it can sometimes be difficult to exclude invasion, 
especially in cases of sclerosing lesions, and special immunohistochemical stains are 
required to highlight the basement membrane and myoepithelial cells. Ottensen et al
(1993) found that LCIS was most commonly associated with fibrocystic change and 
solitary cysts.
More recently LCIS has been documented to be associated with columnar cell change and 
columnar cell hyperplasia (Sahoo et al 2005 & Gopalan et al 2005). This is in keeping 
with a suggestion that Muir (1941) made in his original paper.
Finally, some pathologists have preferred to use a 3-tiered system when classifying 
lobular proliferative lesions. Tavassoli (1998) and Arpino et al (2005) subdivided Lobular 
Neoplasia lesions into 3 grades (Lobular Neoplasia 1 to 3) to reflect the spectrum of 
architectural lesion and cytological changes that occur in this type of lesion.
Differential Diagnosis of LCIS
The differential diagnoses of LCIS include atypical lobular hyperplasia, apocrine 
metaplasia, and pseudolactational hyperplasia. However the most concerning differential 
diagnosis of ALH/LCIS is low nuclear grade DCIS of solid type. It can still be difficult to 
differentiate between the two and in fact they may coexist, sometimes within the same 
duct-lobular unit. The improved awareness of the range of benign lesions and the use of
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E-Cadherin, which will be discussed later, has enabled better differentiation between 
LCIS and these other lesions.
W h a t ’s in  a  N a m e?
After the initial description of LCIS in 1941 by Foote and Stewart (1941), the disease 
began to become more widely recognised and pathologists agreed its diagnostic criteria. 
Then it became clear that there were some patients who harboured lesions that were 
similar to, but less extensive than LCIS. This disease has become known as atypical 
lobular hyperplasia ALH (Page et al 1985 & Dupont et al 1985). Atypical lobular 
hyperplasia is regarded when cells similar to those seen in LCIS only partially occlude the 
lumen and slightly distend the lobule. Central lumina may still be identified and less than 
half the acini in the lobule are affected by the proliferation. Other cell types such as 
myoepithelial cells may also be seen within the lumen.
Haagensen (1978) introduced the term Lobular Neoplasia in the 1980’s largely to alter the 
treatment of LCIS by removing the word carcinoma fi'om the diagnosis. He believed that 
the name Lobular Carcinoma in Situ prejudiced the choice of treatment.
Lobular Neoplasia refers to the spectrum of lobular proliferative lesions that include mild 
atypia, atypical hyperplasia with partial lobular involvement, and fully developed LCIS 
involving one or more lobules. Advocates of this terminology base their arguments in part 
on the existence of differing criteria and imprecision of the diagnoses atypical lobular 
hyperplasia and LCIS. There is a vast element of subjectivity in the diagnosis of these 
lesions despite the pathologist’s attempts to be objective.
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Antagonists of the joint terminology believe that in clinical practice, the use of the term 
Lobular Neoplasia creates a situation whereby a single diagnosis does not discriminate 
between the patient with a minimal proliferative lesion that might only be mildly atypical 
hyperplasia and a patient with fully developed LCIS. This makes it difficult for the 
clinician to predict the risk of future invasive disease, especially as there has been a 
reported risk of developing invasive carcinoma of half that of LCIS after ALH by Page 
(1985). This is approximately a relative risk of 4-5 as apposed to an 8-10 relative risk for 
LCIS. This, therefore, is a strong argument for retaining the separate nomenclature for the 
ALH and LCIS.
The NHSBSP (National Health Service breast screening programme) in the United 
Kingdom have recently adopted the terminology of Lobular Neoplasia (NHSBSP Report 
2006). In this thesis I shall refer to LCIS because the other subtypes of Lobular Neoplasia 
will not be considered.
‘P r ec u r so r  o r  R isk  P r ed ic to r ’
The issue of precursor versus risk predictor is at the crux of the LCIS debate. Initially 
Foote and Stewart (1941) believed that it was always a precursor and then beliefs moved 
away with Haagensen (1978) and others towards the belief that it was always a marker of 
risk. This is important because it has implications for the treatment of these lesions. 
Recently evidence has been accumulating from E-cadherin studies that LCIS can be a 
direct precursor lesion (Berx et al 1996, Moll et al 1993 & Vos et al 1997) and molecular 
studies (Lu et al 1998 & Lakhani et al 1995).
Various authors have suggested that LCIS be removed from the list of pre-invasive 
cancers but leading cancer organizations have been reluctant to do so. The American Joint
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Committee on Cancer (AJCC) continues to list LCIS among Stage 0 breast cancers, 
similar to DCIS. The AJCC has stated that ‘LCIS is increasingly defined as a risk factor 
for subsequent breast cancer although there is some evidence that it may occasionally be 
a precursor o f invasive lobular carcinoma’ (Carlson et al 1997). Thus far, no consensus 
on this issue has been reached among pathologists and clinicians. The debate as to 
whether LCIS is a marker of risk or a precursor lesion is reflected in all of the subsequent 
issues to be discussed.
National Health Service Breast Screening Programme (NHSBSP)
After the publication of the Forrest Report in 1988 (Forrest 1988) the first national 
mammographie screening programme was bom, based upon the Swedish two counties 
programme. It was established in 1988. All women aged between 50-70 years are invited 
at three yearly intervals for a screening test, which comprises of a mammographie x-ray 
examination. Its original target was to detect 50 cancers per 10,000 women screened. 
Screening programmes in the NHSBSP have used either one or two views of each breast 
at the first examination. The benefit of obtaining a second view was subjected to a 
randomised controlled trial and it was found to have a marked effect on detection rates 
(Sickles et al 1986, Andersen 1981 & Kerlikowske et al 1995). In 2004-2005 a total of 
1,748,997 women were screened in the NHSBSP (NHS Cancer Screening Programmes 
2006).
The NHSBSP has its own internal quality assurance measures, which ensures that 
radiology, pathology and surgical standards are high. This has also had an impact on the 
treatment of symptomatic breast cancer patients within the United Kingdom.
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R ea so n s  to  U n d er ta k e  T h is  S tudy
Two independent factors have initiated this study. Firstly, since the advent of screening in 
1988, there has been a small but steady flow of screen detected cases of LCIS with 
between 20 and 40 cases identified each year. Such cases, found in the absence of clinical 
features, rely solely on positive mammographie findings for diagnosis. Given the nature 
of the disease as described earlier, this is surprising because it is not supposed to be 
detected on mammography. The question arose, therefore, as to whether this was truly a 
screen detected disease or incidental LCIS found in association with other benign lesions 
with certain mammographie features?
In addition several papers were published questioning the nature of LCIS and its 
description as a marker of risk. Lakhani et al (2001) proposed that with new molecular 
techniques they could demonstrate that LCIS could be a precursor lesion. Page (2003) 
published a paper on ALH, reporting that two thirds of subsequent breast cancers in his 
study arose in the ipsilateral, breast, which he claimed added weight to this precursor 
theory. This debate and conflict of views between those that believe LCIS to be a marker 
of risk and those that believe it has the potential to be a precursor lesion has implications 
for the management of a woman with LCIS.
The question arose as to whether LCIS could be screen detected and if we reviewed cases 
of LCIS detected within the screening programme could we help to answer some of the 
outstanding issues surrounding LCIS diagnosis and management. This thesis describes 
how we set out to do this and reports on our findings.
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The outstanding questions on LCIS are:
Can the pathological diagnosis be improved upon?
What is the true incidence?
What is the risk of subsequent invasive disease?
Is this risk bilateral?
Can clinicians predict who will develop a subsequent invasive breast cancer?
Can LCIS be screen detected?
WTiat is the appropriate management of LCIS?
Therefore we carried out an extensive literature review to fully assess the current 
understanding of incidental LCIS and any literature that had been published on 
mammographically detected LCIS.
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CHAPTER TWO
THE LITERATURE REVIEW:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Karen with Cushion - Francine Van Hove
L iter a tu r e  R eview
A comprehensive review of the scientific medical literature was undertaken using 
Medline and Embase databases. Searches were performed from 1965 to April 2006 and all 
references were then cross-referenced. The key words used were breast cancer, Lobular 
Carcinoma in Situ and LCIS.
Studies were excluded if they did not pertain to human subjects and they were not written 
in English, as were studies reporting on LCIS associated with other breast malignancies. 
A group of key studies were identified involving prospective and retrospective data that 
provided the core knowledge basis for this literature review.
The literature review includes a description of the pathological features of LCIS and a 
discussion of those studies that have reported on its incidence. The potential risk factors 
predisposing to LCIS are described as well as age at diagnosis. Studies looking at the risk 
of a subsequent breast cancer in women with a diagnosis of LCIS are reviewed, as are the 
attempts by some authors to predict which of these women are more likely to develop 
further cancers. The mammographie features of LCIS and the management options 
available to women are discussed.
B io lo g ica l  M a r k er s  a n d  LC IS
The biological markers shown to be helpful in the diagnosis of Ductal Carcinoma in Situ 
(DCIS) and in predicting its outcome, such as c-erbB-2, Ki-67 and p53, are generally not 
positive in classical LCIS and are therefore not helpful (Ottesen et al 2000, Siziopikou et 
al 1996, Sneige et al 2002, Viacava et al 1999 & Mohsin et al 2005). Sapino et al (2000) 
however did publish data on 10 cases of pleomorphic LCIS that were c-erbB-2 positive.
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IMMUNOHISTOCHEMISTRY IN LCIS
Oestrogen Receptor Status
Oestrogen receptor status is routinely tested for in invasive disease and is a prognostic 
indicator. If positive, patients with invasive disease are treated with adjuvant anti­
oestrogen drug therapy such as Tamoxifen or an Aromatase Inhibitor. In LCIS, oestrogen 
receptors have been shown to be positive in 60-90% of cases with a slightly lower 
percentage for progesterone receptors (Ottesen 2000 & Sneige 2002). Oestrogen receptor 
status can be scored with a rough H score <100, up to 200 and >300 or with a quick score, 
which is related to the proportion of staining and staining intensity.
Score for Proportion Staining
0 = no nuclei staining
1 =<1% nuclei staining
2 = 1-10 % staining
3 = 11-33% staining
4 = 34-66% staining
5 = 67-100% staining
Score for Staining Intensity
0 = no staining
1 = weak staining
2 = moderate staining
3 = strong staining
These two scores are added together to give the quick score (possible range 0-8).
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E-Cadherin
The expression of E-Cadherin, a transmembrane glycoprotein responsible for cell-cell 
adhesion has caused much debate amongst breast cancer pathologists. It is commonly 
identified in DCIS and invasive ductal carcinoma but is rarely seen in LCIS, ALH or 
invasive lobular carcinoma (ILC) (Jacobs et al 2001 & Vos 1997). This loss of E- 
Cadherin in LCIS is thought to be due to somatic mutation, gene promotor méthylation, or 
loss of heterozygosity on chromosome 16q22.1 (Page 2003). This has been a very helpful 
adjunct in helping to categorise those examples of in situ breast cancers with cytological 
or architectural features that deviate from the usual patterns, making it difficult, if not 
impossible, to determine whether the proliferation is lobular or ductal in nature (Jacobs 
2001 & Vos 1997). Masstracci et al (2005) looked at 24 cases of Lobular Neoplasia, of 
which 13 were LCIS and found that 23 of the 24 were E-Cadherin negative. In the cases 
of LCIS this was associated with DNA alterations at 16q but the same was not true for 
ALH.
Ottensen (2000) suggested that constitutional E-cadherin mutations may confer 
susceptibility to LCIS and increase the risk of future invasive disease, although this is 
disputed by others (Nemoto et al 1998). Other than E-Cadherin there are no other known 
genes that confer susceptibility to LCIS.
Lack of E-Cadherin expression has also fuelled the debate as to whether LCIS is a 
precursor of invasive breast cancer or merely a marker of increased risk of developing 
invasive disease in the future. Rieger-Christ et al (2001) studied 16 patients with 
concurrent LCIS and invasive lobular carcinoma, looking for E-Cadherin loss, and found 
that in 12 patients the lack of expression and localisation of E-Cadherin was 
indistinguishable between the LCIS and invasive regions. In the interpretation of these
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results the authors believed that this supported the hypothesis that LCIS is a precursor 
lesion to the invasive disease in these cases.
Berx (1996) also showed that 27 out of 48 patients had mutations in the E-Cadherin gene 
in ILC while showing the same truncation mutation in associated adjacent LCIS, in his 
view this proved that LCIS could be a precursor lesion.
HER -2  Receptor Status
HER-2 is a gene that encodes a cell membrane located growth factor and is amplified in 
15-25% of invasive carcinomas (Slamon et al 1987). It is located on chromosome 17ql2. 
Over expression of this gene in an invasive breast cancer correlates with poor prognosis 
(Varley et al 1987) and overall shorter survival. HER-2 is rarely over expressed in LCIS 
(Gusterson et al 1988 & Sneige 2002).
Cvtokeratin Staining
Several studies have looked at the staining of breast lesions including DCIS and LCIS 
with cytokeratins, with and without E-Cadherin, to attempt to improve the diagnostic 
accuracy of breast lesions (Bratthauer et al 2002 & Otterbach et al 2000). High molecular 
weight cytokeratins CK3/4 and 34B E l2 have been suggested as additional aids in the 
diagnosis of LCIS.
Cytokeratin 5/6 stains positive for myoepithelial cells and hyperplastic cells, as a brown 
colour. Otterbach (2000), based his study on 23 cases of LCIS and 82 cases of DCIS, and 
found cytokeratin 5/6 was not useful in differentiating between the two types of lesions.
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In contrast, Bratthauer (2002) looked at classical and pleomorphic LCIS and E-Cadherin 
in conjunction with cytokeratin 34B E12, which is reactive against high molecular weight 
cytokeratins 1, 5, 10, 14. They suggested it could be helpful in differentiating between 
LCIS and DCIS, with LCIS staining positive and DCIS negative. Laroix-Triki et al 
(2003) also compared DCIS and LCIS using cytokeratin 5/6 and 34B E l2 but their results 
were less conclusive.
These papers (Bratthauer 2002, Otterbach 2000 & Lacroix-Tiiki 2003) suggest that with 
the use of E-Cadherin and some cytokeratins the distinction between LCIS and DCIS can 
be made more accurately but that CK 5/6 was not helpful in this distinction, although 
numbers were small. This is summarized in Table 2.
LCIS DCIS
E-Cadherin negative E-Cadherin positive
CK 5/6 negative CK 5/6 negative
CK 34B Positive CK 34B negative
Table 2: Comparison o f  immunohistochemical staining between DCIS & LCIS
There may be a variation in these markers so a panel of such markers provides an 
increased chance of an accurate diagnosis.
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M o l e c u l a r  Pa th o lo g y
Molecular data on LCIS lesions is limited. DNA ploidy analysis of LCIS (Rahman et al 
2000, Ottensen 2000, Lakhani 1995, Stratton et al 1995) has been done in order to attempt 
to predict which lesions will develop invasive disease later and to link LCIS with ILC.
Lakhani (1995) reported that loss of heterozygosity (LOH) at chromosomal arms that 
occur in high frequency in invasive carcinoma can also be detected in LCIS. They 
believed that this confirmed the neoplastic nature of the disease and suggested that LCIS 
could be a direct precursor of invasive cancer. Further support for this hypothesis came 
from Nayer (1997) who showed LOH in 50% of LCIS cases associated with invasive 
cancer occurred on chromosome 1 lql3.
Hwang et al (2004) looked at 24 cases of ILC with associated LCIS and found a 
substantial proportion of the genome was altered in samples of both LCIS and the 
coexisting ILC, the most frequent being gain of Iq and loss of 16q. In agreement with 
Lakhani (1995) they suggested this data was consistent with a progression pathway from 
LCIS to ILC.
These molecular studies have all added weight to the hypothesis that LCIS is a precursor 
lesion in some instances. However, the studies are small and it is hoped that this 
molecular work will eventually provide tools to separate out those women who go on to 
develop invasive disease.
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L o b u la r  C a r c in o m a  in  S itu  w it h  M ic r o in v a sio n
The definition of microinvasion is Tess than one millimetre of invasion’.
Lack of microinvasion in specimens of LCIS has also supported its assignment as a high- 
risk marker for future invasive disease rather than as a pre-invasive phenomenon, whereas 
microinvasion is a relatively frequent occurrence in DCIS. It may be, however, that 
microinvasion in LCIS is much harder to identify than in DCIS especially where the 
lobules are largely expanded. There have been a few case reports but Nemoto (1998) 
described 6 cases of LCIS associated with microinvasion.
This finding of microinvasion associated with LCIS, only previously described 
anecdotally, lead them to conclude that at least in some patients with LCIS there is a 
progression to invasive lobular carcinoma and that in these circumstances it is a pre- 
invasive cancer. They also believed that clinical or mammographie changes may indicate 
an increased likelihood of this microinvasive transition.
E p id e m io lo g y  o f  LCIS
Disease Frequencv
Lobular Carcinoma in Situ of the breast is a relatively rare disease. Historically it is 
described as a microscopic lesion that generally does not form a palpable tumour and is 
thought not to have mammographie features. Therefore, the incidence of this disease is 
hard to ascertain and some authors have stated that it NEVER makes a mass or reveals 
itself on mammograms (Rosen 1978 & Page 2003). LCIS is thought to be an incidental 
finding in tissue excised for an unrelated benign or malignant condition such as 
fibrocystic change, fibroadenomas or invasive carcinoma (Haagensen 1978). Hence, there 
may be asymptomatic women with LCIS who are never diagnosed because they have
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never had a surgical procedure. Many authors believe therefore, that wg do not know the 
true incidence of LCIS (Rosen 1978, Haagensen 1978, Page 2003).
What data we do have for the frequency of LCIS comes in four forms:
1) Autopsy Studies (prevalence of LCIS).
2) Presence of LCIS in benign biopsies.
3) Incidence rates related to all breast cancers diagnosed.
4) Population based studies.
1) The Autopsv Papers
Post mortem studies have provided some of the data on the frequency of LCIS. Neilson et 
al (1984) examined breasts from young women, many of whom died unexpectedly, 
including 6 of 83 whom had previously had breast cancer. Three other studies, including 
a total of more than 300 women failed to detect any instances of LCIS, (see Table 3). 
Autopsy studies of women dying without breast disease avoid the bias associated with 
biopsy material, but examination of all breast tissue requires a marked effort, and for that 
reason it has only been accomplished in a small number of studies. Autopsy papers are 
also biased in their own way as they underestimate the presence of LCIS in the general 
population, as they reflect an older, especially Kranmer et al (1973) and more select 
population.
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Authors Age of 
Cases
Number of  
Autopsies
No of 
Cases of 
LCIS
Incidence Journal Where 
Published
Kranmer & 
Rush
1973
All over 70 
years of age
70 0 0% Cancer
Neilson et al
1984
Range
22-89
Median
67
83 3 3.6% Cancer 
6 Patients with a 
past history o f breast 
cancer
Alpers
&Wellings
1985
Range
15-99
101 
185 breasts
0 0% Human Pathology
Neilson et al
1987
Age range 
20-54 110 4 3.6%
Cancer 
1 patient with a past 
history of breast 
cancer
Frantz et al
1951
Median age 
45
225 0 0% Cancer
Table 3: Autopsy papers stating incidence o f  LCIS
The other factor that these studies illustrate, Neilson (et al 1987) particularly, is that 
amongst known breast cancer patients, many more cases are identified, suggesting that 
LCIS is a significant marker for clinical carcinoma. This Danish study (Neilson 1987), see 
Table 3, has been criticised for its overly broad definition of both DCIS and LCIS, but the 
authors defended the higher incidence by stating that it reflected the meticulous 
pathological examination (57-166 blocks per breast) in a population with a higher than 
average breast cancer incidence.
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2) LCIS Within Benign Biopsies
Authors
(Period of  
study)
No. of Biopsies 
reviewed
No. 
Cases 
o f LCIS
%  Cases 
o f LCIS Comments
Newman
1963
(1953-1962)
7500
All breast biopsies
32 cases 
in 26 
women
0.3%
Giordano
1973
(1953-1973)
8000
All breast biopsies 124 2.5%
Gaton
1974
(1959-1972)
1778
All breast operations
7 0.4% A further 23 LCIS with invasive disease
Wheeler
1974
(1948-1960)
3570
Reviewed all breast 
pathology specimens
30 0.8% Very definite diagnosis between 
LCIS and ALH
Anderson
1977
(1942-1961)
3299 benign biopsies 52 1.5%
Haagensen
1978
(1930-1972)
5560
All benign biopsies 211 3.8%
Page (2003) believed some did 
not fit criteria and were ALH 
instead
Hermann
1993
(1988-1991)
4771
All breast biopsies 57 2.8%
Bodian
1996
(1930-1972)
2225 benign biopsies 239 10.7% Haagensen’s (1978) patients but the pathology was reclassified.
Page
2003
(1960-1979)
10,000 benign 
biopsies 48 0.5%
Table 4: Papers that have assessed frequency within benign biopsy specimens
Benign biopsy series provide limited information as they involve selected populations 
(see Table 4). These vyomen are usually pre-menopausal and represent the group of 
women who have fibrocystic change or other benign disease that prompted biopsy in an 
era when biopsy of benign disease was common. Also, only a small fraction of tissue 
excised is examined and the LCIS is probably scrutinised less as the pathologists are 
likely to be more interested in the other, original lesion. Autopsy and biopsy studies 
involve different populations; however, the fi*equency of LCIS in both groups is 
extremely low. Haagensen (1978) found that in 73% of his patients the LCIS was found in 
association with gross cystic disease.
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3) Incidence Related to all Breast Neoplasms
Author
(Period of  
study)
Total Number 
o f Neoplasms
Number of  
Cases o f LCIS
Proportion 
of all cancers
Dall’OImo
1975
(1952-1971)
2752 24 1%
Ringberg
1991
(1976-1984)
1693 33 1.9%
Scharf
1991
(1976-1986)
653 6 0.9%
Mackarem
1994
(1969-1990)
3327 47 1.4%
Table 5: Studies showing the incidence o f  LCIS related to all breast neoplasms
These papers are all quite dated and many factors have changed in the diagnosis and 
treatment of breast disease since these were published. The incidence of breast cancer is 
rising and the incidence of DCIS has also increased since the introduction of breast cancer 
screening, rising from 5% to 20% of all screen detected cancers in the United Kingdom 
(Toms 2004). Even prior to the introduction of screening programmes, there was an 
increase in the use of mammography in the 1970s and 1980s, which may have had an 
effect.
Ringberg et al (1991) showed in his paper an increase in the first 3 years following the 
introduction of mammographie screening of the rate of DCIS but no corresponding 
increase in the rate of LCIS.
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4) Population Based Studies
Author
(Period o f study)
LCIS incidence per 
100,000 women per year
DCIS incidence per 
100,000 women per 
year
Comments
Ringberg
1991
(1976-1984)
3.7 14.9
Simon
1993
(1975-1988)
1 in 1975 
2.8 in 1985
2.3 in 1975 
8.7 in 1985
Small number of 
cases
Levi
1997
(1977-1994)
1.0 in 1977-1979 
2.3 in 1992-1994
1.0 inl9 77-1979
7.1 in 1992-1994
Small numbers in 
each year of LCIS
Li
2002
(1978-1998)
0.9 in 1978-1980 
3.19 in 1996-1998
Table 6: Showing population based studies relating to the incidence o f  LCIS
Li et al has recently reported (2005), based on women from the Surveillance 
Epidemiology and End Results (SEER) database that LCIS incidence rates increased 2.6 
fold between 1980 -2001, and that over the last ten years the increase was 1.3 fold, over 
the last 5 years the increase was 1.1 fold. In comparison the incidence of DCIS increased 
7.2 fold from 1980-2001, with an increase of 1.8 fold in the last ten years and 1.1 fold in 
the last 5 years. He noted that the rates of LCIS have only increased among women aged 
50-69 years and he believed that this was due to the increase in mammography uptake and 
that LCIS is found as the result of an incidental finding after a biopsy for another reason. 
He also hypothesised that it could be related to menopausal hormone use.
One of the limitations of these population-based studies is that they require outside 
reporting of LCIS biopsy specimens. Because many pathologists and clinicians consider 
LCIS to be a benign disorder, it can go under reported in a registry-based series. In 
addition the populations themselves may contain bias, Li (2005) states that the SEER 
registries used for his study are not random subsets of the US population, but they are 
from areas that are more urban and affluent.
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When considering all age groups Li (2005) found there was a sharp increase between 
1978-80 and 1987-89 followed by a more moderate increase up to 1996-98. This 
corresponded to an overall fourfold increase (95% Cl, 2.9-5.6) in LCIS incidence rates 
over the whole study period. These trends in LCIS incidence did differ by age, all except 
30-39 year olds experienced a rise during the study period. The study age range was from 
30 to 80+. They found that while rates increased in women over the age of 40 from 1978- 
1989 they only continued to rise among women 50-79 years of age through 1996-1998. 
Other studies have also shown a rise in the frequency of LCIS over time (Zheng et al 1997 
& Barchielli et al 2005).
There seems little doubt that the incidence of LCIS is increasing and there are several 
theories as to why this may be. Some believe it is because of better histopathological 
recognition and greater assiduousness in sampling of excised specimens (Fentiman 2001). 
Other authors believe that the incidence of LCIS increased in the 1980s as a result of the 
increase in screening activity and the subsequent increase in breast biopsies (Frykberg 
1993). Some have suggested that the increase in incidence may be related to the 
concurrent increase in hormone replacement therapy (HRT), particularly the combined 
oestrogen and progesterone preparations (Li et al 2002). Li (2002) has also suggested that 
the rate of invasive Lobular cancer has been increasing in women over 50 years of age. 
He believed that this may be associated with the use of HRT.
Another issue is that some authors believe that LCIS is not a static process and that it 
regresses after the menopause. Haagensen (1978) initially suggested this, but the nature of 
biopsy material and the reasons for biopsy make it difficult to draw such conclusions and 
we must be cautious about such statements.
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There have been some studies that looked at the incidence of LCIS related to race. Over 
all, Li (2002) found that blacks had a lower incidence compared to whites, although the 
incidence in blacks was also increasing. Walt et al (1992) found 86% of his LCIS cases to 
be in Caucasian women although in the study population blacks accounted for 32%. Other 
papers have reported about a ten times increased frequency in American blacks compared 
to whites (Farrow 1970 & Newman 1963)
Incidence Related to Menopausal Status
The age at diagnosis and menopausal status are closely linked. The fact that the majority 
of the women are in there forties at diagnosis and pre-menopausal, is consistent with the 
hypothesis that this might be a hormonally related lesion at its inception. The studies 
relating to incidence associated with menopausal status are listed in Table 7. We now 
know from the National Surgical Adjuvant Breast and Bowel Project, NSABP -  PI study 
(Fisher 1998) that Tamoxifen reduces the risk of invasive disease in women diagnosed 
with LCIS by 50% and this adds strength to the argument that at least some cases of LCIS 
are hormone dependent. This is also supported by oestrogen receptor testing, which is 
positive in 60-90% of cases (Ottesen 2000 & Sneige 2002). Rosen (1978) commented that 
since in some cases but not all LCIS is followed by invasive carcinoma, but not all, the 
hormonal studies may help to identify patients most at risk of developing invasive cancer. 
Some authors have postulated that with the increased use of exogenous hormone 
replacement there may be an increase in the number of cases of LCIS diagnosed.
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Author
(Period of  
study)
No patients 
with LCIS 
in study
% Pre­
menopausal 
women
%
Menopausal
women
%
Postmenopausal
women
Newman
1963
(1953-1962)
26 85 0 15
Lewison & 
Finney 
1968 
(1957-1966)
40 37 46 17
DalFOlmo
1975
(1952-1971)
24 67 12.5 12.5
Haagensen
1978
(1930-1972)
211 90% 10%
Rosen
1981
(1940-1965)
108 46 19 34
Salvadori
1991
(1976-1988)
100 62 0 38
Carson
1994
(1963-1990)
59
Known
53 47
Cutuli
1998
(1980-1992)
17 Not stated 70 Not stated
Table 7: Studies documenting incidence related to menopausal status
These studies suggest that LCIS is more common in pre-menopausal women, although as 
it is almost always an incidental finding at benign biopsy it may reflect that this is the age 
at which biopsies most often are benign. Also the age range and inclusion and exclusion 
criteria varied in the studies. Although historically LCIS was thought to be a disease of 
pre-menopausal women, LCIS may occur in postmenopausal women and that this need 
not be related to exogenous oestrogenic hormones (Rosen 1978, DalTOlmo et al 1975, 
Lewison et al 1968 & Newman 1966).
In summary we can conclude that fi*om the studies to date LCIS is a rare lesion, the 
incidence of which is unknown. It has historically been seen most commonly amongst 
pre-menopausal women. However, more recent studies suggest that the incidence in 
which it is detected in postmenopausal women is increasing.
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R isk  Fa cto r s  f o r  LCIS
Only a few papers have looked at the risk factors for LCIS. Weiss et al (1996) assessed 
the risks associated with all types of in situ carcinoma (DCIS and LCIS grouped together) 
and then compared the two separately. He showed the increased risks of in situ disease to 
be similar to those of invasive disease and these are listed in Table 8. The relative risk is 
related to the risk in the general population.
Risk factor Relative Risk
First degree relative 2 relatives 6.93
Previous breast biopsy 1.99
Race: African-American 1.84
Young age at menarche 12 years 1.19
Parity Nulliparous 2.1
Number of full term births >4 0.55
Age at first full term birth >30 1.34
Interval since last birth >15 years 0.84
Table 8: Risk factors for all in situ disease ( Weiss 1996)
Weiss (1996) also looked at the distribution of risk factors by histological type of the in 
situ tumour, comparing DCIS with LCIS and the results are shown in the Table 9. 
Although there were fewer cases of LCIS, a significant difference was found between 
family history, previous benign breast biopsy and parity when comparing LCIS and DCIS. 
The relative risks had been adjusted for age at diagnosis, site, smoking, number of 
mammograms and all other risk factors illustrated in this table.
When Weiss compared these results to those of invasive breast cancer he felt that they 
supported the theory that ductal carcinoma in situ is more closely related to invasive 
disease than the lobular form of in situ disease.
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Risk Factors Specific for DCIS & LCIS
Risk Factor
Relative Risk 
DCIS n=156
Relative Risk 
LCIS n=43
First Degree Relative
None 
At least one
1.0
2.5
1.0
3.8
Previous Breast Biopsy
No 1.0 1.0
Yes 1.86 3.8
Race
White 1.0 1.0
Afirican-American 1.65 1.99
Parity
Yes 1.0 1.0
No 2.31 1.89
No of full term births
1 1.0 1.0
2 0.8 2.37
3 0.54 1.24
>4 0.47 1.0
Age at first full term birth
<20 1.00 1.0
20-24 0.89 0.32
25-29 1.11 0.99
>30 1.23 1.37
Body Mass index 
<22 
22-24.59
24.6-29.02
>29.03
1.0
0.55
0.57
0.41
1.0
0.99
0.71
0.92
Table 9: Risk factors specific for DCIS & LCIS ( Weiss 1996)
Claus et al (1993) looked at risk factors for all histological subgroups of breast cancer, 
including LCIS and found that age at menopause, age at menstruation, number of 
pregnancies and age at first pregnancy did not show any significant differences by 
histological subgroup. Bodian et al (1996) found that 34% of her cohort of LCIS patients 
were nulliparous and amongst the parous women, ages at first birth ranged from 14-41 
years. She found that 38% of the women were younger than 20 years at the time of their 
first delivery, and 5% were 35 or older.
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LCIS and Family History
Several studies have suggested that LCIS is related to family history (Claus 1993, Rosen 
et al 1982). Claus looked at 90 cases of LCIS and found that LCIS cases were 
significantly more likely to be bilateral cases than other breast cancers, 27% of her cases 
were bilateral. She also found that women with LCIS were significantly more likely to 
have a first-degree relative affected with breast cancer than were women with other 
histological types. Of the 23% cases with LCIS reported, at least one first degree relative 
was affected with breast cancer. This rate is approximately twice that for any other 
histological subgroup. Claus found no relationship between bilaterality and family history. 
She also looked at specific family history and found that 15.6% of LCIS cases had an 
affected mother and 10% had at least one affected sister. In a later study Claus et al (2003) 
reviewed 123 cases of LCIS and compared them to 999 controls and found that they were 
significantly more likely to report a first degree relative with breast cancer, with a 
significantly increased risk for mothers and an elevated (but not significantly) increased 
risk for sisters.
Other authors have looked at the frequency of a positive family history in women with 
LCIS and they are listed in Table 10. It is important to note that the authors did not always 
use the same criteria for positive family history, some used first-degree relatives only and 
others any female relative, which makes it difficult to compare them.
Rosen (1982) found 14.5% of his patients had a least one female relative with breast 
cancer. He also compared LCIS to DCIS in his study and found there to be no difference 
in the frequency of breast carcinoma in their mothers.
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Author No. or % o f Cases With 
Positive Family History
Comments
Farrow 16%
1968
Rosen 14.5% Any female relative
1992
Claus 23%
1993
Carson 32% T* degree relative
1994
Singletary 9% Mother, sister or daughter
1994
DalFoImo 5 of 24
1995
Bodian 20% of 236 24 women with mother
1996 19 with one or more sisters 
4 with both
Cutuli 7 of 17
1998
Claus 28 of 123 (22.8%) First degree relative
2003 30 of 123 (24.4%) Second degree relative
Table 10: Studies describing family histoiy rates in women with LCIS
Heritable cancer predispositions syndromes are often indicated by the pattern of early age 
onset and multicentricity of neoplasms. As LCIS shows both of the attributes it has been 
suggested that LCIS may arise fi*om an inherited susceptibility. This can be supported by 
data from Lakhani (1999) that showed that the foci of LCIS are likely to be clonal.
The elevated incidence of bilateral LCIS and invasive disease in relatives also supports 
the hypothesis that a proportion of LCIS results from genetic susceptibility. The identity 
of this gene remains unknown but it is likely to be a low penetrance invasive breast cancer 
susceptibility gene (Rahman 2000) as the rate of progression to invasive disease is lower 
than that of DCIS. There is also evidence from systematic studies, discussed previously 
that both LCIS and invasive lobular cancer are associated with higher familial risks of 
breast cancer than other histological types (Cannon-Albright et al 1996 & Claus 1993).
Since the identification of the predisposing genes BRCAl and BRAC2 by Miki et al
(1994) & Wooster et al (1995) a number of studies have compared the morphology of
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LCIS with mutations in these genes, but there is no evidence that LCIS or ILC form part 
of the BRACl phenotype (Breast Cancer Linkage Consortium Lancet 1997 & Marcus et 
al 1997). An association between ILC and BRAC2 has been reported and LCIS and 
BRAC2 by Marcus (1997) but this was not confirmed in a larger study performed by the 
Breast Cancer Linkage Consortium (BCLC), (1997).
Hormone Therapv
In one of Rosen’s early papers (et al 1979) he commented that it was unlikely that 
exogenous hormones played an important role in LCIS but there were only 37 women 
with LCIS of whom 10 were taking hormones. He stated that there was no evidence at 
that time that LCIS was an oestrogen dependant disease. No other studies to date have 
commented on HRT as a risk factor for developing LCIS although some authors have 
postulated that there may be a link.
Summarv
1) LCIS appears to be higher frequency of positive family history in women with 
LCIS compared to other malignancies.
2) There is no evidence that LCIS is associated with HRT usage.
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A g e  a t  D ia g n o sis
In all reports LCIS has been noted to be more common in younger women with a mean or 
median age at diagnosis of between 43 and 51 years and an age range of between 20 and 
85. Bosincu and Eusebi (1972) described a case of LCIS in a 15-year-old girl, within a 
fibroadenoma and this is the only case of its kind in someone of such a young age. The 
papers pertaining to age at diagnosis of LCIS are shown in Table 11.
Rosen (1979) noted that patients with LCIS and Invasive Lobular Carcinoma were on 
average more than 5 years older than those with LCIS alone. Rosen in an earlier paper 
(1978) stated that the average age of diagnosis of LCIS is 5 years younger than that of 
invasive ductal carcinoma and 10 years younger than the average age at diagnosis of 
invasive lobular carcinoma. Haagensen (1978) speculated that the reason LCIS was less 
common in older women, was because the disease regressed after the menopause, 
although he offered no biological explanation for this. More recently authors have urged 
caution in this belief as it clearly does occur in postmenopausal women. Many women 
may have LCIS with no symptoms or signs and are therefore never diagnosed, so the age 
at diagnosis may be related to the way in which the LCIS is identified.
The age at diagnosis can be attributed to several things; the fact that the majority of cases 
are diagnosed after a benign biopsy as an incidental finding, means that the age at 
diagnosis relates to the age of diagnosis of these benign lesions that induce the surgical 
procedure. Fibrocystic change, a common reason for benign biopsy has a peak incidence 
at 31-40 years of age, and fibroadenoma’s are commonest in women in their 20s.
Many of the authors in the key studies suggested that with the introduction of breast 
screening, owing to more biopsies being performed in an older age group of patients, (50-
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70 years of age), that there would be a shift or an increased range of the age at diagnosis 
ofLCIS.
Author Age range 
(years)
Median/mean Comments
Newman
1963
Unknown 45
McDivitt
1967 27-55
44
Lewison & Finney 
1968
33-65 Mean 46
Wheeler
1974
33-49 Mean 43.9 Very careful to check between ALH and 
LCIS
LCIS classed as one lobule involved
Dall’OImo
1975 38-54
46
Andersen
1977
20-76 Mean 46 One lobule for diagnosis of LCIS
Carter
1977
Unknown Mean 47.2
Haagensen
1978
33-55 44
Rosen
1978
28-78 Mean 45
Rente
1991 26-81
Mean 49
Ringberg
1991
36-71 Median 51
Salvadori
1991
25-72 Mean 49
Donegan
1992
30-64 Mean 45
Ottensen
1992
29-85 Includes cases of DCIS but paper states no 
difference between two
Walt
1992
Unknown Mean 50.7
Ward
1992
Unknown Mean 49.3
Carson
1994
37-81 Median 48 Included 5 patients with previous breast 
cancer
Mackarem
1994 36-79
Mean 51
Bodian
1996
29-82 Median 47
Habel
1997
20-84 Included patients with DCIS
Page
2003
31-55
Table 11: Papers containing information on age at diagnosis o f  LCIS
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S u m m ar y
1) Previous papers have shown LCIS to be found in younger women.
2) Who by the nature of their age are likely to be pre-menopausal.
3) This is largely related to the reasons for initial breast biopsy.
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B il a ter a lity  & M u lt ic e n t r ic it y  o f  LC IS a t  D ia g n o sis
Multicentricity and bilaterality are interrelated anatomical characteristics of breast 
carcinoma, which have a significant impact on treatment. The frequency of these 
phenotypes varies depending on the histological type of the cancer. LCIS has been found 
to have a high rate of both of these phenomena.
Bilateralitv in LCIS
Information regarding the bilaterality ofLCIS is found by reviewing patients who had had 
bilateral mastectomies or mirror image biopsies at the time of diagnosis. This happens in 
only a few cases so the true rate is uncertain. Foote and Stewart failed to comment on the 
bilaterality of LCIS in their original 1941 paper but it was first described in 1959 by 
Bames (1959). He described two patients, with LCIS, which were treated with bilateral 
mastectomies and found them to have bilateral disease.
Bilaterality of LCIS is hard to predict as few surgeons have routinely biopsied the 
contralateral breast, but in studies where this has been done it has been shown to be 
between 26% and 47% (see Table 12), in these studies biopsy related to excision biopsy 
not core biopsy. Another fact observed by Hutter (1984) was that when mastectomies are 
done for LCIS there is a 4% to 6% rate of invasive cancer being found elsewhere in the 
unilateral breast.
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Author Mastectomy or Biopsy Number Positive for 
Contralateral LCIS
Newman 6 bilateral mastectomy 9
1963 18 who had contralateral biopsy 
Total 26
Benfield 5 2
1965
McDivitt Not stated 30%
1967
Urban 26
1967 Random contralateral Biopsy 9
Lewison & Finney 15
1968 Bilateral Mastectomy 7
Kaufmann 15 2
1971 Mastectomy
Warner Not stated 15%
1969
Perez-Mesa 23 6
1972 Mastectomy
Anderson 25 8
1974 Biopsy or Mastectomy
DairOImo 24 6
1975 Mastectomy or biopsy
Carter 39 14
1977 Biopsy or Mastectomy
Rosen 57 28
1978 Contralateral biopsy Not just LCIS in 
contralateral breast 
included
Davies 15 8
1979 Mastectomy or biopsy
Neilson Mastectomy 0
1986 4
Beute 82
1991 Mirror image biopsy or mastectomy 41
Ringberg 16 9
1991 Mastectomy
(20-29)
Ringberg 22 8
1991 Mastectomy, reduction. Biopsy
(466-476)
Carson 5 0
1994 Mastectomy
Singletary Mastectomy 4
1994 18
Bodian 14 1
1996
Table 12: Studies relating to the incidence o f  bilateral LCIS
Toker and Goldberg (1977) looked at 8 patients with bilateral LCIS who didn’t have 
mastectomies and 3 developed invasive cancer in twelve years of follow up. Carter et al 
(1977) had a series of 14 patients with bilateral disease who went on to have bilateral
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mastectomies, and 12 had residual disease in which 3 had invasive disease, an incidence 
of 21% in patients with biopsy proven bilateral LCIS. Both Carter and Toker’s groups 
suggested that bilateral LCIS was potentially more sinister in its implication although the 
two studies are not directly comparable.
Some of the papers that looked into bilaterality, did so after the initial diagnosis of LCIS. 
Carter (1977) performed random biopsy in the contralateral breast of 25 patients and only 
one was positive for LCIS. Farrow et al (1969) found 12.3% of cases to be bilateral at the 
time of diagnosis and a further 6% were found to have bilateral disease at a later date.
Singletary published two papers in 1994, both of which included data on the bilaterality of 
LCIS. In one paper focusing on 16 patients with an initial diagnosis ofLCIS who went on 
to have bilateral mastectomy, lo f these had associated tubular cancer and 2 had invasive 
lobular cancer in the ipsilateral breast. Nine of the women were found to have LCIS in the 
contralateral mastectomy specimen. Singletary felt that the rate of diagnosis of bilateral 
LCIS was proportional to the amount of tissue examined. She suggested that the incidence 
of bilateral disease would increase with the use of more extensive diagnostic procedures, 
prophylactic contralateral operations and plastic adjustments.
Multicentricity
Multicentricity, which is also sometimes referred to as multifocality, is difficult to define. 
There are two schools of thought, some believe that it refers to two areas of disease 
separated by 5mm of normal tissue and others believe that it refers to disease in different 
quadrants of the breast. In all of the papers reviewed, the authors did not state what their 
definition was, this makes them difficult to compare.
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Specific types of carcinoma associated with a high frequency of bilaterality are more 
likely to occur as multicentric foci in the affected breast. Foote and Stewart found this to 
be true ofLCIS in 1941 and subsequent studies have confirmed multicentric foci in 60- 
80% of patients undergoing mastectomy for LCIS.
In Lewison’s study (1968) all patients with bilateral LCIS had multicentric deposits in the 
contralateral breast. In 21 of the 34 patients having mastectomy multicentric deposits of 
LCIS were found in the ipsilateral breast. Ringberg (1991) found that 14 out of 17 patients 
had multifocal disease at the time of subcutaneous mastectomy for LCIS and Hutter 
(1984) suggested that in his study 60-90% of cases were multicentric.
Beute et al (1991) found multifocal disease in 96 out of 138 breasts (70%). Salvadori et al 
(1991) looked at 100 cases of LCIS and found 40 to be multicentric and 60 cases had a 
single focus of LCIS. Of 33 cases in which the patients had a subsequent mastectomy 10 
were found to have residual disease. Carson’s (et al 1994) study included 14 patients 
having an ipsilateral mastectomy and 8 of these had fiirther areas of LCIS within the 
breast.
Carter et al (1977) performed unilateral mastectomy on 47 patients with LCIS following 
biopsy and found 31 (63%) had residual LCIS. In 3 cases there was invasive lobular 
carcinoma all of whom had bilateral LCIS which the authors suggested may predict an 
increased risk. Andersen (1974) found that 9 of 19 cases were multifocal and he felt like 
Singletary (1994) it was proportionate to the number of blocks examined.
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Ringberg (1991), found in 17 patients with an initial diagnosis of LCIS who then had a 
subcutaneous mastectomy, that 14 had residual LCIS, although the quadrant of the breast 
was not described and 3 of these were also found to have a focus of DCIS.
Dall’Olmo (1975) found residual LCIS in 14 of 25 cases that had had a mastectomy for 
LCIS and McDivitt et al (1967) found that 1 of 8 patients having unilateral mastectomy 
had extensive LCIS in the mastectomy specimen. Rosen (1978) in his large series of 
patients found that 48% of the 50 women with residual LCIS, had disease that was distant 
from the original biopsy site.
These risks of multicentricity and bilaterality of LCIS impact on the treatment of LCIS. 
Those surgeons who believe LCIS is a marker of risk need not worry about either of these 
factors but those that believe it is a precursor lesion have a difficult dilemma in their 
hands. Total excision of the lesion in the ipsilateral breast and full evaluation of the 
contralateral breast are then imperative issues.
Sum m ar y
1) Bilaterality of LCIS is hard to assess as not all patients have contralateral surgery.
2) Those studies that have reported data, the rates are 26-47%.
3) Multicentricity has various definitions.
4) Rates are also difficult to assess as limited biopsies are often performed.
5) Those studies that quoted data, the rates are up to 90% although authors agree that 
it is related to the extent of pathological assessment.
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T he  P o sitio n  o f  LCIS W ith in  th e  B reast
Several of the key studies have looked at the position of LCIS within the breast. Carson 
(1994) found that 32 of his 65 cases of LCIS were positioned in the upper outer quadrant 
of the breast. Andersen (1977) found that 17 of his 47 cases of LCIS were in upper outer 
quadrant with equal distribution in the right and left breasts. Fourteen of 29 in 
DairOlmo’s (1975) series were in the upper outer quadrant and 6 of 29 were retroareolar.
Singletary (1994) found 38% of lesions were in the central portion of the breast, 16% in 
the upper outer quadrant, 13% in the lower outer quadrant and 33% were unknown. 
Lambird and Shelley (1969) found that LCIS was most common in the upper outer 
quadrant of the 9 breasts that they examined.
Haagensen (1978), however, felt that as his patients were diagnosed by limited biopsy he 
could not comment on the rest of the breast and therefore the position of the LCIS. He did 
find that LCIS, like other breast cancers is more common in the left side, with 51.7% in 
the left breast and 43.6% in the right and the rest being bilateral.
It is however difficult to comment on the position of LCIS, if the disease is often 
multicentric and many of the biopsies are limited.
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R ela tio n sh ip  w it h  In v a siv e  D isease
The biological nature of LCIS and its relationship to invasive disease is a controversial 
issue around which most of the other LCIS debates rest. When Foote & Stewart first 
described the disease in 1941, it was thought to be a pre-cancerous lesion which, given 
time, would develop into invasive lobular cancer if it went untreated. As all pathologists 
assumed that the progression from Lobular Carcinoma in Situ to the invasive stage was 
inevitable, i.e. that it was a precursor lesion, it meant that the treatment at that time was 
mastectomy. However, as these women were followed up and as more information about 
the disease was assessed, it became clear that progressive disease was not, as first thought, 
inevitable and this was when the marker of risk theory was bom. Since then the risk of 
invasive cancer is thought to affect both the biopsied and the contralateral breast, but to 
what extent remains controversial.
After the initial description (Foote & Stewart 1941) several case reports followed over the 
next decade, of patients who died of ipsilateral invasive lobular cancer more than 10 years 
after a diagnosis of LCIS (Godwin 1952 & Miller 1992). One of these authors also 
described the development of contralateral breast cancer after a biopsy of LCIS (Godwin 
1952). The risk associated with incomplete mastectomy was also documented by Newman 
(1966) in a report that described a patient treated with mastectomy who had recurrent 
LCIS and invasive lobular carcinoma in the inferior aspect of her scar presenting as a 
lump four years after surgery. Subsequently a small number of papers were published 
describing small groups of patients with LCIS with moderate follow up. These 
investigators noted that the majority of patients not treated with mastectomy remained 
well. Benfield et al (1965) reported 5 patients who remained well 11 years after a biopsy
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ofLCIS. Lewison & Finney (1968) reported a similar outcome of 3 patients, with a follow 
up of 3-10 years who remained well.
Haagensen et al (1981) working in the laboratory of Surgical Pathology at Columbia 
University was the first to question the inevitability of this progression and concluded that 
it was a benign lesion when not accompanied with invasive disease. His study included 
patients that other authors would have described as lobular atypia, which made 
comparisons difficult and one of his patients had previously had breast cancer, which 
would also affect the subsequent risk.
Following this, in order to clearly define the risk of subsequent invasive disease, 
associated with a diagnosis of LCIS treated with less than a mastectomy, a number of 
retrospective pathology studies were undertaken in the 1970’s and 1980’s. These studies 
aimed to identify consecutive series of patients with LCIS and to ascertain what the true 
rate of invasive disease was in these patients in the years since their initial diagnosis. 
However, there is some difficulty in comparing the results of the various studies, as in 
some cases patients were treated with a variety of either a local wide excision, an excision 
biopsy or unilateral or bilateral mastectomy, meaning that there are varying numbers of 
ipsilateral and contralateral breasts remaining.
Another problem is that the various authors have considered recurrence to be a variety of 
situations. Some have only included invasive recurrence and excluded in situ recurrence 
and others have included DCIS and/or LCIS. Some felt that a further diagnosis of LCIS 
did not amount to a recurrence where as others included this. This makes direct 
comparison complex.
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Another confounding factor is that bilateral disease is, in some papers counted separately. 
Other problems in these studies were that patients in some series were included who had 
previously had a contralateral cancer diagnosed. This made the calculation of true 
incidence confusing. The percentage of patients developing invasive disease may not be 
the best way to assess LCIS risk because it depends on the length of follow up and the 
number of patients lost to follow up. The ratio of observed to expected cases is better 
since it not only takes into account the years of follow up but also the age of the patient, 
which is an important risk factor. Table 13 describes those studies that have addressed the 
malignant potential of LCIS. Some of the follow up is relatively short and as discussed 
there are the variations in the diagnostic criteria. Some of these studies will be described 
in more detail in the text.
McDivitt (1967) looked at the risk for ipsilateral and contralateral breasts separately. He 
felt that the risk of contralateral breast cancer developing in patients with LCIS to be 13.4 
per 1000 patient years or about ten times the overall risk in the general population.
Hutter et al (1969) described 46 patients with LCIS, 6 of whom had a mastectomy and 40 
had excision biopsy. 15 patients developed recurrences, 5 of which were bilateral, giving 
20 cancers. Of the 14 ipsilateral cancers, 7 developed in the first 10 years and 7 between 
10 and 22 years from diagnosis and of the 6 contralateral cancers 3 developed before 10 
years and 3 after 10 years of follow up. There were 2 deaths from recurrence and 2 other 
patients had metastatic disease at the time of writing.
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S u b se q u e n t  b r e a s t  c a n c e r s  F o l l o w i n g  a  D ia g n o s is  o f  LCIS
Author No.
Cases
Length of 
Follow-up
Patients Who 
Developed 
Subsequent 
Cancer
Breast cancers
%
-as described 
in the study
Relative Risk 
-if described 
in the study
McDivitt
1967
50 1-23 years 16
Hutter
1969
46 4 -2 7  years 15 33
Giordano
1973
19 Variable 
8 patients for more 
than 5 years
2 10.5
Gaton
1974
7 Mean 7.7 years 1
Wheeler
1974
38 1-24 years 4 9.7
Andersen
1977
47 Mean 
15 years 
Range 2 -28
13 28 12
Haagensen
1978
287 18y 53 18% 6.9
Rosen
1978
99 24y 29 34.5%
(only 84 pts with 
follow up)
9
Page
1991
44 18y Greatest risk in 
first 15 years
23 9
Ringberg
1991
33 Median 8 years 1
Salvadori
1991
78 5 years 5 6.3 10.3
Walt
1992 250
Mean 
93.1 months 15
Ottensen
1993
69 Median 61 months 15 11.6 11
Carson
1994
51 Median 83 months 
Range 12 - 239
11
Mackarem
1994
47 51 months 1 3%
Singletary
1994
45 Median! 0 years 5
Bodian
1996
236 Median 18 years 
Range 1-50 years
62 26% 5.4
adjusted for age
Znrrida
1996
157 Mean 5 years 10 6.7%
Habel
1997
282 Average 
56 months
21 4.9% at 5yrs 
8.3% at lOyrs
Fisher
2004
180 12 years 40
Chnba
2005
4853 10 years 350 7.1% at 10 years
Levi
2005
88 20 years 11 Expected was 
2.6 
SIR = 4.2
Table 13: Studies relating to subsequent breast cancer following a diagnosis ofLCIS.
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Giordano et al (1973) published a group of 19 patients who refused to have mastectomies 
and who were placed in a program of frequent breast examination and only 2 of these 
developed an invasive cancer after 3 and 6 years of follow up. They were both invasive 
lobular cancers (ILC) and ipsilateral. He also described a case of ILC recurrence in the 
skin flap of a woman treated with mastectomy, who, then subsequently died of metastatic 
disease and stated that mastectomy was no absolute guarantee against recurrence.
Wheeler’s (et al 1974) study included women diagnosed between 1948 and 1960 and 
there was no regular follow up for the women. Wftieeler felt that his rate of recurrence was 
less than other papers and the ipsilateral risk at 20 years was only 4%. Wfiien subsequent 
authors commented on Wheeler’s results they felt he had very large standard deviations as 
many of the patients were lost to follow up.
Andersen et al published their data first in 1974 and then updated data in 1997 on 47 
patients with 15 years of follow up, 13 of whom developed a subsequent cancer. His 
conclusion was that all women diagnosed with LCIS warranted life-long follow up.
Haagensen (1978) and Rosen (1978) both used data from the Connecticut Tumour 
Registry for the baseline breast cancer rates and Relative Risks of 6.9 and 9 respectively. 
Therefore, the results of the two largest studies are similar and provide the best guide to 
the natural history ofLCIS treated by biopsy alone.
Salvadori (1991) compared his rate of invasive recurrence to that of the cancer registry to 
obtain expected rates of breast cancer in the population he studied. The relative risk was 
10.3 per 1000 with a confidence interval of 3.4-24, p<0.0001. Page et al (1991) identified
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a relative risk of 10.8 in first 15 years, which then decreased to 4.2 in women who were 
disease free at 15 years.
Ringberg (1991) found 1 of 11 patients who had breast conserving surgery had an 
invasive recurrence at 4 years and there were no recurrences in women who had either 
subcutaneous mastectomy or mastectomy.
Walt (1992) looked at 250 women from Michigan diagnosed with LCIS, 65 of whom 
were treated with less than mastectomy, whereas 185 had a unilateral mastectomy. Of 
these 65 patients who still have an ipsilateral breast only one developed a recurrence, 
which is a particularly low rate when compared to the other studies. Of the 38-recorded 
recurrences, the majority (23) were of contralateral LCIS and were within a year of the 
initial diagnosis, illustrating the difficulty in comparing studies.
Carson (1994) considered 51 patients treated with excisional biopsy alone and follow up 
clinically of every 4 months for the first 2 years then 6 monthly with annual 
mammography. Five patients, who had previously had an invasive cancer, were included 
in this study and therefore will have biased the results.
Bodian (1996) has written one of the most comprehensive studies so far regarding 
recurrence rates in LCIS. The patients were largely those initially described by Haagensen 
(1986), but all cases were independently reviewed and reclassified by the authors. Twenty 
of the patients were treated by mastectomy alone, the rest by excisional biopsy alone. The 
criteria for diagnosis was that at least 50% of the acini showed the characteristic features 
of LN, but in fact 90% of the patients had at least 90% of the relevant acini involved. 67% 
of the cases showed ductal involvement. Sixty-two patients developed invasive disease or
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DCIS from 1 to 30 years after their initial diagnosis of Lobular Neoplasia. These 62 
patients were followed for an additional 0 to 32 years (median: 6years), by which time 8 
of them developed a second primaiy cancer in the remaining breast, and 3 others had 
additional biopsies showing Lobular Neoplasia in the remaining breast, 1 of whom went 
on to develop a second primary cancer 2 years later.
More than half of the patients in this series had other evidence of breast disease preceding 
or after their diagnosis of LN. Bodian (1996) showed that the cumulative risk of 
developing cancer was 13% by 10 years, increasing to 26% at 20 years, after which it 
continued to increase, but at a slower rate. The risk of developing breast cancer among 
patients who survived 35 years after diagnosis was 35%. Thus illustrating the continuing 
risk of the subsequent development of breast cancer.
Fisher et al (1996) felt that their recurrence rate was very low, with an incidence of 2.2% 
of invasive ipsilateral recurrences and 1.1% of invasive contralateral recurrences after 5 
years of follow up. They felt that this may be related to the fact that all but 6 of their 
patients had clear margins at surgery and most of the other papers had no data on their 
margin status. All except one of Fisher’s recurrences were picked up by mammography. 
In all cases tested Fisher’s patients were oestrogen and progesterone receptor positive. 
Fisher et al (2003) re-reported his series with 12 years of follow up and stated that 85% of 
the ipsilateral recurrences were detected by mammography.
Zurrida et al (1996) described 157 women with unexpected LCIS who had excision 
biopsies to exclude malignant disease with a mean 5 year follow up there were 4 
subsequent ipsilateral cancers and 6 contralateral cancers. All the recurrences were picked
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up at the early pTl stage and he recommended 6 monthly clinical review and annual 
mammography as surveillance for women diagnosed with LCIS.
Habel et al (1997) only looked at women who went on to get contralateral cancers. 
However, they also looked at the number of years after diagnosis that these contralateral 
cancers developed. They found that a high proportion of these recurrences occurred 
within the first year after initial diagnosis but the total numbers were small. The study also 
compared the relative risk of contralateral invasive disease with 1929 women with an 
initial diagnosis of DCIS and found that the relative risk with DCIS at 5 years was 2.4% 
(4.9% with LCIS) and 6.1% at 10 years (8.3% with LCIS). This demonstrates the 
bilaterality ofLCIS and therefore the bilaterality of risk for the future.
More recent information about the invasive cancer risk comes from the National Surgical 
Adjuvant Breast and Bowel project (NSABP) Tamoxifen prevention trial (Fisher et al 
2000). There were 826 women who had been diagnosed with LCIS, and the rate of 
invasive carcinoma development was 12.99 per 1000 women in the placebo arm. The use 
of Tamoxifen reduced this risk to 5.69 in the treated group. The 5-year risk in the placebo 
arm was 6.47%, which is 3.9 times the risk of an average 60-year-old woman in this 
population.
Levi et al (2005) in a population based study of women with LCIS (n=88) and DCIS 
(n=482) and found that the standardized incidence ratio was 4.6 after a diagnosis of DCIS 
and 4.2 after a diagnosis ofLCIS and was similar with passing time after diagnosis.
Chuba et al (2005) has published the largest study by far with 4853 cases of LCIS 
diagnosed between 1973 and 1998 with 350 recurrences. He excluded all recurrences that
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occurred less than one year after diagnosis to eliminate the possibility of concurrent 
missed diagnosis. The incidence of invasive breast cancer (IBC) was greater with 
increasing age, as one would expect in the general population. For women diagnosed with 
LCIS <40 years incidence of IBC at 10 years was 5.6% compared to 10.4% for patients 
60-69years of age at diagnosis and 13.9% for patients with LCIS over 70 years. The SIR 
(Standardized Incidence Ratio) of observed to expected of all patients was 2.4. He showed 
that this incidence was not different in women diagnosed in the 1973-1985 period 
compared to those diagnosed between 1986-1998. Chuba (2005) also looked at IBC 
events compared to the type of surgery women had received, at 10 years those women 
who had, had a mastectomy had a rate of 5.7% compared to 8.8% in women who had 
received a partial mastectomy.
Su m m ar y
1) There have been many studies looking at the risk of breast cancer following a 
diagnosis of LCIS.
2) A large proportion of them contain women diagnosed many years ago.
3) Comparison is difficult due to varying inclusion criteria and definitions of 
recurrence.
4) In general, the studies show 4-10 times risk of that of the index population.
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P r ed ic tin g  W h ic h  W o m en  A re  M ore  L ik el y  to  H a v e  a  Su bseq u en t  B r ea st  C a n c er
There is little and inconsistent information relating to the risk factors that may predict 
which women will develop invasive disease following a diagnosis of LCIS.
A ge
Bodian (1996) showed a trend towards greater risk with a young age at initial diagnosis 
although the groups were small this was statistically significant. In the group diagnosed 
younger than 40 years of age the relative risk was 8.1 compared to 3.0 in the over 55-year 
age group. Walt (1992) found that younger women were no more likely to develop a 
recurrence.
Familv Historv
Bodian (1996) illustrated that women diagnosed before the age of 40 who also had a 
family history of a mother or sister with breast cancer were at considerable increased risk 
of developing a recurrence although precise estimates were not possible due to the small 
numbers of cases. Conversely in this study, family history had no apparent effect among 
older women.
Carson (1994) found that 2 of 3 of his patients with invasive recurrence had a positive 
family history. However both Rosen (1978) and Page (1991) found that family history 
was not associated with increased risk among their patients. Haagensen (1978) looked at 
the risk of recurrence and family history of an affected mother or sister and found a 
cumulative risk ratio of 13:8 of developing a carcinoma.
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Reproductive Factors
Again Bodian’s data (1996) contained small numbers but did show trends that were 
consistent with the known risk factors for cancer. Those aged 35 years or older at the birth 
of their first child developed cancer following a diagnosis of LCIS with a relative risk of 
8.3, compared with relative risks of 5.3 and 5.9 for younger ages and nulliparous women.
Race
Chuba (2005) found no difference in race regarding subsequent invasive breast cancer. He 
compared women of white, black, Hispanic and other race categories.
P a t h o l o g i c a l  F e a t u r e s  o f  LCIS a t  I n i t i a l  B io p sy
Several authors have addressed the question of whether specific pathological findings of 
the initial biopsy influence the relative risk of developing cancer in the future.
Toker and Goldberg (1977) examined the maximum size of the lesion iii an attempt to 
relate this to other parameters, clinical and pathological, and especially to prognosis. They 
showed the fifteen-year cumulative risk of developing invasive cancer in either breast was 
the same with small and moderate size lesions and a somewhat elevated risk for 43 
women with large lesions, but this was not statistically significant. This study suggested, 
that the size of the lesion may not be related to risk, although, the authors did conclude 
that the risk in the ipsilateral breast may be greater with large lesions. Rosen (1978) 
looked at 10 pathological features to try and predict recurrence and none were found to be 
significant.
Bodian (1996) showed that if the characteristic features of Lobular Neoplasia, in the 
lobule of maximum involvement, was less than 90% (which was only 24 cases) the
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relative risk was only 2.0 compared to 6.0 if 90% of the relevant acini were involved. This 
reflects the fact that those cases with less than 100% involvement, would be classified by 
other pathologists as atypical lobular hyperplasia, which is known to have a lower rate of 
invasive recurrence.
Bodian (1996) also showed a small and non-significant increase in relative risk associated 
with duct involvement. A slightly greater, but still not significant trend related to the 
number of lobules within the specimen that were involved, relative risk of 4.9 if less than 
10% compared to 7.7 if more than 10% of lobules involved.
Ottensen (1993) considered the influence of the number of involved lobules and found a 
significantly greater risk if the number of involved lobules was more than 10 compared to 
those with less than 10 involved. They also found a significant difference in risk 
according to nuclear size and a markedly greater risk for patients with both large nuclear 
size and more than 10 involved lobules, although his study included a group of patients 
with a diagnosis of LCIS and concurrent DCIS. However, in his most recent review of 
these Danish patients (2000) with LCIS alone this was not confirmed and he noted that 
there were at present no biological or morphological markers to allow us to discriminate 
between subgroups of patients with invasive potential.
Fisher (1996) classified his patients as Type 1, 2 and 3 LCIS, which related to lobular 
expansion. One related to slight or no distension, two related to modest distension and 
three to marked ductular and hence lobular distension. This was the only pathological 
factor of 19 factors, which showed statistical significance of increased hazard rate of 
invasive disease and DCIS in his series. With a trend of no increase in Type 1 LCIS, to 
the greatest risk in Type 3. This was confirmed in his 2003 publication (Fisher 2003) with
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fiirther follow up but was only significaut when grade 1 and 2 were compared with grade 
3 for all ipsilateral recurrences. No other pathological factor was predictive of recurrence.
The NSABP P-1 study (Fisher 2000) looked at 15 pathological variables in an attempt to 
predict recurrence but only one was significant in predicting recurrence. That was if the 
LCIS extended into the ductules.
LCIS Associated With Other Benign Pathologv
Again Bodian (1996) looked at the association of Lobular Neoplasia with adjacent 
pathology and found that there was no increased risk of future malignancy if it was 
associated with concurrent atypical hyperplasia, papillomas or cysts.
Recurrent Episodes of LCIS
The patient group used by Bodian (1996) included 232 patients with follow up afl;er a 
single operation for Lobular Neoplasia (LN) of whom 53 developed cancer without any 
additional operations. This was compared to the data from the Connecticut Tumour 
Registry incidence rates for the same ages, follow up times, and calendar years of 
exposure and this gave a relative risk of 4.9 (95% Cl: 3.7-6.4). 16 patients had a second 
operation revealing LN of who 8 subsequently developed invasive cancer or DCIS. This 
exhibits a substantial increase in relative risk to 16.1 (95% Cl: 6.9-31.8), which was 
statistically significant. Only 3 of Bodian’s patients had a third episode of LN and one of 
these subsequently developed a cancer.
Of Carson’s (1994) 51 patients, 7 developed further LCIS indicating multifocal disease of 
which 3 were ipsilateral. These patients were treated with observation alone and at the
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time of writing none of these progressed to get an invasive cancer. Carson felt that a 
further biopsy of LCIS did not add an increased risk of developing invasive disease.
Previous Historv of Benign Breast Disease
Bodian (1996) did not find an increased risk of developing a cancer in patients’ who had a 
confirmed history of benign breast disease or in those who had an episode of benign 
breast disease following their diagnosis of Lobular Neoplasia.
Passage of Time
Both patients and clinicians are keen to know if the predisposition to developing cancer 
after LCIS or LN continues as a patient remains cancer fi*ee over increasing intervals of 
time. In Bodian’s (1996) cohort of patients the risk remained substantially elevated, 
compared to women of comparable ages and calendar years of exposure, for a period of at 
least 20 years after their initial diagnosis. This was true for each age category. The 101 
women who survived beyond 20 years without developing cancer seemed to remain at 
increased risk, but to a lesser extent. As with all studies that show follow up this long the 
numbers in each group are small.
Table 14 lists those studies that have looked at the risk of LCIS at time intervals after the 
initial diagnosis:
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Author 5 years 10 years 15 years 20 years 35 years
McDivitt
1967 
- ipsilateral 
-contralateral
10%
10%
15%
15%
30%
25%
Haagensen
1978
6% 7% 22% 22%
Rosen
1978
3.6% 11.9% 15.5% 25% 40%
Bodian
1996
13% - 26% 35%
Bodian
1996
13% - 26% 35%
Habel
1997
4.9% 8.3% -
Chuba
2005
4.1% 7.1% 11.3%
Table 14: Studies assessing risk o f subsequent disease at time intervals since diagnosis.
Page (2003) reported high relative risks for the first 15 years of follow up, after which 
there was a sharp drop off Rosen (1978) found that there was no decrease in risk over the 
24-year period that he followed women over. He stated that about 38% of women with 
subsequent cancer did not have evidence of disease until at least 20 years after the LCIS 
was found. He felt that studies with 15 years or less of follow up would underestimate the 
subsequent risk of carcinoma. Also the studies with patients with follow up of 25 years 
have so few patients that their significance is doubtful.
Rosen (1981) found that the average interval to infiltrating ductal cancer was 16.3 years 
where as the average time to infiltrating lobular cancer was 20.4 years. Fisher et al (2005) 
found that invasive contralateral recurrences occurred later than invasive ipsilateral 
recurrences, with 70% of invasive ipsilateral recurrences recognized after 5 years 
compared to 44% of invasive contralateral recurrences.
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S u m m ar y
1) There is no conclusive evidence suggesting any patient factors that may predict 
which women will go on to develop breast cancer following a diagnosis of LCIS.
2) Several pathological factors have been suggested, predicting which women will 
develop a subsequent breast cancer, but studies are contradictory.
3) The risk of developing a subsequent breast cancer remains elevated over time, 
with some studies showing risks at > 20 years.
66
T h e  L a t e r a l i t y  o f  S u b se q u e n t  B r e a s t  C a n c e r s  F o l lo w in g  a  D ia g n o s is  o f  LCIS
The risk of invasive cancer seems to affect both the biopsied and the contralateral breast, 
but to what extent remains controversial. Table 15 lists the studies that have looked at the 
laterality of subsequent breast cancers following a diagnosis of LCIS.
Author Treatment Total no o f  
subsequent 
cancers
Ipsilateral Contralateral Bilateral
McDivitt
1967
WLE and 
MX
16 9/40 breast 7 of 47 breasts
Hutter
1969
WLE /MX 15 9 1 5
Giordiano
1973
WLE 2 2 0 0
Gaton
1974
WLE&
MX
1 0 1 0
Salvadori
1974
WLE/MX 5 5 0 0
Wheeler
1974
WLE/MX 4 1/25 WLE 3/32 with 
contralateral breasts
Andersen
1977
WLE only 13 9 2 2
Haagensen
1978
WLE 48 24 24 0
Rosen
1981
WLE 28 12 9 7
Walt
1992
WLE 65 
M xl85
15 1 14 0
Carson
1994
51 WLE 11 3 1 0
Bodian
1996
WLE 48% 39% 13%
Habel
1997
MX only 21 N/A 13 0
Cutuli
1998
17WLE&
DXT
1 0 1 0
Ottensen
2000
WLE 18 16 2 0
Fisher
2001
WLE 16 12 3 1
Fisher
2003
WLE 40 26 14 0
Chuba
2005
Partial
mastectomy
N=3141
26.2%
Incidence
30.5% 
Incidence *
Chuba
2005
Mastectomy
N=1281
0.9%
Incidence
6.2%
Incidence*
Levi
2005
Not stated 11 4 5 2
Table 15: Studies showing the laterality o f  subsequent breast cancers 
Chuba et al (2005) published their subsequent cancers as a cumulative incidence at 25 years.
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It is difficult to make a direct comparison between these studies as the treatment of the 
initial LCIS is variable, as is the definition of a recurrence, and some cases were included 
that had previously had an invasive cancer diagnosed in the contralateral breast. Also 
bilateral disease was sometimes included in the ipsilateral and contralateral group and 
sometimes counted separately.
Most papers suggest that the risk is associated with both breasts but despite this fact it has 
been difficult to demonstrate the lesion in the opposite breast at the time of the initial 
diagnosis of the LCIS. Researchers widely believe that the risk of invasive breast cancer 
after the diagnosis of Lobular Neoplasia is evenly distributed between both breasts 
(Haagensen 1978 & Rosen et al 1981). However, review of the published work showed 
that in some series, it was about two-thirds in the ipsilateral breast and a third in the 
contralateral breast (Fisher et al 2001, Fisher 2003 & Bodian 1996).
Page (2003) looked at atypical lobular hyperplasia in a retrospective cohort study of 252 
women, treated with biopsy alone between 1950 and 1985. He found 50 women 
developed invasive cancer (20%), 68% in the ipsilateral breast and 24% in the 
contralateral, 4% were bilateral and 4% were unknown. Based on these results the authors 
suggested a model of pre-malignancy for women with atypical lobular hyperplasia 
intermediate between a local precursor and a generalised risk for both breasts. London et 
al (1992) showed similar results with twice as many women developing ipsilateral breast 
cancer as contralateral cancer.
Carson (1994) found that all of his invasive recurrences were ipsilateral, the single DCIS 
recurrence was contralateral and 3 of the 7 LCIS recurrences were ipsilateral.
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Ottensen (2000) noted that in his series a high proportion of the ipsilateral recurrences 
occurred in the area of the original lesion although he did not divide the breast into 
quadrants and he felt that this could suggest that LCIS may behave more as a pre- 
malignant lesion and not necessarily a marker of risk. There were 3 out of 8 at the biopsy 
site and 5 at another site.
Fisher (1996) found that all his invasive ipsilateral recurrences were in the same quadrant 
of the breast as the index LCIS. With fiirther follow up (Fisher 2003) this was also the 
case. Rosen’s data (1978) included 3 women with prior breast cancer and once these 
women were removed from the analysis his results found an equal number of women with 
ipsilateral and contralateral recurrences.
Chuha (2005) showed that with the patient having a partial mastectomy the frequency of 
subsequent ipsilateral and contralateral invasive breast cancer was nearly identical, and 
this was true 5 to 25 years after LCIS. In the substantial group of patients who had a 
mastectomy there was a dramatic reduction (although not complete) in the rate of 
ipsilateral occurrences of IBC, 0.5% to 1.0% 15-25 years after mastectomy.
In these studies the percentage of bilateral recurrences was quite varied Newman (1963) 
had 23% while Farrow (1969) had only 10%.
Su m m ar y
1) Published studies show a varied proportion of subsequent cancers in the ipsilateral 
and contralateral breast.
2) Some authors found a higher proportion in the ipsilateral breast, which they feel 
supports LCIS being a precursor lesion.
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H isto lo g ic al  T y pe  & C h a r a c te r ist ic s  o f  a  Su bseq u en t  M a lig n a n c y  F o l lo w in g  
A D ia g n o sis  o f  LC IS
Some of the key studies have looked at the type of malignancy that occurred following a 
diagnosis of LCIS. They are listed below in Table 16. Some of these studies did not 
include recurrence of LCIS as the authors felt that this was not a true recurrence.
Salvadori (1991) commented on whether the recurrence was close to the original biopsy 
and in all 5 of his cases it was distant to initial LCIS, although there was no comment as 
to how far away. Carson (1994) found that all of his invasive recurrences were node 
negative and 2 of the 3 were less than 1cm in diameter. Ottensen (2000) looked at the 
grade of the IDC recurrences seven were Grade 1, one was Grade 2 and one was Grade 3.
Fisher (2001) found all ipsilateral recurrences to be Invasive Lobular cancers. In his 
invasive recurrences where lymph node status was assessed none were positive. With 
further follow up (Fisher 2003), 8 of 9 ipsilateral invasive recurrences were of Lobular 
origin. Rosen (1981) found 54% of ipsilateral and 47% of contralateral recurrences were 
lymph node positive. Sixteen of 32 women died of their recurrence.
Chuba (2005) compared the extent of invasive disease after a diagnosis of LCIS compared 
to patients with a primary diagnosis of IBC, specifically tumour size and nodal positivity. 
Women diagnosed with IBC after LCIS had a larger percentage of tumour less than 1cm 
in diameter (42.9% verses 21.4%) and a higher percentage of lymph node negativity 
(59.7% versus 52.8%).
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Author Invasive Special
Type
DCIS DCIS + 
LCIS
LCIS Total
McDivitt
1967 13 0 0 0 3 16
Hutter
1969 15
20
5 in situ not specified
Giordiano
1973 2 0 0 0 0 2
Salvadori
1974 5 0 0 0 0 5
Wheeler
1974
4 0 0 0 4
Andersen
1977 13 6 19
Haagensen
1978
26 3 9 0 0 38 bilateral counted 
sep
Rosen
1981
33 2 5 0 10 50 (bilateral counted 
separately)
Ringberg
1991 1 3 4
Ringberg
1991 0 1 0 0 3 4
Walt
1992 12 1 1 0 1 15
Carson
1994 3 0 1 0 7 11
Bodian*
1996 32 3 10 0 19 64
Habel
1997 13 0 8 0 20 41
Habel
1997
Only looked 
at
contralateral
disease
10 IDC OILC Only described 
patients >1 
year after 
diagnosis
Cutuli
1998 1 1
Ottensen
2000 13 1 4 8 26
Fisher
2001 5 1 3 2 6 17
Fisher
2003 
Ipsilateral cancers
9 6 1 10 26
Fisher
2003
Contralateral
cancers
10 2 1 1 14
Table 16: Studies that include frequency o f  invasive and non-invasive subsequent breast cancers following a diagnosis o f  LCIS. 
*only 45 o f  the invasive or DCIS recurrences were classified.
These studies are difficult to compare, as the classification and inclusion criteria are all 
different. For example Levi (2005) described his recurrences only as either ductal or 
lobular and did not separate them in to into invasive or in situ recurrences. He found that
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of his 11 recurrences, 5 were of ductal origin, 5 were of lobular origin and 1 was a special 
type cancer. As he was comparing groups of women with DCIS and LCIS, he commented 
that ductal invasive breast cancers were more common after DCIS and lobular after LCIS.
Tvpe of Invasive Recurrence
Some of the studies classified the type of invasive recurrences and they are listed below in 
Table 17.
Author Invasive
Lobular
Invasive Ductal 
+/-D CIS
Mixed ILC 
and IDC
Special type
Giordiano
1973
2 0 0 0
Andersen
1974
9 6 1 0
Rosen
1981
13 20 0 2
Ringberg
1991
0 0 0 1 Tubular
Salvadori
1991
0 5 0 0
Walt
1992
1 9 2 0
Carson
1994
1 1 1 0
Bodian
1996
12 20 0 0
Ottensen
2000
1 9 1 2
Fisher
2003
14 3
Chuba
2005
81 174 10 33
Fisher
2005
5 0 0 1 Mucinous
Table 17: Studies that include histological type o f  subsequent invasive breast cancer following a diagnosis o f  LCIS.
Chuba (2005), with the largest study, also compared the percentage of Invasive Lobular 
Cancer after a diagnosis of LCIS to the percentage of ILC as a primary invasive breast 
cancer (IBC). The histology for IBC was more often lobular (23.1%) after a diagnosis of 
LCIS compared with primary IBC (6.5%), this difference was mostly accounted for by a 
difference in the percentage of invasive ductal cancers (71% for primary IBC vs. 49.7%
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for IBC after LCIS). This has also been shown in other studies: Andersen (1977), 
Haagensen (1978) and Rosen (1978).
Fisher (2003) found that 8 of 9 of his ipsilateral and 6 of 8 of his contralateral invasive 
recurrences that were available for histological review were of the lobular type.
S u m m ar y
1) Several studies have shown a high proportion of invasive lobular cancers 
following a diagnosis of LCIS.
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D e a t h s  D u e t o  B r e a s t  C a n c e r  F o l l o w i n g  a  D ia g n o s is  o f  LCIS
Some of the key studies published data on breast cancer deaths following a diagnosis of 
LCIS and these are listed in Table 18.
Author No of cases LCIS No of Deaths Year after initial 
diagnosis
McDivitt
1967
50 2 Not stated
Hutter
1969
39 1 21
Andersen
1974
47 4 1,9,12,23
Haefliger
1974
17 3 7,11,14
Wheeler
1974
33 1 17
Haagensen
1978
211 6 Not stated
Walt
1992
250 2 Not stated
Singletary
1994
45 3 Not stated
Fisher
2003
180 2 Not stated
Table 18: Studies that have included breast cancer deaths following a diagnosis of LCIS.
Kinne (2005) described 43 cases of LCIS with a mean follow up of 11.5 years (range 5- 
17.4 years) and there were no breast cancer deaths. Fisher (1996) had no breast cancer 
deaths in his 182 patients with 5 years follow up, but at 12 years of follow up (2003) had 
2 deaths.
Salvadori (1991) had no deaths in 78 patients with a median follow up of 58 months 
(range 4-158). McDivitt’s (1967) study described 2 patients with widespread metastatic 
disease at the time of diagnosis of their subsequent invasive recurrence and another 
patient had widespread metastatic disease at the time of writing.
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Rosen (1978) stated that the relative risk of death after a diagnosis of LCIS was 10.7 
compared to women without LCIS (p<0.001), he calculated the number of deaths 
expected in a population from breast cancer using the Connecticut Tumour Registry. 
Sixteen of Rosen’s 32 recurrences died of their disease with an average survival of 4 years 
following diagnosis of invasive disease, which was higher than other author’s results.
In Haagensen’s data (1978) all 6 deaths were in patients who’s LCIS was found 
retrospectively, when the initial pathology was reviewed after a subsequent invasive 
breast cancer. The LCIS was initially missed and they therefore had no follow up and died 
from invasive carcinoma of the breast.
Su m m ar y
1) Many studies have described breast cancer deaths following a diagnosis of LCIS.
2) Although most of these studies are based on women diagnosed many years ago.
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M a m m o g r a ph y  o f  t h e  B r ea st
Mammography of the breast is one of the major tools in breast cancer diagnosis. It 
requires compression of the breast and is taken in the oblique and/or cranio-caudal view. 
Supplementary views are used if an abnormality is detected to further identify its origin 
these include true lateral and magnification or compression views.
Density of breast tissue on mammograms is usually classified by the Wolfe Patterns 
(Eberl et al 2006). This density is an important factor as it affects the ease of diagnosis of 
breast lesions using mammography. Breast density decreases with age and this is the 
reason mammograms are less useful in women under the age of 35. HRT increases breast 
density and can cause diagnostic problems in women who have been taking it for many 
years.
W o lfe  D en sity  C lassifica tio n s
N1 Fatty replaced breasts
PI Mostly fatty with less than 25% prominent duct pattern
P2 Prominent duct pattern involving more than 25% of the breast
DY Sheet like areas of density
Table 19: Wolfe Density Classifications
M a m m o g r a ph ic  A bn o r m a lities
Widespread use of mammographic screening has focused on invasive cancer and DCIS as 
they are commonly identified by mammography alone. Screening mammography has 
changed carcinoma in situ (DCIS) from a rarely seen curiosity to a fi*equently seen entity, 
4% of cancerous lumps and 21% of screened cancers. Invasive cancers are usually seen as 
a spiculated, mass lesion or distortion of the parenchyma whereas DCIS commonly 
presents as microcalcifications. When LCIS has been found by mammographic screening
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it has usually been shown to be an incidental finding. Mass lesions on mammography 
usually relate to invasive disease, simple cysts or fibroadenomas.
Calcifications
Mammographic calcifications were first described by Leborgne in 1951 and he suggested 
that in 30% of all breast cancers, microcalcifications could be detected. Calcifications are 
associated with several benign and malignant alterations of the breast parenchyma. Most 
commonly the calcification is composed of calcium phosphate, often as hydroxyapatite, 
(Caio (P04)s (0H)2) which forms concentric concretions and amorphous masses. Less 
often, calcium oxalate dihydrate (Weddellite) calcification is deposited and this is thought 
to be benign. Calcifications are now a fi-equent mammographic finding and account for 
50% of all biopsies of non-palpable lesions (Monsees 1995). They are formed in the 
breast for numerous reasons and they can be classified as obviously benign, indeterminate 
or suspicious. Calcifications are generally detectable in patients, regardless of the 
background pattern of density on the mammograms, although very fine calcifications may 
be difficult to classify in very dense breasts.
The majority of calcifications that are seen mammographically are classified as benign 
due to their distribution (e.g. diffuse, vascular, scattered or large size > 1mm), (Sickles 
1986 & D’Orsi et al 1993). Calcifications that are highly suspicious of malignancy are 
fine linear or branching in morphology and in a ductal or segmental distribution, with 81- 
92% proving to be malignant in several series (Eberl 2006). Pleomorphic calcifications 
are suspicious, with 41% of such lesions malignant in the series by Liberman et al (1999). 
Punctate and rounded <0.5mm calcifications have been considered probably benign 
(Eberl 2006) with less than 2% proving to be malignant. The remainder of calcifications 
have been considered indistinct or amorphous, because they are too small for definitive
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characterization of their shape even on spot magnification views. The overall rate of 
malignancy among calcifications that are referred for biopsy ranges fi*om 22-37% (Eberl 
2006). The classification of all calcifications is highly subjective. Roubidoux et al (1997) 
and Berg et al (2001) both noted that patient risk factors also affected the likelihood of 
malignancy, when considering the nature of calcifications.
LCIS AND M a m m o g ra p h ic  A b n o r m a lit ie s
To our knowledge, most of the historical papers regarding LCIS imply that there are no 
mammographic features that relate to this disease process and that mammography is not 
helpfiil in its detection. Going et al (1990) described 18 cases with Weddellite 
calcification one of which was associated with LCIS but the calcium was separate from 
the LCIS and associated with benign cystic elements of the breast parenchyma. The 
general feeling is that LCIS is an incidental finding to the mammographic abnormality. 
Carson (1994) stated that although 27% of biopsies for LCIS are done for 
microcalcifications, the pathology shows that the microcalcifications are generally not 
associated with the LCIS.
Several papers have reviewed this question and are summarised in Table 20.
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P a p e r s  I n c lu d in g  C a s e s  o f  LCIS W ith  P o s i t iv e  M a m m o g ra p h ic  F in d in g s
A u th or N o o f  C ases  
o f  L C IS
C ases W ith  M am m ograp h ic  
A b n orm alities
A u th ors C om m en ts C om m en ts/
L im ita tion s
Snyder
1966
27 10 Calcifications on mammography 3 or more random punctate 
or linear flecks were 
indicative o f  LCIS. 
Calcium in neighbouring 
lobules but she felt it was 
helpfiil in preoperative 
diagnosis
Some patients had DCIS 
as well
Hutter
1969
61 13 positive mammograms Calcium rarely located in 
LCIS but in adjacent 
lobules
Some patients had 
previously had 
contralateral cancer.
Dall’Olmo
1975
11 5 suspicious for cancer
Morris
1982
14
26 breasts
3 had a manunographic abnormality 
and LCIS 
13 had LCIS and normal 
mammograms
Felt has not improved 
ability to detect LCIS
All patients presented 
with a mass
Tinnemans
1987
8 7 microcalcifications 
1 mass with microcalcifications
Pope
1988
13 7 microcalcifications 
1 distortion 
1 mass 
2 asymmetry 
2 were cases o f  LCIS within a 
fibroadenoma
Calcifications had no 
distinctive features
There were other women 
in this study but they had 
palpable masses.
Kinne
1989
22 13 positive mammogram 
abnormality not stated
Beute
1991
67 
73 breasts
41 mammogram abnormal 
10 microcalcifications 
10 microcalcifications +density 
6 suspicious mass 
11 benign mass 
4 density/distortion
Veiy varied types o f  
microcalcifications 
5/10 were punctate and 
clustered 
5 cases associated with 
fibroadenomas
Didn’t look and see if  
calcification was in LCIS 
pathologically
Singletary
1991 33
13 Calcifications 
1 Distortion
Sonnenfeld
1991
41 31 calcifications 
7 mass 
2 mass with calcifications 
1 opacity
Wide range o f  number and 
type o f  calcifications 
prompted biopsy
Ward
1992
63 7 abnormal mammogram 
abnormality not stated
Hermann
1993
17 17 calcifications Calcium associated 
pathologically with distinct 
dots with lucent centres
Carson
1994
65 19 abnormal mammograms 
18 calcifications 
1 mass
Mackarem
1994
47 14 abnormal mammograms 
14 calcifications
LCIS always incidental 
finding with calcium in 
benign tissue
4 patients had 
contralateral invasive 
cancer
Singletary
1994 45
46% positive 
18% mass/distortion 
24% microcalcifications
Lantsberg
1999
6 2 calcifications 
4 distortion
5 women were over 50 
years old
Sapino
2000
10 10 calcifications Mainly coarse granular 
calcifications
4 were associated with 
invasive disease
Smith
2001
7 7 calcifications 2 types o f  calcifications 
were noted
2 cases were associated 
with invasive disease
Table 20: Papers that have considered mammographic features associated with LCIS.
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Hutter (1969) three women had bilateral LCIS but only the unilateral mammogram was 
positive. He concluded that mammography was a useful adjunct in these patients but its 
limitations must be understood.
Many of the papers did not correlate mammographic findings with the pathology, to 
ascertain if the calcification identified on the mammogram was in fact related to the LCIS 
pathologically. This is important, as the calcium may be present between the epithelial 
cells of the involved lobules or in the immediately adjacent or even in the distant stroma. 
Those studies that did are listed below in Table 21.
Pope et al (1988) felt that calcifications were not common in LCIS and that it was 
impossible to correlate calcifications on the mammogram to those in the pathology 
specimen. He noted that ofl:en the size of calcium seen in the pathology specimen was too 
small to have been visualized on the mammograms. Although he felt that is many of these 
small calcifications were superimposed on one another within a small volume, they could 
cause one or more grains of calcium to be discernible at mammography. The study 
performed by Lanyi et al (1985) showed that of the 43 patients with microcalcifications 
detected within the LCIS, all were too small to be detected radiologically when they were 
measured at pathological analysis.
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Author No of 
Patients
Calcium in 
LCIS and 
Surrounding 
Tissue
Calcium Only in 
Surrounding 
Tissue
Calcium Only in 
LCIS
Synder
1966 10 0 10 0
Lanyi
1985 43 4 18 21
Singletary
1991 13 0 13 0
Selim
1998 7 Not stated Not stated 3
Sonnenfeld
1991 31 7 21 0
Herman
1993 17 5 8 4
Carson
1994 19 0 15 4
Smith
2001 7 2 0 5
Table 21 : Papers that correlated mammographic findings with pathology.
Sonnenfeld et al (1991) suggested that even when the calcifications were associated with 
LCIS the calcifications had begun in benign tissue and had subsequently been engulfed by 
the LCIS. He did not believe that calcification was part of the pathological process of 
LCIS. He also stated that the calcifications visualized histologically were sometimes 
smaller than those seen at mammography. Calcifications as small as 0.02mm in diameter 
had been noted and some of these could be seen on the magnified images of the 
specimens but not on the preoperative mammograms. The benign processes found in 
Sonnenfeld’s study included sclerosing adenosis, proliferative fibrocystic change, 
intraductal hyperplasia, atypical ductal hyperplasia, and lobular hyperplasia.
Herman et al (1993) felt that the calcium associated solely with LCIS were indistinct dots 
with lucent centres. It was ill defined and of low density. He challenged Sonnefield’s 
(1991) theory that the calcifications predated the LCIS that later developed and 
subsequently engulfed and incorporated them. Herman felt that this was probably not the 
case and that LCIS may be capable of producing certain biochemical changes responsible
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for the calcifications especially if the calcium was packed and of a small diameter. Pope 
(1988) like Herman (1993) also felt that it was possible that certain types of calcium could 
be precipitated by biochemical abnormalities associated with LCIS and other proliferative 
lesions.
Beute (1991) compared his patients to age matched control subjects and their 
mammograms and found that breasts with LCIS had greater than 50% fibroglandular 
density compared to the control subjects, with a higher DY pattern and rarely NI pattern. 
The frequency of DY pattern in postmenopausal women in the LCIS group was double 
that in the control group. He suggested that this increased density of the whole breast on 
marmnography supported the theory that patients with LCIS have a disease of the whole 
breast parenchyma and a spectrum of multifocal lobular abnormalities. He also felt that 
the persistence of the DY pattern or large amounts of fibroglandular density post- 
menopausally supports the concept that mammographically dense breasts are a marker of 
increased cancer risk in women 50 years and older. Breasts fi*om the DY pattern with 
LCIS showed a propensity for bilaterality and multifocality of various forms of lobular 
disease. Pope (1988) in contrast found no difference in density in women with LCIS.
Some authors suggested that those cases of LCIS diagnosed by mammographical 
abnormality may be pathologically different than those that were manunographically 
occult. Sapino (2000) described 10 cases of LCIS that were difficult to distinguish from 
DCIS on mammography. Pathologically they were different from the classical LCIS, with 
larger nuclei, a greater degree of pleomorphism and central necrosis. She felt that 
mammographic screening selected this specific variant of LCIS and that it should be 
regarded as a more aggressive lesion than the classic LCIS and that its treatment should 
reflect this, by mastectomy. The coarse rounded calcifications were suggestive of a
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lobular location and the central necrosis fitted in with the diagnosis of Lobular Neoplasia 
Grade 3 described by Travassoli (1997). These cases showed marked lobular distention, 
numerous neoplastic lobules and large nuclear size, i.e. all the features recognized as 
aggressive parameters in LCIS.
Smith et al (2001) looked at 7 cases of mammographically detected LCIS all had calcium 
in the lobules affected with LCIS and were selected for this reason. Five of these patients 
had large calcifications with central necrosis and the lobule was distended to the shape of 
the calcification, the cells in these cases were larger and pleomorphic. In 2 patients the 
calcification was identical in morphology to that present in the surrounding tissue and the 
cells were small and uniform -  the classical form. So in contrast to Sapino (2000) no 
mammographic features distinguished between the two types of LCIS. Almost all of the 
calcifications were equal to or smaller than 0.5mm but they varied in size. All 
calcifications were high in density and punctuate in shape. None were branching, 
amorphous or indistinct. The authors felt that there were two types of calcifications found 
pathologically, one had a common appearance to the surrounding calcifications in benign 
proliferative change and the other was reminiscent of comedo necrosis found in DCIS. 
Tavassoli (1998) noted that necrosis does rarely occur in LCIS and that it does not 
necessarily imply ductal growth. Smith like Sapino (2000) summarised that pleomorphic 
LCIS may warrant further excision after core biopsy and that classic LCIS with non- 
necrotic calcifications may not warrant further tissue excision, particularly if similar 
calcifications are noted in adjacent benign tissue without other atypical findings.
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B r ea st  B io psies Per fo r m e d  fo r  M a m m o g r a ph ic  A bn o r m a l it ie s
Abnormalities found on mammography will often lead to fiirther investigation such as a 
biopsy. Several papers have looked at the frequency of LCIS foimd at biopsy for specific 
mammographic abnormalities and are listed below in Table 22.
It can be seen from Table 22 that LCIS is an infrequent finding when biopsies are 
performed for mammographic abnormalities. Ward et al (1992) stated that as only a small 
proportion of cases of LCIS had a mammographic abnormality there would be a less 
dramatic rise of LCIS cases with screening of its incidence compared to DCIS.
No. of Needle 
Localisation Biopsies
Total no. of 
Malignancies
No. of LCIS 
cases
Tinnemans
1987
359 118 8
Pope
1988
820 319 26
Petrovich
1989
106 13 3
Meyer
1990
1261 275 38
Papapestas
1990
475 149 8
Bauer
1991
2077 284 15
Miller
1991
530 90 5
Sonnenfeld
1991
2184 437 48
Perdue
1992
536 69 2
Herman
1993
1245 17
Opie
1993
332 48 1
Lantsberg
1999
438 149 6
Berg
2001
150
Amorphous
Calcifications
30 malignant 
30 high risk 
lesions
1
(plus 8 ALH)
Berg
2001
442
all calcifications
91 18 LCIS or ALH
Cangiarella
2001
160
Mammotome Biopsies 
All for Calcification
17
12 Atypical 
lesions
1
Table 22: LCIS cases identified when biopsies were performed for mammographic abnormalities.
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Mackarem et al (1994) noted that after his institute commenced mammographic screening 
the proportion of women diagnosed with LCIS solely on mammographic abnormality 
increased from 20% to 37%. He also concluded that the advent of mammographic 
screening had not dramatically increased the total number of cases of LCIS identified. He 
felt that this increase in diagnosis was related to the increased activity in the degree of 
biopsy activity.
T he  A c c u r a c y  o f  Pr e -o per a tiv e  T issu e  B io psy  o f  LC IS
Several papers with small numbers of patients have documented the difficulty in the pre­
operative tissue diagnosis of cases of LCIS. There are two ways of identifying breast 
lesions pathologically pre-operatively, core biopsy and fine needle aspiration.
Needle Core Biopsv (NCBI
Core biopsy is a technique used to obtain tissue for histological diagnosis in situations 
where there is a mammographic or clinical abnormality. It is usually done using a 14 
gauge needle and can be done free hand, under ultrasound guidance or stereotactically. 
Percutaneous image guided core breast biopsy is most often performed for non-palpable 
lesions detected by mammography.
Core biopsy results are classified as follows;
B1 = Normal breast tissue.
B2 = Benign breast disease.
B3 =Lesions of uncertain malignant potential (papillomas, LCIS).
B4 = Suspicious of malignancy.
B5 = Malignant disease (B5a = in situ, B5b = invasive).
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Recently there has been intense debate as to what the management of a patient should be 
if LCIS is foimd at stereotactic core biopsy, of a mammographic lesion. The debate hinges 
around whether there may be missed associated invasive disease adjacent to the LCIS or if 
core biopsy is accurate enough to distinguish LCIS from DCIS or from Invasive Lobular 
Carcinoma i.e. whether the CNB specimen provides an accurate representation of the 
mammographically detected target lesion. Clinically this means the difference between 
performing a surgical biopsy after a CNB of LCIS and adopting a ‘close surveillance’ 
approach without further biopsy.
The concerns of leaving a biopsy containing LCIS are fuelled by studies such as Wheeler 
et al (1974) stating that LCIS was associated with invasive disease in 66% of cases and 
Sapino (2000) stated that 40% of florid LCIS is associated with concurrent Invasive 
Lobular Carcinoma. Carson (1994) found that of 149 cases of LCIS identified, 84 or 56% 
had a synchronous invasive cancer or DCIS. Carter (1977) found 6% of LCIS at biopsy 
was associated with ILC at subsequent mastectomy and Shah et al (2005) found a rate of 
invasive carcinoma in 5% of patients at mastectomy for LCIS. These studies make 
clinicians wary that a diagnosis of LCIS on CNB may be missing these commonly 
associated invasive or pre-invasive disease processes.
There are several small studies that have tried to address this issue which are mostly 
retrospective. They involve cases of LCIS diagnosed on core biopsy, that have 
subsequently gone on to have a surgical biopsy and then there is a comparison between 
these two pathological findings. The studies are limited to small numbers mainly due to 
the fact that LCIS is relatively uncommon. Table 23 lists those studies that have addressed 
this issue.
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Author No. o f cases o f LCIS 
on CNB
No. with Carcinoma 
at subsequent 
surgical Biopsy
Comments
Lechner
1999
58 20% invasive 
14% DCIS
Liberman
1999
14 3 2 DCIS 
1 ILC
Hyser
2000
4 2 ILC
Philpotts
2000
5 1 DCIS
Berg
2001
8 0 1 ADH
O’DriscolI
2001
7 3 1 ILC 
2 DCIS
Pacelli
2001
14 0
Renshaw
2002
9 0
Shin
2002
14 3 2 DCIS 
1 ILC
Verkooijen
2002
26
Included cases of ALH
6
Crisi
2003
9 2 2 ILC
Middleton
2003
14 6 6 Invasive disease
Foster
2004
12 4 1 IDC, 1 ILC 
2 DCIS
Elsheikh
2005
13 4 IILC 
4 DCIS
Table 23: Papers addressing pathology o f  further excision when LCIS is identified in NCB biopsies.
Liberman (1999) suggested that with the increased use of core biopsies there would be an 
increase in the number of cases of LCIS diagnosed. She felt that further surgical excision 
is warranted if there is discordance with mammographic findings, coexisting atypia, or 
radial scar, or if the pathologist cannot distinguish between LCIS and DCIS in the core 
specimens. Arpino et al (2004) separated biopsy specimens into LN and LN with ADH 
and showed that 3 out of 21 of the LN only contained malignant disease at surgical 
excision compared to 4 out of 12 when there was LN and ADH and suggested that like 
ADH when LN is found on core biopsy a surgical excision should follow. Renshaw et al 
(2002), Cardenosa et al (1991) & Middleton et al (2003), agreed with Liberman (1999) 
although Cardenosa (1991) admitted that if the cells distending the lobular elements were
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pleomorphic, LCIS would be difficult to distinguish from DCIS that extends into the 
lobules, on a core biopsy specimen.
Others believe that surgery should always be recommended. Reynolds (2000) said that as 
there is a high proportion of cases of LCIS with invasive disease found nearby at surgical 
follow up and that DCIS co-existent with LCIS is not rare. Excision biopsy should always 
be performed after a CNB of LCIS. Shin et al (2002) recommended that surgical excision 
was always necessary. Crisi et al (2003) also described in their study of 35 patients, with 
Lobular Neoplasia found on core biopsy, whom were followed up for 3 years, and 5 were 
subsequently diagnosed with invasive carcinoma within that time. This represented a 4.7 
fold increase/year when compared with the generally accepted 1% annual risk following a 
diagnosis of LCIS on excision. It was, therefore their feeling that all cases should have an 
immediate excision biopsy.
With the use of E-Cadherin immunohistochemical staining increasing, Jacobs et al (2002) 
suggested that this would make it easier to discriminate between ductal and lobular 
lesions at core biopsy. Although, he felt that it would still be prudent to recommend 
excision, if the routine histological features were ambiguous until additional data becomes 
available.
The second generation of NCB devices, such as Mammotome, use vacuum assistance to 
draw the tissue into the needle and permit the use of larger-calibre needles (usually 11 
gauge). One of the major advances of the vacuum assisted devices over the more 
traditional biopsy gun is the procurement of larger volume tissue specimens.
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Damascelli et al (1999) used the larger ABBI (Advanced Breast Biopsy Instrumentation) 
system, which has a variety of cannula up to 2cm in diameter and allows the removal of 
larger volumes of tissue. He found that 1 of his 2 cases of LCIS contained concurrent 
DCIS at surgical excision and suggested that even these larger biopsy systems could not 
prevent the need for further surgical excision in cases of LCIS. Although, other authors 
have suggested that the use of these larger biopsy guns will make sampling of LCIS more 
accurate (Jacobs 2002).
Most of the authors discussed above recognised that their studies were small and that a 
large study is required to try and answer this dilemma regarding the finding of LCIS in a 
percutaneous biopsy specimen. However, they seem to be split into two camps, those who 
believe that all cases of LCIS at CNB should be followed by surgical excision and those 
who think that as long as there is concordance between radiology and pathology and that 
there is no association with another high risk lesion LCIS at CNB can be left to close 
surveillance.
P r e -o p e r a t iv e  T issu e  D ia g n o s is  o f  LCIS w it h  F in e  N e e d le  A s p ir a t io n  (FNA )
This is one of the ways of making a pre-operative diagnosis in breast disease and involves 
the passage of a green needle, 22 gauge, through the abnormality and the harvest of cells, 
which are then spread onto slides and either air dried or fixed in formalin and reviewed 
under a microscope. The result is graded according to the level of suspicion. Martin and 
Ellis first reported fine needle aspiration of breast tumours in 1934. It was however, not 
used initially for fear of tumour spread. Franzen and Zajicek (1968) re-introduced the 
technique in 1960 and it is now widely used. The grading used in FNA is listed below.
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Cl = Inadequate sample (not enough cells to make a confident assessment).
C2 = Benign.
C3 = Suspicious probably benign.
C4 = Suspicious probably malignant.
C5 = Malignant.
Ustun et al (2002) looked at 21 patients with LCIS and their pre-operative FNA, some of 
these had previously had a breast cancer. The results were as follows; Cl =6, C2=8, C3=3, 
C4=2, C5=2. When he reviewed the slides he felt it was possible to diagnose 9 of 21 as 
LCIS on cytological examination. He felt that it was possible to separate ADH, DCIS and 
LCIS with confidence on FNA. Masood et al (1990) reviewed cases of LCIS and stated 
that cytologically he could differentiate it fi*om ILC due to its monomorphic and well 
differentiated appearance but he recognised that there would be a degree of false negative 
results. Salhany et al (1989) also felt that it may be possible to distinguish between LCIS 
and ILC but not between LCIS and ALH on FNA.
Ringberg (1991) described 11 patients with LCIS who had a pre-operative FNA and only 
2 were suspicious of malignancy, the rest were benign. More recently Ustun et al (2002) 
reported a series of 21 cases of histology -  proven LCIS, 8 out of 21 of the FNA’s showed 
cell groups diagnostic for or compatible with LCIS, 2 out of 21 were felt to resemble 
Invasive Lobular Carcinoma on FNA and the remaining 11 aspirates were diagnosed as 
benign or non-diagnostic. The authors felt that the main difficulty of diagnosing LCIS on 
FNA was sampling error. They also felt that it was particularly difficult to differentiate 
between pleomorphic and dissociated LCIS fi*om Invasive Lobular Carcinoma. Ayata et al 
(2005) found no features specific to LCIS that would have allowed pre operative 
diagnosis on FNA.
All of the above papers show that the diagnosis of LCIS on FNA is generally inaccurate.
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LCIS AND F ibr o a deno m as
Several of the studies discussed previously have noted LCIS detected both within and 
adjacent to a fibroadenoma. Pick et al (1984) stated that LCIS represented 41 of the 
malignancies observed in 62 cases of carcinoma within a fibroadenoma. He felt that this 
probably related to the common lobular origin of the epithelial components of both 
fibroadenomas and LCIS. The coexistence of fibroadenomas and LCIS was discovered in 
0.2% of cases of consecutive breast biopsy specimens by McDivitt (1967) and the authors 
concluded that the true prevalence of cancer in a fibroadenoma was low enough to make it 
clinically irrelevant.
Ottensen (1993) described 8 of his 100 cases of LCIS associated with a fibroadenoma, all 
of which presented as a palpable lesion in the breast. Andersen (1974) found 3 of 64 cases 
of LCIS associated within a fibroadenoma. Other authors have reported single cases of 
LCIS and fibroadenomas (Stafyla et al 2004), however the clinical implications of dual 
findings are uncertain.
LCIS and Radial Scars
Radial scars and complex sclerosing lesions (those >10mm) are benign pseudo-infiltrative 
lesions characterised by a central zone of fibro-elastosis fi*om which epithelial structures 
radiate out to produce an architectural pattern reminiscent of a flower head. Their major 
diagnostic significance lies in their resemblance to low-grade infiltrating carcinomas both 
macroscopically and histologically. Also, studies have shown that women with a radial 
scar had a twofold increase in breast cancer risk, independent of the category of benign 
breast disease. The larger lesions are also visible on mammography where they are
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virtually indistinguishable from infiltrating carcinomas. Consequently, their clinical 
importance has increased with the introduction of mammographic screening.
Sloane et al (1993) looked at 126 cases of radial scars to assess their relationship with 
malignancy and atypia. Although not all were mammographically detected and their entry 
criteria varied considerably, they found 3 cases of associated LCIS, amongst a total of 27 
associated with atypia, in situ or invasive carcinoma. This was related to the increasing 
age of the patient and size of the radial scar, it was more common in lesions greater then 
7mm and in women over the age of 50. They concluded that all radial scars found by 
mammography should be excised and subjected to thorough histological examination.
LCIS Presenting as a Mass
It has previously been thought that LCIS could not form a mass effect that is visible on 
mammography, however in the recent literature Stein et al (2005) documented a case of a 
9mm hypoechoic, micro-lobulated mass seen on mammographic screening. This was later 
confirmed to be LCIS with no other pathology accounting for the radiological mass.
Sum m ar y
1) Mammography is not regarded as an effective way of identifying LCIS.
2) Mammography is not regarded as an effective way of assessing extent and 
bilaterality of LCIS.
3) There is a necrotic form of LCIS that often contains calcifications and cells that are 
pleomorphic but its clinical prognosis is not known -  it has been speculated that it 
may behave more like DCIS.
4) There are contrasting views on what should be done if LCIS is found at core 
biopsy.
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O t h e r  Im a g in g  M o d a lities  a n d  LCIS
Ultrasound and LCIS
Hamada et al (2000) identified LCIS by ultrasound in 2 women who were being followed 
up for a previous breast cancer. In both of these cases the lesion was less than 5mm and 
not palpable. The ultrasound revealed an irregular margin to the masses and biopsy was 
performed under ultrasound guidance. Pure LCIS was diagnosed in both cases, showing 
like Stein (2005) LCIS can form a mass which can be identified on ultrasound.
Magnetic Resonance Imaging (MRU and LCIS
Magnetic Resonance Imaging (MRJ) is being used increasingly to image the breast and 
several papers have documented the ability to detect LCIS with MRI (Lee et al 2003, 
Bluemke et al 2004 & Kriege et al 2004).
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M a n a g e m e n t  o f  LCIS
The uncertainties about the biological significance of a diagnosis of LCIS have caused 
considerable confusion and debate regarding its management, and its treatment has vexed 
both surgeons and patients for many years. Treatment of LCIS has changed over the years 
in parallel with the change in thinking about its natural history.
Mastectomv for LCIS
Foote & Stewart found that one of their original cases developed infiltrating malignant 
disease and nodal metastasis within a few months of diagnosis, although this may have in 
fact been present at the time of diagnosis but had merely not been represented in the 
biopsy specimen. This then led them to state that ‘it is our feeling that simple mastectomy 
is essential’ (Foote 1941). Thus mastectomy became the treatment for LCIS worldwide in 
the 1940s and 1950s. Furthermore with the discovery of the bilateral nature of the 
condition many surgeons were routinely performing bilateral mastectomies.
When the prevailing opinion was that progression to invasive disease was inevitable, 
treatment was straightforward, however, when it became apparent that the majority of 
patients did not develop invasive disease the concepts became more complex. Haagensen, 
working in the Surgical Pathology Department at Columbia Presbyterian Medical Center, 
USA, was the first to question the inevitability of this progression. He was sufficiently 
convinced of its benign nature to change the name to Lobular Neoplasia, as discussed 
earlier (1978).
Some surgeons felt that mastectomy was still necessary to exclude invasive disease close 
to LCIS, as the two processes are known to have a close association. Salvadori (1991), 
however found no invasive disease in 33 cases that either had mastectomy or wide
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excision. Recently, Garreau et al (2005) found that 11 of 54 women with LCIS diagnosed 
recently were treated with bilateral mastectomy, showing that there is still a wide 
variation in surgical treatment.
Conservation and Observation for LCIS
In an era where conservative treatment is curative for small invasive tumours, it became 
difficult for the surgeon to suggest, and for the patient to accept, the old idea of bilateral 
mastectomy for LCIS simply to avoid the risk of possibly later developing an infiltrating 
carcinoma. This in conjunction with Haagensen’s (1978) views that progression to 
invasion was far from inevitable and with papers quoting a 20% risk at 20 years after 
diagnosis of LCIS (Rosen 1978), meant that the medical profession began to doubt that 
mastectomy was the correct management for LCIS. From the 1970s some surgeons began 
performing less radical surgery in the form of wide local excision, and used clinical and 
mammographic follow up to identify any subsequent breast cancer as early as possible. 
There remained however, a divide between clinicians and it was particularly difficult for 
patients when one surgeon was recommending a bilateral mastectomy and another a 
‘watch and wait ‘policy with no active treatment (Knapick 2001).
Although efforts have been made to identify patients who are more likely to go on to 
develop invasive disease none have been conclusive enough to be able to influence 
treatment options.
There would be little debate about treatment if there were a truly effective method of 
surveillance available. Haagensen (1978) initiated this policy of observation with close 
follow up and patients were seen every 4 months with annual mammography in the 
expectation that if a cancer developed, it would be detected early enough to institute
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successful treatment. However, there is current world wide debate about the effectiveness 
of mammographic screening for LCIS and as the risk of patients with LCIS spans 25 
years then these patients would be coming to the clinics hundreds of times if reviewed 
four monthly. Haagensen (1978) did however find that most of the breast cancer deaths in 
his LCIS series occurred in women who had failed to return for follow up.
Despite all the concerns involving methods of follow up, in general the current surgical 
treatment of LCIS is excision for diagnostic purposes and some form of follow up. Debate 
remains, however, on both of these issues. The goal of follow up /observation is to detect 
a subsequent cancer at the earliest possible stage.
Diagnostic Biopsv for LCIS
As LCIS has mainly been an incidental finding after biopsy for another breast lesion it is 
usually found either on core biopsy or/and surgical excision. There is much debate in the 
literature regarding the management of LCIS at core biopsy and this has been discussed 
earlier. About two thirds of Invasive Lobular Carcinomas have associated LCIS/ALH, 
significantly more than IDC (Dixon et al 1982).
Follow Up/ Surveillance
The recommendations in the literature, for the type and length of follow up for patients 
with LCIS, are varied and are not based on any clinical trials. Simmons et al (1999) 
suggested clinical follow every 3-4 months with annual mammography whereas Dershaw 
(2000) recommends annual mammography only.
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Haagensen (1978) described 202 patients followed up, by 4 monthly breast examination, 
by a clinician with no mammography, and 28 patients subsequently developed breast 
cancers, 73% of these were node negative and he suggested this degree of follow up 
resulted in the detection of early stage disease. Rosen (1978) followed Haagensen’s lead 
and recommended 4 monthly follow up for life, he did however, add that the addition of 
mammography would help detect small invasive disease.
Bodian (1996) who has published data on Haagensen’s patients subsequently recommends 
‘the need for frequent and careful follow up\ Salvadori’s (1991) patients were followed 
up with annual mammography and 3 monthly clinical breast examination. Garreau (2005) 
looked at the management of 54 women diagnosed with LCIS and found that 
recommendations from the treating physicians were that 64% recommended annual 
mammography.
Further imaging techniques such as MRI have been implicated in the observational follow 
up and assessment of the opposite breast (Lee 2003 & Kriege 2004).
Margins of Excision
Many surgeons felt that once they had decided that this was a lesion that served as a 
marker for risk, and not a precursor lesion the need for re-excision of biopsy sites and 
clear margins became irrelevant (Haagensen 1978 & Bodian 1996). Therefore, the 
majority of clinicians do not excise LCIS to clear margins. Those clinicians that believe 
LCIS to be a precursor lesion excise to clear margins, even if that means mastectomy 
(Dershaw 2000). In DCIS, which is believed to be a true precursor lesion, the excision to 
clear margins is paramount in the reduction of the risk of local recurrence of either more 
DCIS or invasive disease.
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Radiotherapy
Radiation therapy has been applied sporadically for LCIS. One paper by Cutuli et al 
(1998) described 17 women with LCIS who had conservative surgery and whole breast 
unilateral irradiation, 12 of whom also received Tamoxifen for two years. After a median 
follow up of 88 months one woman developed an infiltrating recurrence 20 months after 
the first surgery, it was however in the contralateral breast. The author went on to report 
longer follow up (Cutuli et al 2005) on 25 women, with a median follow up of 153 
months, and one local recurrence was observed. This is a very small study and is 
confounded by the use of Tamoxifen, which may be causing some risk reduction.
There have been is no large systematic studies of radiotherapy for LCIS management but 
also there is no evidence of radioresistance. Many authors believe it makes little sense to 
irradiate a marker of risk, and the bilaterality of any such risk would mean bilateral 
radiotherapy, which is not without significant risks. This is especially important to those 
authors who believe the risk of progression to invasive disease is low.
Tamoxifen
Tamoxifen is a SERMS 3, which are oestrogen antagonists and reduce the risk of breast 
cancer by reducing the rate of cell division. Randomised controlled trials of Tamoxifen 
have shown a significant reduction in deaths fi-om breast cancer and a significant 
reduction in contralateral cancers (EBCTCG 2005). This has led on to the concept that it 
may be of use in breast cancer prevention and was investigated as such in several large 
randomised controlled studies.
The National Surgical Adjuvant Breast and Bowel -  PI Study (NSABP-Pl) began in the 
USA in June 1992 and recruited high-risk women into three groups for a double
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blind/randomised prospective study. This included (1) women aged 35-59 with no 
additional risks for developing breast cancer, (2) women with a 5 year predicted risk of 
developing breast cancer of greater than 1.66% or (3) women with proven LCIS. The Gail 
Model was used for risk prediction, which was developed by Gail et al (1999) to predict a 
woman’s likelihood of developing breast cancer based on her age and certain other risk 
factors, such as family history. The women with LCIS were evaluated in a separate arm of 
the trial and were found to have more than twice the risks of other participants in the 
placebo arm of the trial, using the Gail Model.
The end points of the study were the development of invasive or non-invasive breast 
cancer, myocardial heart disease, fractures and endometrial cancer. There was a mean 
follow up of 47.7months. In the LCIS arm of the trial there were 836 women, 415 of 
whom received Tamoxifen and 411 received the placebo. In the Tamoxifen group there 
was a highly significant reduction in the risk of invasive and in situ disease, with 244 
breast cancers in the placebo group and 124 in the Tamoxifen group. Tamoxifen reduced 
the incidence of invasive breast cancer by 56% in women with LCIS and, even more 
dramatically in, by 86% in women with atypical hyperplasia. The risk reduction due to 
Tamoxifen was seen in the first year and all subsequent years. The reduction in risk was 
only in oestrogen receptor positive cancers, higher in smaller tumours and in lymph node 
positive tumours.
The risks of Tamoxifen treatment were shown to be an increase in the endometrial cancer 
rate although they were all Stage 1 cancers when diagnosed. There was also a higher 
incidence of ischaemic heart disease events in the Tamoxifen group but there were less 
fatal myocardial infarcts. There were more vascular events in the Tamoxifen group, 
including cardiovascular accidents, pulmonary emboli and deep vein thrombosis.
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The Tamoxifen group also had more cataracts. The placebo group had more hip, Colles 
and spinal fractures but this was not significant. Overall there were more deaths in the 
placebo group with the increase in cancer deaths outweighing the increase in vascular 
deaths. There were also quality of life issues in that women on Tamoxifen had a reduced 
quality of life compared to the placebo mainly related to hot flushes. The patients with 
LCIS treated with placebo, had an annual subsequent breast cancer rate of 12.98/1000.
Two European studies have attempted to add to this study by also treating women with a 
higher than normal risk of developing breast cancer with Tamoxifen. Veronesi from 
Milan, Italy (et al 1998) and Powles T. from the Royal Marsden Hospital, London (1989) 
failed to show a significant benefit of Tamoxifen in high-risk women. However, in the 
Italian trial there was not a separate category for women with LCIS, and the English trial 
contained no women with LCIS.
Gareau et al (2005) assessed 55 patients with LCIS and found 14 had been put on 
Tamoxifen after their diagnosis. Hershman et al (2002) suggested that the use of 
Tamoxifen in women with LCIS would prolong survival by 27-70 days with the most 
benefit seen if initiated at the age of 35, and that’s its use seems to be cost effective. 
Tchou et al (2004) reviewed 219 women with a high risk of developing breast cancer and 
found that the main predictor of being offered and accepting Tamoxifen chemoprevention 
was a diagnosis of LCIS or ALH. 42% of women offered Tamoxifen took the drug.
Researchers in America are now undertaking the STAR or P2 trial to compare Tamoxifen 
with Raloxifene for breast cancer prevention following the success of the PI Trial. The
1 0 0
aim is to include 22,000 postmenopausal high-risk women and hopefully reduce the 
unwanted events that Tamoxifen treatment produces.
In 2001 the Canadian Task Force on Preventative Health Care and the Canadian Breast 
Cancer Initiative’s Steering Committee on Clinical Practice published guidelines for 
chemoprevention in the Canadian Medical Association Journal (Levine 2001). They felt 
that there was fair evidence to recommend counselling women at higher risk, LCIS 
included, about the potential benefits and risks of Tamoxifen therapy to reduce the risk of 
breast cancer, and hence support individual choice.
HRT Therapv Following the Treatment of LCIS
There is still debate regarding the use of HRT to control oestrogen deficiency problems 
after local breast cancer therapy. There have been several small trials of post-menopausal 
women receiving HRT after successful local breast cancer treatment showing an 
improvement in oestrogen deficiency symptoms with no increased relapse rate after HRT. 
A national trial began in the United Kingdom to ascertain the risk-benefits of such a 
treatment being used but it was stopped due to the reporting of two Swedish studies 
suggesting adverse events (Mueck et al 2007).
Contralateral Biopsv at Time of LCIS Diagnosis
There has been some controversy about contralateral biopsy in the treatment of LCIS. 
Singletary (1994) performed contralateral surgery on 27 patients; 18 had mastectomies 
and 9 had contralateral biopsies. None of the random biopsies showed tumour and 4 of the 
contralateral mastectomies showed additional LCIS.
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Bilateral Mastectomv in the Century as a Treatment for LCIS
Due to the bilateral predisposition of the subsequent invasive carcinoma with LCIS some 
patients choose to have bilateral prophylactic mastectomies to decrease this risk. Those 
patients with a strong family history or especially those who have tested positive for the 
BRACl or BRAC2 breast cancer genetic mutations may also consider this. Another group 
of women where this may be an appropriate procedure, are those who suffer extreme 
psychological anxiety relating to their increased risk. Some women have such an 
incapacitating fear of developing breast cancer, that it adversely affects their quality of 
life. Unfortunately, this anxiety may actually lead to diminished adherence to regular 
mammographic, clinical and self-breast examination (Kash et al 1992).
Hartman et al (1999) showed that in a high risk group the risk reduction of bilateral 
mastectomies could be greater than 90%. It is important, therefore, that the patient be 
informed and understands that bilateral prophylactic mastectomy does not completely 
eliminate the subsequent risk of developing breast cancer.
Sum m ar y
Patients and surgeons are faced with difficult choices of the various treatment options for 
LCIS:
1) Observation - recognising the limitations of clinical and mammographic 
surveillance.
2) Chemoprevention, with Tamoxifen -  trials show risk reduction but significant 
treatment side effects.
3) Ipsilateral mastectomy with contralateral biopsy, with the fate of the opposite 
breast dependent on the biopsy result.
4) Bilateral mastectomy -  with a risk reduction of >90%
1 0 2
Despite the reluctance of many surgeons to do mastectomies for LCIS there is still a role 
for this as a form of treatment. Some women will find the risk of surveillance 
unacceptable and with the advancement in reconstructive techniques mastectomy is not 
now the mutilating operation it once was. In all cases of treatment of breast cancer the 
emotional impact of surgery has to be balanced against the patients’ anxiety about breast 
cancer and this is clearly a personal choice. The informed patient must therefore select 
fi-om among the choices above which will best satisfy her medical as well as psychosocial 
needs.
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S u m m ar y  o f  L itera tur e  R e v iew
There are many studies describing the important features of LCIS. The majority of these 
are based on patients diagnosed many years ago and contain small numbers. These studies 
are often difficult to compare due to variables in the inclusion criteria and description of 
subsequent events. Pathologists are, with discussion and debate, beginning to formalise 
the criteria necessary for a diagnosis of LCIS although there are still some aspects in 
which they remain divided.
The true incidence of LCIS remains unknown but population studies show that the 
number of cases being identified is rising. LCIS is, however, rare in comparison to other 
breast cancers. Risk factors for LCIS are similar to other cancers but studies have shown a 
higher rate of associated family history than with other cancers. At present most studies 
include younger women diagnosed with LCIS. This is likely to reflect on the way in 
which diagnosis occurs and with the increase of breast screening and the increase in the 
number of biopsies being performed in the older age group, recent studies are showing an 
increase in older women being diagnosed with the condition.
The studies have all shown that LCIS is a powerful risk factor for developing breast 
cancer, with most showing a 4-10 times risk of that of the index population. Though as yet 
no study has been able to find any patient or pathological features that predict which of 
these women are at a higher risk of developing a subsequent breast cancer. Some of the 
studies have looked at these subsequent breast cancers to attempt to determine whether 
LCIS is a marker of risk or a precursor lesion. Those authors finding high rates of 
invasive lobular cancers suggest that LCIS is a precursor.
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Few studies have found that LCIS has any distinguishing manunographic features and 
only a handful have provided mammographic -  pathological correlation of these. 
However some authors have described a very small numbers of cases of LCIS, which 
have formed calcifications, they have noted that it is usually the pleomorphic form that 
does so.
The management of LCIS has changed dramatically over the last 60 years but there is still 
a diversity of management from core biopsy and surveillance to bilateral mastectomy. 
These studies reviewed have provided some evidence into the nature of LCIS but there are 
still a plethora of unanswered questions relating to this elusive lesion.
In 1980 Rosen wrote that because of the scarcity of patients in most institutions and the 
need for long-term follow up, most investigators are discouraged from attempting 
prospective studies into LCIS. He stated that had a prospective study been started when 
the first retrospective studies began there would have been 10-15 years of follow up in 
1980 and this would have been 25-30 years now.
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CHAPTER THREE
AIMS OF THE STUDY:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Nu Au Braclet - Francine Van Hove
Aims and Objectives
At the time of the study start no consensus existing regarding diagnosis or management of 
LCIS. There was debate within the clinical conununity regarding whether LCIS can be 
screen detected or not, what the optimum pathological tests for LCIS are, and whether 
people with LCIS should receive more intensive follow up than people without. We aimed 
to answer these questions. The hypotheses explored in this thesis, therefore, are as 
follows:
LCIS can not be screen-detected
- The risk of developing breast cancer does not differ between women with LCIS 
and women without LCIS
- Adding E cadherin, Cytokeratin 34B E l2, Cytokeratin 5/6, Mucin staining and 
oestrogen receptor staining to the diagnosis of LCIS based on histopathology does 
not improve the ability to confirm the diagnosis.
Specifically our objectives were:
1. To identify all women diagnosed with LCIS within NHSBSP since its inception;
2. To obtain mammograms, pathology specimens, hospital notes and general 
practitioners’ records for each of these women;
3. To evaluate the mammograms obtained with respect to the following:
a) whether the LCIS was identifiable on mammography and if so,
b) what the defining characteristics of LCIS are on mammography
c) and whether screen-detected LCIS is associated with a different prognosis 
than incidental LCIS and therefore if it should be managed in a different 
way;
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4. To carry out a pathological review of all pathology specimens obtained to
a) check the LCIS diagnosis
b) identify any defining characteristics, and
c) to define the pathological evaluation that will be conclusive with respect to 
a diagnosis of LCIS;
5. To evaluate what disease management women diagnosed with LCIS received.
Whilst we had agreement in principle fi-om the NHSBSP to help us identify all LCIS 
cases, we thought in practice we should be able to obtain the full data on at least 250 
women with LCIS.
107
CHAPTER FOUR
THE METHODS:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
M eth ods 
St u d y  P opu la tio n
The population included all women screened in the NHS screening programme since its 
inception to date. This start date varied between units, as after 1988, centres were set up to 
commence screening over the following 2 years. Screening was initially fi*om the age of 
50 to 65, however some centres offered a self-referral policy to women aged between 65 
and 70 and since 2003 the age of screening has been extended to include all women up to 
the age of 70.
All Quality Assurance offices and the Screening Centres in the United Kingdom were 
asked to supply us with cases of asymptomatic, screen detected LCIS with no pathological 
evidence of associated invasive breast cancer or DCIS. Women were excluded if they had 
a previous history of breast cancer. Interval cancers were also excluded.
O b t a in in g  Pa t ie n t  N a m e s
Letters were sent out at the beginning of September 2003 with reminders sent in early 
November 2003 and in March 2004 to those screening centres that had not replied (see 
Appendix I). In order to maximise the number of participating units Mrs Julietta Patnick, 
Director of the NHS Screening Programme, was also approached and several 
presentations were performed at National and Regional meetings in an attempt to 
encourage further units to participate.
Names were either identified by the individual screening centres ftrom their own screening 
databases using LCIS as the keyword or by the treating hospitals via their pathology
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records. Some screening centres were unable to obtain this information from their 
databases. In these cases the QA offices were able to identify women within their region 
and then send it to the individual screening centres.
Data Collection
Once the names of the women had been identified for each of the participating screening 
centres a visit was arranged to review the screening packets, which contained the 
screening mammograms and other relevant information collected by the screening 
centres. This information included copies of referral letters to surgeons and oncologists, 
letters to the patient’s General Practitioners (GPs) and some follow up information in the 
form of letters back to the screening centres from the treating hospital consultants. 
Wherever possible the hospital notes were reviewed at the same time as the screening 
packets. This was possible if the screening centres were located within a hospital or if the 
screening centre requested the hospital notes to be sent to the centre for review.
In some instances it was necessary to contact the treating consultant surgeon from the 
hospital to ask permission to review the notes. If this was necessary it was done in the 
form of a letter (Appendix II). To obtain complete follow up information regarding the 
patients well-being and recurrence status to date (either 2003 or 2004 depending on when 
the information was collected) it was necessary to write to a proportion of the patients 
GPs if the patient had been discharged from hospital care, had moved away or if the 
hospital notes were missing or had been destroyed. This was done with a standard letter, 
which was adapted to the individual depending on what information was required from 
the GP (see Appendix III).
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In fo rm a tio n  C o llected
The information collected from the screening mammogram packets, hospital notes and 
from the GPs included details on patient characteristics, risk factors, mammographie data, 
pre-operative diagnosis, treatment data and follow up information. This information was 
collected in the form of proformas (Appendix V-VIII). Where available a copy of the 
pathology report was obtained on all women. Expert advice was sought regarding the 
collection and analysis of pathology and radiology information. I was trained by 
Consultants in radiology and pathology to interrupt mammograms and pathology slides.
Pa tien t  C h a r ac ter istics
Patient names and individual screening numbers and the name of the screening centre 
where their mammograms were performed were collected. The patient’s date of birth and 
the date of their first abnormal screening mammogram were recorded, also whether and 
when they had had previous screens and whether these had been normal. Details of the 
hospital and consultant surgeon to whom the women were referred by the screening 
centres were recorded. Any relevant past medical history or medication was also collected 
(Appendix V).
R isk  Fa cto r s
Menopausal status at the time of the abnormal mammogram (pre, peri or post) was 
recorded. The number of children or pregnancies and the age at the first pregnancy was 
documented, as was any recorded family history of breast or ovarian cancer. Exposure to 
hormones including hormone replacement therapy and the oral contraceptive pill was 
collated; including duration of exposure and whether the women were taking hormones at 
the time of diagnosis. Previous breast surgery and the previous diagnoses were recorded.
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however if the women had had a previous diagnosis of invasive breast cancer, DCIS or 
LCIS they were excluded from the study.
M a m m o g r a ph ic  D a ta
Detailed information was collected from the mammograms, such as the type and number 
of first stage mammogram views (cranio-caudal and/or oblique) and the type of views 
performed to aid diagnosis e.g. magnification views. The density of the mammograms 
was assessed and documented using the Wolfe Classification. The mammographic 
abnormality was classified as a mass, an asymmetry, a distortion and calcification and the 
position in the breast was documented according to the quadrants of the breast (upper 
outer, upper inner, lower outer, lower inner or central), as was the side of the abnormality. 
The size of the abnormality was recorded in millimetres and this was measured on a non­
magnified view.
If the abnormality was calcification, further observations were recorded. These were the 
distribution (segmental, rounded or pleomorphic), whether the calcium was in a tight or 
loose cluster and whether there were fine particles present on the magnification views. 
Variability of the calcium particles in the cranio-caudal and oblique mammographic views 
and the density of the particles were also documented (Appendix VI). The mammograms 
were read by two trained individuals and arbitration occurred if there was dispute.
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Pr e -o pera tiv e  D ia g n o sis
Any symptoms and clinical signs present at the time of the first mammographic screen 
were documented. If an ultrasound was performed at the time of recall, information 
regarding this was collected. Tissue diagnosis is obtained by fine needle aspiration or core 
biopsy and if either of these had been performed, results were documented. This included 
any repeat biopsies and information whether the core biopsies had been x-rayed to 
document the presence of calcium (Appendix V).
T r ea t m en t  & F o llo w -up
Data regarding the surgical treatment, if any, was recorded including type of surgery (e.g. 
needle localized biopsy) and the date of the operation. It was also documented if there was 
any further surgery and when and what this was, as were the reasons recorded for this 
decision (e.g. patient choice). The weight of the specimen was recorded if it had been 
documented and information Jfrom the pathology report was assessed to ensure that the 
mammographic abnormality had been removed. Adjuvant treatment in the form of 
hormone therapy or radiotherapy was also recorded.
The follow up that the patients received was collated, such as mammographic and clinical 
follow up. The time intervals between these episodes were recorded. The date that they 
had last been seen by either a hospital consultant or GP was documented. If patients had 
suffered a later episode of invasive breast cancer, DCIS or LCIS this was documented as 
was the date of this recurrence, the size, grade and lymph node status. In addition the 
treatment received by women with a recurrence was recorded (Appendix VIII).
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Pa th o l o g y  R e view
Once cases had been identified as possible screen detected LCIS and the mammograms 
had been reviewed we wrote to the treating hospitals’ pathology departments requesting 
the original pathology blocks and slides in order to perform a formal review of the 
pathology (Appendix IV). We requested the relevant slides and one representative 
paraffin block to enable us to perform new immunohistochemical analysis. If the hospitals 
were unable to send us slides we cut and stained a new Haematoxylin & Eosin (H & E) 
slide from the paraffin blocks. This allowed us to review the morphology of the LCIS 
(Appendix VII).
From the H&E stain we were able to ascertain whether the lesion was in fact pure LCIS, 
and not invasive breast cancer or DCIS nor LCIS in association with another malignant 
lesion. We attempted to determine the size of the LCIS and if it was large and un­
measurable we classified it as widespread. If we could not measure the size on the slides 
sent to us we obtained the size from the initial pathology report. Multifocality of the 
lesion was assessed, as was the nuclear grade of the LCIS (A, B or mixed). Margin status 
was reviewed to determine whether the margins of the surgical specimen were clear of 
disease, where possible.
If the mammographic appearance was of calcification, we looked for calcium associated 
with the LCIS in the pathology specimen and documented whether this was within the 
LCIS, adjacent to or separate from the LCIS. We measured the size of the calcium 
particles in millimetres using the stage micrometer to ascertain if these were large enough 
to be visible on the mammograms. The presence of the calcification was recorded as 
ductal or lobular in nature.
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Ductal involvement of the LCIS was assessed and classified as pagetoid, comedo or solid. 
Ductal necrosis within the LCIS was also assessed. The lobular size was documented as 
normal, mildly expanded or expanded. We looked for associated benign conditions and 
calcification, if present, to assess whether there was calcium within the LCIS only, 
calcification in the benign lesions only or calcification within both LCIS and benign 
lesions.
If the pathological abnormality was a fibroadenoma or radial scar associated with LCIS 
we documented whether the LCIS was solely within the benign lesion, completely outside 
the lesion or both involving and outside the lesion
All this information was used to ascertain whether the LCIS related to the mammographic 
abnormality that had initially been detected and to allow us to classify the disease as 
screen detected or incidental LCIS. We defined screen detected LCIS as those cases 
where calcifications were solely within the LCIS and not in the surrounding tissue. The 
remaining cases where the mammographic abnormality was adjacent to or both adjacent 
to and within the LCIS were defined as incidental cases. As the LCIS was then not 
deemed to be the reason for the detection of an abnormality on mammography. The 
pathology was reviewed by two trained individuals and arbitration occurred if there was 
dispute.
IMMUNOHISTOCHEMISTRY
On all lesions that were pure LCIS and in whom we were in possession of a paraffin block 
that had been formalin fixed we processed new slides in order to perform oestrogen 
receptor staining, E-Cadherin staining, two cytokeratin stains (5/6 and 34BE12) and a 
mucin stain (combined Alcian blue and PASD). The immunohistochemical stains involve
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the detection of cell products or surface markers (antigens) by monoclonal antibodies. The 
binding of the antibodies and therefore the detection of these products can be revealed by 
fluorescent labels or chemical reactions that result in the generation of a coloured product.
Formalin-fixed paraffin embedded blocks were sectioned at Sum on a rotary microtome. 
Immunohistochemistry was performed under the streptavidin-biotin peroxidase complex 
(ABC) method using the K5001 detection kit from DakoCytomation Ltd (Glostrup, 
Denmark). Appropriate positive controls were used for all cases. These were the stains 
commonly used at the Royal Surrey County Hospital.
The E-Cadherin stain that we used was a DAKO monoclonal mouse anti-human E- 
Cadherin, clone NCH-38 4 which recognizes the 120kDa mature form and 82kDa 
fragment within the E-Cadherin. The cytokeratin stains for 5/6 and 34BE12 were also 
DAKO monoclonal mouse anti-human antibodies, with the clones being, D5/16 B4 and 
34B E l2, respectively. The positive control for all three of these was the basal layer of 
tonsillar epithelium.
The oestrogen receptor stain used was from Lab Vision (England) in a dilution of 1:200. 
ABPAS-D (Alcian blue periodic acid Schiff diastase) is a stain for mucin. The Alcian 
blue stains acid mucins light blue and PAS stains neutral mucins pink, whereas the nuclei 
stain dark blue with a haematoxylin counter stain. Diastase digests glycogen, which will 
stain PAS positive.
All the above stains except PAS staining were graded as negative (-), equivocal (+/-) or 
positive (either + or ++). Mucin staining was classified as negative, focal or prominent.
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As the scoring for these stains is subjective, two people independently examined the slides 
and discrepancies were resolved by consensus.
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Sta t ist ic a l  A nalysis
We used the student t-test to test any differences in means, chi squared to test differences 
in proportions and if the cell value was less than 5 we used a Fisher exact test. Disease 
free survival (DFS) was calculated using Kaplan Meier survival estimates and differences 
in potential DFS were analysed using Cox proportional hazards, adjusting for confounders 
such as age, parity. Stata version 7.0 was used to make all the above calculations.
D a ta  C o n fid en tiality
In order to protect patient confidentiality each patient was given a unique and non- 
identifiable tag based on their initial screening centre, e.g. Jarvis 1, Jarvis 2, Brighton 1, 
and all of the previously mentioned data was stored under this tag the key of which was 
kept securely in the Royal Surrey County Hospital, in a locked office on a PC that was 
password protected. Although I was exposed to the identity of the patients the pathologist 
and MLSO were blinded to these. Pathology blocks were sent from other hospitals 
directly to the pathology department of the Royal Surrey County Hospital in the standard 
way.
E t h ic a l  A ppr o v a l
Multi-Centre Research Ethical (MREC) approval was sought in November 2002 from the 
MREC Committee for Scotland and was granted after three small changes in the letters to 
the GPs and consultants were performed on 30^ of January 2003, (MREC/02/10/49).
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E t h ic a l  a n d  L eg a l  Issues  Su rr o u nd in g  T h e  R esea r c h  P r o je c t :
Owing to the multiple information sources involved, it was impossible to carry out this 
study using data that were anonymised at source. For various reasons, it could be argued 
we should obtain informed consent from the women whose confidential information we 
wanted to retrieve. Examples of such reasons are respect for people’s autonomy and their 
right to privacy, the fact that medical confidentiality is protected under section 8 of the 
Human Rights Act 1998, through the NHS guidance on confidentiality (DoH 2003), and 
use of data as proposed by us would be covered by the Data Protection Act 1998 and the 
Human Tissue Act 2004.
For various other reasons it could be argued we should not obtain informed consent. 
Many of these women would have been diagnosed with LCIS around a decade ago; they 
may have been reassured that ‘the lump is benign’ and our request for informed consent 
might lead to potentially unfounded concerns; certainly we would not be able to provide 
any recommendations regarding treatment, monitoring, or follow-up. Women may not 
want to be reminded of a health scare they faced years ago. The uncertainty surrounding 
LCIS and its prognosis, which formed the basis of the research question, may be 
unwelcome new information to the women we would be asking for informed consent. On 
the other hand, these considerations might be viewed as being paternalistic and they might 
be disapproved of if paternalism is considered unethical under these circumstances.
From a research perspective, requiring informed consent would adversely affect the 
validity of our study because we were trying to establish the association between 
treatment and survival to subsequent breast cancer diagnosis or death. It is impossible to 
obtain informed consent from deceased individuals. Although in some cases it may be 
possible to obtain consent by proxy, requiring informed consent would, in practice,
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inevitably lead to an under-representation of data from deceased women and it might lead 
to an under-representation of women with malignant breast cancer subsequent to their 
LCIS diagnosis. This, in turn, would lead to biased estimates of the rate of recurrence or 
death associated with the various disease management options.
We decided that, on balance, the best approach would be not to ask for informed consent 
and to anonymise the data as soon as possible after retrieval, with only two —medically 
qualified- people having access to the patient identifiers. We applied for approval from a 
MREC on this basis, and this was granted upon our first application.
We were unsure whether this study would fall under the remit of the Patient Information 
Advisory Group of the Department of Health (PIAG), and we applied for approval from 
PIAG as well. PIAG indicated that, because of the low numbers of study participants 
anticipated (between 200 and 400) this study did not fall within their remit, and at the 
same time insisted we should obtain informed consent because ‘surely, there should be no 
objection to researchers being required to obtain consent from patients to use their 
confidential information if it is practicable to do so’. We tried to enter into a dialogue with 
PIAG and obtain insight into their counterarguments to our beliefs that in this particular 
case, approaching women was likely to do more harm than good. However, we never 
received any further clarification and after some correspondence with PIAG without 
managing to change their views, we wrote to the MREC with a suggested protocol change 
and a proposed informed consent form. The MREC responded we had been given MREC 
approval on the basis that we would not approach the women, and insisted we should 
conduct this study without obtaining informed consent.
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Two expert committees, therefore, came to opposite conclusions as to the appropriateness 
of obtaining informed consent and the legally and ethically correct way to conduct this 
study. This highlights that despite the existence of quite a bit of law, and despite society’s 
learning from past experiences of conducting research with and without consent, there 
remains an ethical and possibly a legal dilemma in this area.
1 2 0
CHAPTER FIVE
THE RESULTS:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Study for the Odalisk - Francine Van Hove
R esults
We had hoped to obtain data on 250 cases but full data was only available on 166 cases of 
which 28 were screen detected. There was also limited data on patient demographics and 
risk factors due to poor documentation in the screening records. As a result the data we 
are about to present is of a qualitative nature rather than quantative.
D a ta  C o l l e c t io n :
The data we are about to present After writing to the 83 NHS breast screening centres in 
England 3 times between September 2003 and September 2004, 60 (72%) centres 
provided us with the information of the names and unique screening numbers of the 
women diagnosed with LCIS since they had initiated screening. Of the 23 remaining 
centres who did not participate, 17 contacted us and stated they were unable to supply 
data for 3 reasons:
a) Patient confidentiality -  Ethically did not wish to supply named data (n=3).
b) Manpower -  Not enough personnel to retrieve data (n=10).
c) Technical Retrieval -  Unable to extract data from their database (n=4).
Some of the centres were able to use their Quality Assurance Reference Centre (QARC) 
to extract data. From these 60 centres information was collected on 366 women who had 
been diagnosed with LCIS (Appendix IX).
Figures 28 & 29 (pg 167 & 168) and Appendix X (pg 215) show the screening centres 
that submitted data and those that did not.
In the results section n=366 are those cases ‘assumed’ to have LCIS.
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1) Population Characteristics
366 women were identified between 1988 and 2003 by these 60 participating screening 
centres and the distribution of the year of diagnosis is seen in Figure 7.
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Figure 7: Number o f cases o f LCIS diagnosed each year.
At the time of data collection women were screened routinely in the NHSBSP from 50 - 
65 years of age. There were some women who were older than 70 who had self -  referred 
to the screening programme and some women aged 40-50 who were part of the ‘40’s’ trial 
looking at the efficacy of mammographic screening in this younger age group. Women 
are often invited before their 50* birthday, if screening is implemented in their 
geographical area at that time. This also accounted for some of the women younger than 
50 included in the study.
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2) Patient Demographics
The average age at diagnosis was 54.4 (range 40 -  74, SD 4.97). See Figure 8.
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Figure 8: Age o f women at their diagnosis o f LCIS.
Most of the women (n=205) were diagnosed with LCIS at their first or incident screen, 79 
at their second screen and 82 at subsequent screens. Of these 366, 11 had had an 
abnormality on a previous screening mammogram: 8 were calcification, 2 were masses 
and one showed distortion. In only one of these, an area of calcification was biopsied and 
diagnosed as benign; the remaining 10 were recalled but classified as not suspicious after 
further mammographic views and no action was taken.
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3) Patient Characteristics
Table 24 provides the data collected on menopausal status, HRT, and family history. 
There ’was very little data documented in either the screening notes or the hospital notes to 
allow meaningful analysis on parity, age at first child, breast feeding, and oral 
contraceptive use.
Patient Characteristics Number of 
women
% of number 
known
Menopausal Status Pre menopausal 50 22.7
Peri menopausal 57 25.9
Postmenopausal 113 51.4
Unknown 146
History of HRT use Yes 131 46
No 152 54
Unknown 83
Average duration (months) 66
Range(l-360)
Current at diagnosis 102
Positive Family History Yes 84 32
No 180 68
Unknown 102
Details Known 73
First degree 52
Second degree 21
Table 24: Population characteristics o f  366 women with LCIS identified in NHSBSP.
NB: Menopausal status was defined by the diagnosing clinician.
Twenty-two women had had previous benign surgery to one or both breasts. Co-morbidity 
had been listed in 14 women including 5 with diabetes, 3 with thyroid disease, 2 with 
multiple sclerosis, 2 with lymphoma, 1 with multiple deep vein thromboses and 1 with a 
previous diagnosis of bladder cancer.
124
4) Non- Surgical Breast Assessment
a) Clinical Assessment
None of the 366 women had a clinically palpable abnormality at the time of diagnosis.
b) Mammographic Assessment
The mammographic features that resulted in the detection of LCIS are listed below in 
Table 25.
Feature Description Number of 
women
Percentage
Side Right 180 49.2
Left 186 50.8
Position in breast Upper outer quadrant 235 64.2
Lower outer quadrant 23 6.3
Lower inner quadrant 24 6.6
Upper inner quadrant 23 6.3
Central 61 16.6
Mammographic density N1 44 12
PI 169 46.2
P2 134 36.6
DY 19 5.2
Mammographic features Calcification 234
Mass 74
Distortion 79
Asymmetry 5
Table 25: General mammographic features (n=366)
Some of the patients presented with more than one feature (e.g. calcification within a 
mass lesion) therefore the number of mammographic features equal more than 366. An 
example of distortion is seen in Figure 9.
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The size of the presenting mammographic abnormalities relating to their type is listed in 
Table 26.
Type of abnormality Average (mm) Range (mm) SD
Calcification (n=234) 16.2 3-90 15.34
Mass (n=74) 13.2 4-35 5.96
Distortion (n=79) 14.8 5-30 5.78
Asymmetry (n=5) 16.8 7-30 8.32
Table 26: Mammographic presentation and size o f lesion.
Figure 9: An example o f a 
distortion on mammography 
prompting a biopsy, which 
r reveals 
LCIS.
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Of those patients that presented with calcifications (n= 234) a more detailed description is
listed below in Table 27.
Description of calcifications Number of 
women
Percentage
Formation of calcification Tight 162 69.2
Loose 72 30.8
Fine particles present Yes 110 47
No 124 53
Variable particles in different 
views
Yes 46 19.7
No 188 80.3
Dense particles Yes 191 81.6
No 43 18.4
Degree of calcification Extensive 10 4.3
Limited 224 95.7
Shape of Calcification Rounded 29 12.4
Pleomorphic 205 87.6
Table 27: Detailed description o f  the calcification (n=234).
189 of the 234 of the calcifications were further described as rounded punctuate lesions. 
There was no relationship to this further description and the shape of the area of 
calcification. An example of calcification on mammography is shown in Figure 10.
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■Figure 10; An example o f calcification on mammography prompting a needle core biopsy, which revealed LCIS.
c) Ultrasound
Of the 366 women, 192 (52.5%) had an ultrasound, which was abnormal in 122 (63.5%) 
cases. Of these, 30/122 (24.6%) cases showed changes of benign cystic disease only. The 
remaining 92 cases were classified as follows:
Abnormal distortion -14(11.5%)
Suspicious mass -  71 (58.2%)
Complex cystic lesion -  2 (1.6%)
Suspicious -  5 (4.1% with no further description)
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d) Pathology
i. Fine needle aspiration cytology (FNAC)
132 (36%) women had a fine needle aspiration and the specific results were as follows:
C5 - Malignant -16 (12.1%)
C4 - Suspicious of malignancy -  23 (17.4%)
C3 -  Atypia probably benign -  26 (19.7%)
C 2-B enign-3 8  (28.8%)
Cl -  Inadequate -  29 (22%)
11 women had repeat cytology. One result changed from suspicious to malignant, and one 
suspicious result remained C4. One of the atypia (C3) results changed to benign (C2) and 
two to suspicious (C4). Three of the benign results became atypia (C3) or suspicious (C4). 
Of the 3 inadequate results one became benign (C2), other two changed to suspicious 
(C4). Overall 8 were upgraded and 2 were downgraded.
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ii. Core Biopsy
Of the 366 women, 206 (56.35%) had a core biopsy, 57 of whom had also had an FNA. 
Results for the core biopsies are shown in Table 28.
Core Classification Number Description by Original 
Pathologist
B5
Malignant
30
(14.6%)
DCIS = 21 
LCIS = 6
Invasive Lobular cancer = 1 
Unknown = 2
B4
Suspicious
18
(8.7%)
DCIS = 6 
LCIS = 5 
Radial scar = 1 
Lobular Neoplasia= 1 
ADH=1 
ALH=1 
Atypia = 1 
Unknown = 2
B3
Lesion of uncertain 
malignant potential
122
(59.2%)
LCIS = 61 
ALH =14
Lobular Neoplasia = 4 
Atypia =14 
ADH=11 
Hyperplasia = 2 
Papilloma = 3 
Radial scar = 3 
Atypical Fibroadenoma = 2 
Sclerosing Adenosis = 1 
Unknown = 7
B2
Benign lesion
35
(17%)
Non atypical lobular 
hyperplasia = 2 
Radial scar = 1 
Fibroadenoma =1 
No description = 31
B1
Normal breast tissue
1
(0.5%)
Table 28: Core biopsy results
Five women had repeat core biopsies. Four patients who initially had a B2 core result had 
a further biopsy, two of which revealed LCIS, one ALH and the other atypia. One patient 
who had a B1 result went on to have a second biopsy revealing LCIS.
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In total of the 216 women who had a core biopsy 92 had a diagnosis of LCIS, lobular 
neoplasia or ALH based on this biopsy. 28 (12.5%) women were diagnosed as having 
either an invasive cancer or DCIS. Figure 11 shows a mass lesion on mammography, 
which on core biopsy revealed a Fibroadenoma containing LCIS.
Figure 11 : An example o f a mass on mammography prompting a 
needle core biopsy, which revealed a fibroadenoma with LCIS.
5) open Surgical Biopsv
The initial and subsequent surgical procedures of the 366 women diagnosed with LCIS is 
displayed in Figure 12.
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366 cases diagnosed with LCIS
Diagnostic biopsy only: 
no Surgery (n=9)
Core biopsy 7 
Mammotome 2
Localized Biopsy 
(n=354)
Blue dye 1 
Ultrasound guided 9 
Isotope guided 2 
Needle localized 142
Margin & sentinel node 1 
Repeat NLB 1 
Axillary Dissection 1 
Partial Mastectomy 2
Margin excision 32
r^
Mastectomy
(n=3)
Unilateral 3
Further Surgery 55/354
(15.5%)
Mastectomy
(n=18)
Unilateral 9 
Bilateral 9
Third operation 8/254 
(n=3.1%)
Mastectomy
(n=6)
Unilateral 6
Further margin excision 2
Figure 12: A  schema o f the surgical procedures o f  the 366 women diagnosed with LCIS,
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In summary, of the 366 women 27 (7.4%) had a mastectomy of which 9 were bilateral. 
Nine (2.5%) women had no surgery but were managed with biopsy alone and the 
majority, 330 (90.2%), had a surgical excision of the area of LCIS. Two of the women 
underwent an axillary procedure.
S u r g ic a l  M a n a g e m e n t  R ela ted  T o  M a m m o g r a ph ic  S ize
The size of the mammographic abnormality in the 27 women who had a mastectomy was 
compared with the 330 women who had conservation surgery. In the mastectomy group 
the mean size was 23.7mm, SD 21.49 (range 7 -80) compared with 15.2mm SD 12.04 
(range 3-90) in those women who had conservative surgery. In 11 of the 27 women who 
had a mastectomy ‘patient choice’ was documented as the reason for this surgical 
management. Also some of these women were thought to have DCIS due to the result of 
the core biopsy.
A d ju v a n t  T r ea tm en t
Information regarding adjuvant treatment was known in 324 women, 73 (22.5%) of these 
received adjuvant treatment.
a) Tamoxifen
68 (21.0%) women received adjuvant Tamoxifen, 1 of whom switched to Arimidex after 
5 years. 4 of these 68 women continued on HRT. The duration of Tamoxifen treatment 
was known in 33 patients. 20 women took it for 5 years and 5 women took it for 2 years, 
two of the women took it for more than 10 years and 6 for less than 1 year. Of the 68 
women who received Tamoxifen 22 were diagnosed between 1988 and 1994, 29 between 
1995 and 2000 and 17 after 2000.
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b) Radiotherapy
Ten (3.1%) women received adjuvant radiotherapy, 5 of these had treatment between 
1988 and 1995, 5 between 1996 and 2000 and none after 2000. Five women had 
Tamoxifen in addition to radiotherapy.
P ost Treatm ent Surveillance (Follow -up)
a) Clinical Surveillance
Information regarding clinical and mammographic follow up was ascertained on 319 of 
the 366 women. 33 women had no clinical follow up (including two women who had had 
a bilateral mastectomy). 69 women had their first outpatient appointment less than one 
year following diagnosis and 16 of these subsequently went on to annual review. The 
majority (n=213) had annual review and where it was documented 10 women were 
followed like this for 3 years and 190 for five years. Two of the women had 18-monthly 
reviews and 3 were seen every two years.
b) Mammographic Surveillance
Mammographic follow up was known for 319 women. Nine women had no 
mammographic follow up as they had had bilateral mastectomies. 29 women had their 
first mammogram at less than one year, 15 of which then changed to annual 
mammograms. The majority of women (n=251) underwent annual mammograms, 24 of 
whom moved to 3 yearly after their first post-diagnosis mammogram. Twelve women had 
their first mammogram at 18 months, 9 at two years and 9 at three years. Two women had 
magnetic resonance imaging surveillance as well as mammograms and no one had 
ultrasound follow up.
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Pathology  R eview
Of the 366 cases we obtained 205 (56.0%) pathology specimens for review from 
departments who were able to find the manpower to locate and send the material. The 
aim of this pathology review was:
1) To confirm that the lesion initially identified was truly LCIS,
2) To build up a profile of Immunohistochemistry findings of LCIS.
3) To identify any cases of truly screen detected LCIS.
4) To identify any differences in pathology between incidental and screen 
detected LCIS.
There were no apparent variations between the group of patients for whom we received 
blocks and the others.
We were unable to establish a definitive diagnosis in 22 (10.7%), as the blocks we 
received contained either benign change only or the lesion appeared to have been cut from 
the block vdth previous sampling. Of the remaining assessable 183, 164 (89.6%) we 
found to be LCIS, 17 (9.3%) DCIS, and 2 had a focus of invasive disease wdth DCIS.
Immunohistochemistry was performed on all available specimens. The H&E slides were 
looked at first to see whether a diagnosis could be made solely on this slide. The cases 
were then divided into those where we were confident of a diagnosis and those that were 
equivocal. For the equivocal cases the Immunohistochemistry was reviewed to aid 
diagnosis of the lesion. This enabled us to build up a large profile of the 
immunohistochemical features of LCIS as suggested by other authors.
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a) H & E Staining
We were able to make a diagnosis confidently on H&E staining alone for 140 of the 164 
(85%) cases of LCIS and 13 of the 19 cases of DCIS. This left 30 (18.3%) cases that were 
equivocal after H&E staining. Although we had hoped to perform immunohistochemistry 
on all cases it was not possible as a few of the blocks sent with the original slides did not 
always contain representative tissue. We were able to perform immunohistochemistry on 
177 of the 183 cases that had a definitive diagnosis, all nineteen of the cases of DCIS and 
158 of the LCIS cases. Of those on which we were unable to perform 
immunohistochemistry, none were equivocal after H&E staining.
b) Immunohistochemistrv
For those 30 cases that were equivocal after H&E staining we used the 
immunohistochemistry to help us make a definitive diagnosis. Results for all stains 'will be 
discussed separately and then combined in Table 32 at the end of this section (Page 142).
c) E-cadherin
151 of 158 (95.6%) LCIS cases were stained negative with E-cadherin compared to 17 of 
19 of the DCIS cases, which stained positive. E-cadherin staining of the 30 equivocal 
H&E cases showed that 20 were E-cadherin negative (supporting a diagnosis of LCIS) 
and 4 were E-cadherin positive (supporting a diagnosis of DCIS), the remaining 6 were 
equivocal. Table 29 shows the comparison of DCIS and LCIS with E-cadherin staining 
and Figure 13 is an example of negative E-cadherin staining in LCIS filled lobules.
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î-Cadherin
DCIS LCIS
Positive 17 0
Equivocal 2 7
Negative 0 151
TOTAL 19 158
Table 29: E-cadherin results for LCIS and DCIS cases.
Failure of LCIS to 
take up E cadherin 
stain
Figure 13: An example o f negative E-cadherin staining o f  LCIS containing lobules
d) Cvtokeratin 34B E l2
138 (87%) of the cases of LCIS stained positive for 34B E l2, this positive staining was 
cytoplasmic in all cases, with loss of the membranous accentuation seen with DCIS. 14 of 
the 19 cases of DCIS showed loss of staining as seen in Table 30.
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34 E12
DCIS LCIS
Positive 2 132
Equivocal 3 12
Negative 14 14
TOTAL 19 158
Table 30: 34 B E12 results for LCIS and DCIS cases.
Of the remaining equivocal 6 cases after H & E  and E-cadherin, 34B E 12 provided a 
definitive answer, 4 were positive confirming LCIS and 2 were negative confirming 
DCIS. Therefore in the cases of equivocal diagnosis after H&E staining the E-cadherin 
and 34B E12 enabled us to make a definitive diagnosis of either DCIS or LCIS. This is 
demonstrated in Figure 16. Figure 14 shows positive cytoplasmic staining of LCIS with 
34B E12.
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Figure 14: Positive cytoplasmic with 34B E12 staining in a case o f LCIS.
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Immunohistochemistrv
Equivocal n = 30
E Cadherin stain
Equivocal n = 6
34 B E 12 stain
H & E  stain n=l 83 
22 unable to make a 
diagnosis
205 cases with pathological
review
£  cadherin
Equivocal = 2
34 B E 12 Negative 
n = 2DCIS
E cadherin
Equivocal = 4
34 B E 12 Positive 
n = 4LCIS
34B E 12
Equivocal = 1 
Negative = 2 
Positive = 1
E cadherin Positive 
n = 4DCIS
34 B E 12
Equivocal = 2 
Positive = 2 
Negative = 1
E Cadherin
Positive = 13
DCIS n=13 
Diagnosed on 
H&E
34B E12
Equivocal = 2 
Negative = 2 
Positive = 16
E cadherin Negative 
n=20 LCIS
E cadherin
Equivocal = 3 
Negative = 125 
34B E 12 
Equivocal =10 
Negative = 12 
Positive = 112
LCIS n=140 
Diagnosed on H&E
Figure 15: A  flow diagram illustrating the use o f  E-cadherin and 34B E12 in the differentiation o f  LCIS and DCIS.
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e) Cvtokeratin 5/6
155 of 158 of the LCIS and 19 of 19 of the DCIS failed to stain with cytokeratin 5/6 as 
seen in Table 31. Figure 16 shows failure of staining of LCIS with cytokeratin 5/6.
Cytokeratin 5/6
DCIS LCIS
Positive 0 3
Equivocal 0 0
Negative 19 155
TOTAL 19 158
Table 31 : Cytokeratin 5/6 results for LCIS and DCIS cases.
Distended
Lobule
with LCIS
Figure 16; Failure o f staining with Cytokeratin 5/6 o f LCIS lobules.
f) Oestrogen Receptor Staining
136 of the 149 (91.2%) patients where oestrogen (ER) receptor status was obtainable 
showed positive staining for oestrogen receptors in the LCIS group. 9 were equivocal and 
4 showed negative staining. This compared to 17 in the DCIS group that stained positive, 
1 was equivocal and 1 showed negative staining. It was not obtainable in three due to
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insufficient material in the block sent. There was no difference in oestrogen receptor 
status between the pathological variants of type A and type B LCIS.
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Figure 17: LCIS showing positive staining for oestrogen receptors.
g) Mucin Stain
119 of 158 (75.3%) cases of LCIS showed positive mucin staining and 15 of 19 cases 
showed no mucin staining in the DCIS group. There were however 31 cases in the LCIS 
group that were equivocal and 8 that showed negative staining. In the DCIS group 1 was 
equivocal and 3 showed positive staining, with the remainder not staining.
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Figure 18: Mucin within LCIS, revealed by the ABPAS stain.
A summary of all stains performed in the study is shown in Table 32.
E-Cadilerin CK 5/6 34B E12 Mucin ER
LCIS DCIS LCIS DCIS LCIS DCIS LCIS DCIS LCIS DCIS
Negative 151 0 155 19 14 14 8 15 4 1
Equivocal 7 2 0 0 12 3 31 1 9 1
Positive 0 17 3 0 132 2 119 3 136 17
Unknown 6 0 6 0 6 0 6 0 3 0
Table 32: Summary o f stains performed
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P a th o l o g ic a l  a n d  M a m m o g r a ph y  C o r r ela tio n
This section of the study was vital in order to ascertain whether any of the cases were 
truly screen detected.
Of the 164 cases that were confirmed as LCIS, 99 had presented with calcifications on 
mammography, 48 with a distortion, 28 with a mass lesion and 2 with asymmetry. A 
detailed description of the calcifications is listed in Table 33.
Mammographic description of calcifications No. of women
Formation of calcification Tight 68
Loose 31
Fine particles present Yes 48
No 51
Variable particles in different views Yes 29
No 70
Dense particles Yes 82
No 17
Shape of area of calcification Segmental 4
Widespread 7
Rounded 19
Pleomorphic 69
Table 33: The mammographic characteristics o f  the 99 LCIS cases presenting with calcifications.
i) Radiological Extent of abnormality
The calcifications on mammography (n=99) had an average size of 15.9mm (range 3- 
70mm: SD 14.03). 48 women presented with distortion and these had an average size of 
13.2mm (range 5-26: SD 5.23). 28 women presented with a mass on their screening 
mammogram with an average size of 15.6mm (range 5-26 mm: SD 6.49).
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ii) Pathological Extent
The extent of the area of LCIS was assessed for the 164 cases on the blocks and slides 
sent to us. In six cases we were unable to assess the size, and in 28 (17.1%) it was 
widespread. In 130 in which a measurement was possible the average size was 9.3mm 
with a range of 1- 60 mm. In 18 (11.0%) cases the disease was multifocal.
iii) Margins
We were able to re-evaluate margin status on 158 cases. 82 (51.9%) had involved margins 
and 56 (35.4%) had margins of greater than 5mm. Eight women had a 1mm margin, a 
further 8 had a 2mm margin, 2 had a 3mm margin and 2 had a 4mm margin.
iv) Additional Pathological Features
Further pathological features of the 164 cases of LCIS were noted and are listed below in 
Table 34.
Pathological Features Number of women Percentage %
Type A classical 112 68.3
B pleomorphic 41 25.0
Mixed A & B 11 6.7
Multifocality Yes 18 11.0
No 146 89.0
Duct Involvement Yes 96 58.5
No 68 41.5
Necrosis Yes 13 7.9
No 151 92.1
Lobular size Unknown 9 5.5
Mildly expanded 69 42.1
Expanded 86 52.4
Table 34: Additional pathology features o f  proven LCIS cases
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Of those with duct involvement 20 were solid, 6 were solid and pagetoid and 70 were 
pagetoid only.
Î
Central
necrosis
Ductal
involvement
Figure 19; An example o f extensive LCIS with ductal involvement and necrosis.
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Is LCIS A  T r u ly  S c reen  D e tec ted  D ise a se?
As discussed in the literature review, most authors believe that LCIS cannot be detected 
on mammography and it is always an incidental finding. We compared the pathology and 
mammography in each case to ascertain if LCIS could have been detected by an 
abnormality on screening mammography, which prompted the recall and investigation 
leading to biopsy, and not an associated disease process.
C a se s  T h a t  P r e s e n te d  W ith  C a l c i f i c a t io n  O n ly  (n = 8 7 )
99 cases presented with calcification; 12 presented with a mass or distortion in addition to 
calcifications, leaving 87 presenting only with calcification. The cases that presented with 
calcification were divided into three groups:
1. Where the calcification was separate from the LCIS (n=51).
2. Where the calcification was in the LCIS and the surrounding tissue (n=9).
In these two groups LCIS was likely to have been an incidental finding to the 
mammographic abnormality.
3. Where the calcification was only within the LCIS (n=27).
The latter was defined as screen detected LCIS.
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deposit
Figure 20: Large deposits o f calcium within LCIS
1) Calcification in benign disease only (n=51)
51 women presented with calcification in benign disease only; the types of benign disease 
that were screen detected are listed in Table 35.
Pathology No. of women
Blunt duct adenosis 13
Fibrocystic change 12
Blunt duct adenosis & Fibrocystic change 6
Sclerosing adenosis 8
Fibrosis 3
Columnar cell change 3
Typical hyperplasia 2
Fibroadenoma 2
Atrophy 1
Fibrocystic change & Columnar cell change 1
Table 35: The cases of LCIS where calcifications were found only in the benign disease.
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The size of the calcium in this group measured microscopically ranged from 0.03 -  
0.75mm.
2) Calcification in both benign disease and LCIS (n=9)
The benign disease associated with this group is listed below in Table 36. In this group of 
patients the calcification was associated with the benign disease and engulfed the areas 
affected with LCIS and therefore, the LCIS was incidental and not specifically screen 
detected. The size of the calcifications in this group ranged from 0.05 -0.3mm.
Fibrocystic change 3
Sclerosing adenosis 2
Fibrocystic change & Columnar cell change 1
Blunt duct adenosis & sclerosing adenosis 1
Blunt duct adenosis 1
Blunt duct adenosis & Radial scar 1
Table 36: The cases o f  LCIS where calcifications were found in both the benign disease and the LCIS.
3) Calcification Only in LCIS In = 27): Screen Detected
In this group, 19 cases were only associated with LCIS. In the remaining 8 there was a 
benign process adjacent to the LCIS but this contained no calcification. Five cases were 
adjacent to fibrocystic change, one to blunt duct adenosis, one to a radial scar and one to 
fibrocystic change and blunt duct adenosis.
The size of the calcium in this group ranged from 0.05 -  0.6 mm. One of the cases 
presented with Weddellite calcification.
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Figure 21: Ductal calcification associated with LCIS.
The following tables 37, 38 & 39, show the pathology findings in those cases where LCIS 
was NOT the lesion causing the abnormality on the screening mammogram, i.e. Incidental 
LCIS.
Fibroadenoma with LCIS 10
Fibrocystic change & Blunt duct Adenosis with LCIS 10
Blunt duct adenosis & Columnar cell change with LCIS 3
Table: 37 Cases that presented with a mass lesion only (n=23)
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Radial scar with LCIS 33
Blunt duct adenosis & Fibrocystic change with LCIS 1
Sclerosing adenosis with LCIS 3
Blunt duct adenosis with LCIS 1
No cause for distortion seen with LCIS 1
Table 38: Cases that presented with distortion only (n=39)
Two cases presented with asymmetry only, one was found to have fibrocystic changes 
with LCIS and another sclerosing adenosis with LCIS. One case presented with a mass 
and a distortion and this was found to be a radial scar with LCIS.
Radial scar with LCIS 5
Sclerosing adenosis with LCIS 2
Sclerosing adenosis and Blunt duct adenosis with LCIS 1
Table 39: Cases that presented with calcification and distortion (n=8)
Four cases presented with a mass associated with calcification, two were blunt duct 
adenosis with LCIS and one was fibrocystic change and sclerosing adenosis with LCIS. 
The fourth case presented with a radiologically benign mass and suspicious calcifications. 
Pathologically the fibrocystic change was forming a mass lesion with no calcifications 
associated with it and there was 0.1mm targetoid calcification only within the adjacent 
LCIS. This case was, therefore believed to be screen detected as it was the calcification 
that was thought to be suspicious on mammographic screening, not the mass lesion.
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S u m m ary
Of the 164 cases of LCIS where pathological and mammographical correlation was 
possible 28 (17%) were screen detected. 27 presented with calcification only and one case 
presented with a benign mass but suspicious calcification.
Figure 22: Weddellite calcification within LCIS.
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Pr e -o per a tiv e  A ssessm en t
1) Ultrasound
86 (52.4%) of the 164 women with proven LCIS on pathology had undergone an 
ultrasound as part of their assessment; 45 of these were documented as abnormal. 2 were 
called complex cystic lesions, 25 were suspicious masses, 6 distortion and 3 were labelled 
only as suspicious. The remaining 9 were classified as benign cystic change only.
2) Fine Needle Aspiration
Of the 164 pathologically confirmed cases of LCIS, 60 (36.6%) had a pre-operative FNA 
with the results listed below in Table 40.
FNA
result
Number of 
patients
Cl 16
C2 11
C3 15
C4 9
C5 9
Table 40: FNA results
3) Core Biopsv
99 (60.4%) of the 164 women under went a pre-operative core biopsy and the results are 
listed below.
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Core Results Number 
Of women
Description
B1 7
B2 15 2 women had a repeat biopsy = LCIS
B3 51 17 = LCIS or Lobular Neoplasia 
8 = Atypical lobular hyperplasia 
3 = Atypical Ductal Hyperplasia 
2 = Radial scar 
21 = Atypical
B4 9 3=  DCIS 
3 = LCIS 
3 = Atypia
B5 17 13= DCIS 
4 = LCIS
Table 41: Core biopsy results
Of the 99 women, 39 had a core biopsy diagnosis of LCIS or lobular neoplasia and an 
additional 8 had a diagnosis of atypical lobular hyperplasia, giving a pre operative 
diagnosis rate with core biopsy of 47.5% (49.5% including the two patients who had a 
second core biopsy). 16 (16.2%) women had a false positive diagnosis of DCIS.
The relationship between the use of the three investigations is shown in Figure 23.
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Figure 23: A Venn diagram showing the women, who underwent assessment with ultrasound,
FNA and core biopsy.
By using more modalities there was an increase in the detection of a suspicious 
abnormality. Of the 14 women who had a B2 core biopsy result, 4 had a suspicious FNA, 
Two with C4, one with C5 and one with C3. There were 11 women with a C2 FNA and 
two of these had a B3 core result and 3 had an abnormal ultrasound.
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Screen  D ete c te d  LCIS C o m pa r e d  t o  In c id e n t a l  LCIS
The mammographic characteristics of the screen detected cases and the incidental cases of 
LCIS that presented with calcification are shown in Table 42. There were no statistically 
significant differences between the two groups.
Mammographic feature
Screen 
detected 
LCIS n=28
Incidental
LCIS
n= 71
Presented with Mass & calcification 1 3
Calcification 
Or ca + distortion
27 68
Architecture of calcification Tight 18 50
Loose 10 21
Fine particles present Yes 17 30
No 11 41
Variable particles in different 
views
Yes 9 20
No 19 51
Dense particles Yes 21 59
No 7 12
Shape of area calcification widespread 2 8
Rounded 5 13
Pleomorphic 21 50
Size mm 15.7
(6-50)
15.9
(3-70)
Table 42; A  comparison o f  the mammographic features o f  the calcification seen in
screen detected LCIS and incidental LCIS.
Similarly we compared the pathological characteristics of the screen detected LCIS 
(n=28) with the incidental LCIS (n=136)
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Pathological
feature
Screen detected LCIS 
n=28
Incidental
LCIS
n=136
Statistical
significance
Size of lesion 2 widespread 
Average size of other 26 
15.9 mm 
Range 6-50mm 
SD 10.57
25 widespread 
6 unknown 
Average size of other 105 
7.79mm 
Range 1 -  30mm
P=0.038 *
Type of LCIS Type A = 20 
Mixed = 1 
Type B =7
Type A = 92 
Mixed =10 
Type B = 34
NS
Multifocal 4 14 NS
Necrosis 9 4 P<0.001*
Lobules 18 expanded 
7 mildly expanded 
3 ductal disease only
61 expanded 
65 mildly expanded 
9 ductal disease only
NS
Duct involvement 15 pagetoid 
8 solid
58 pagetoid 
14 solid P=0.014*
Margin involvement 21 involved 
7 clear >5mm
63 involved 
66 clear>5mm 
7 unknown
P<0.001*
Table 43: A  comparison o f  pathological features o f  screen detected LCIS & incidental LCIS.
* Statistical significance at level p< 0.05
There was a significant difference in the pathological size of the screen detected LCIS and 
the incidental LCIS, p=0.038. There was a statistical difference in the margin status 
p=0.006, OR 4.81, (Cl 1.08-13.29) with more of the screen detected group having 
involved margins and with the presence of necrosis. Also statistical significance was seen 
with duct involvement p=0.014, OR 3.45, (Cl 1.1-11.1). None of the other variables 
were statistically significant.
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Figure 24: Necrosis associated with LCIS.
LCIS Associated With A Radial Scar and Complex Sclerosing Lesions
41 cases of LCIS were associated with a radial scars or complex sclerosing lesion (CSL). 
31 were with a radial scar (10mm or less) and 10 were associated with a CSL, of more 
than 10mm. The way these presented is shown in Table 44.
Mammographie
Abnormality
No. of Cases of LCIS 
Associated with Radial 
Scars/CSL
Distortion only 33
Mass & distortion 1
Calcification only 2
Distortion & calcifications 5
Tahle 44: Mammographie presentation o f LCIS within RS or CSL
The average size of the radial scar was 8.7mm (range 7-10mm) and the average size of the 
CSL was 15.4 mm (range 11-20mm). Of these 41 cases the LCIS was completely
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contained within the radial scar or CSL in 27, inside and outside the lesion in 11 and 
completely separate from the lesion in 3. In three of the cases the LCIS was widespread 
and these were cases where the LCIS was within and around the lesion. The average size 
of the remaining areas of LCIS (38 cases) was 7.5mm (range l-28mm).
L C IS A sso c ia ted  W ith  F ib r o a d e n o m a s
In 12 cases LCIS was found to be associated with a fibroadenoma, 10 of whom were in 
women who presented with a mass on their screening mammogram. The remaining 2 
were associated with calcification which, when excised, was pathologically found to be 
related to a fibroadenoma. In 2 instances the fibroadenoma was associated with 
widespread LCIS and in the remaining 10 cases the average size of the LCIS was 9.6mm 
range 3-22mm. In 6 cases the LCIS was contained within the fibroadenoma, in 4 it was 
both in and around the fibroadenoma and in 2 it was adjacent to and not associated with 
the fibroadenoma.
Su bseq u en t  E v en t s  R e la t ed  to  Pa th o l o g ic a l  R e v iew  
a) Subsequent Events in Cases Reclassified as DCIS
There were three subsequent breast cancer events in the group of patients reclassified by 
us as DCIS or DCIS with invasive disease (n=19). There was follow up information on 18 
of the 19 of these cases with a total of 96 years of follow up. The average follow up for 
this group was 5.2 years (Range 312 -  5661 days). This equates to a subsequent event rate 
of 31.0/1000 women years of follow up. The subsequent events were that one lady 
developed invasive lobular cancer with DCIS and two women developed DCIS.
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b) Subsequent Events in Confirmed Cases o f LCIS
There was 701.3 years of follow-up information on 151 of the 164 cases. There were 17 
subsequent breast cancer events in this group giving a total crude rate of 24.2/1000 
women-years of follow-up. The crude subsequent invasive event rate was 17.1/1000 
women-years of follow up. The 5-year disease free survival was 89.7% (95% Cl 82.0 -  
94.3). Some of the women in our series were treated with unilateral or bilateral 
mastectomies. Taking this into account, there was follow-up on 143 ipsilateral breasts 
with a total of 663.5 years of follow-up, in which 10 events subsequently occurred, 7 of 
these were invasive. This gave a total ipsilateral rate of 15.0/1000 women years of follow- 
up and an invasive ipsilateral rate of 10.5/1000 women years of follow-up. There were 
151 contralateral breasts with 690.9 years of follow up and there were 7 subsequent breast 
cancers, 5 of which were invasive. This gave a total contralateral rate of 10/1000 women 
years of follow up and an invasive contralateral rate of 7.2/1000 women years of follow 
up.
One woman presented with abdominal pain and was subsequently found to have liver 
metastasis as a first presentation of recurrent disease and after biopsy these were found to 
be of breast origin. She presented 10 years and 7 months after her initial presentation with 
LCIS. The remaining 16 events are described in Table 45 by type, laterality and time 
between diagnosis of LCIS and subsequent breast cancer event.
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Laterality of Event Histological Type
Time in Months 
From Diagnosis of 
LCIS to Event
Ipsilateral Events (n=10) Invasive lobular cancer 24
Different Quadrant (ILC)
ILC& DCIS & LCIS 14
DCIS & LCIS 10
Same Quadrant DCIS & LCIS 66
ILC & DCIS & LCIS 44
IDC&DCIS 16
IDC & DCIS 46
ILC 111
DCIS 65
ILC & LCIS 48
Contralateral Events (n=6) Medullary 56
IDC 85
Tubular 13
Tubular & DCIS 123
IDC & DCIS 178
DCIS 19
Table 45: Subsequent events after a diagnosis o f  LCIS
One subsequent event occurred less than one year after initial presentation, which may 
mean it was a missed diagnosis initially. The disease free survival is illustrated in the 
Kaplan Meier curve in Figure 25. This figure shows that the subsequent events occurred 
in a uniform way over the years following a diagnosis of LCIS.
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Figure 25; Disease free survival following a diagnosis o f  LCIS from the NHSBSP.
Five of the 7 ipsilateral invasive events were invasive lobular cancer and 2 invasive ductal 
carcinoma. None of the contralateral events were invasive lobular disease.
Of these 16 subsequent breast cancers 4 presented clinically and 12 presented 
mammographically. The size of the second cancer was known in 11 cases and the average 
size was 16.1mm with a range 2 -22mm. Tumour grade was known in ten cases and 3 
were grade one, 4 were grade two and 3 were grade three. Nodal status was known in 9 
invasive cancers, six were node negative and three were node positive. The type of 
surgery used to treat the subsequent cancer was known in 11 cases and 5 women had 
conservation surgery, all of whom were in the ipsilateral cancer group, and 6 were treated 
by mastectomy. At the time of data collection there were no deaths due to breast cancer.
There were 2 subsequent events in the patients where LCIS was found in association with 
a radial scar or CSL, one following the diagnosis an 18mm area of LCIS and another was 
following excision an area of LCIS of 1mm.
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c) Screen Detected Disease and Subsequent Events
Seven of the 17 subsequent breast cancer events occurred in the screen detected LCIS 
group and 10 v^ere in the incidental group.
Type and time to subsequent event is shown in Table 46. Four of these were invasive. 
Follow up information was available on all of these with a total of 142.6 years. This gave 
an adjusted total rate (not taking into account whether patients were treated with a 
unilateral or bilateral mastectomy) in the screen detected group of 49.0/1000 women years 
of follow up, and a rate of invasive events of 28.1/1000 women years of follow up. Two 
of the women in this group were treated with a unilateral mastectomy.
Three of the subsequent events were in the ipsilateral breast and 3 were in the 
contralateral breast and one was metastatic at presentation. This gives an ipsilateral follow 
up of 129.6 women years and a contralateral follow up of 142.6 women years, with an 
ipsilateral rate of subsequent events of 23.1/1000 women years and 21/1000 women years 
for contralateral events.
Side of Subsequent Event Type of Breast Event Time to Subsequent 
Event 
(Months)
N/A Metastatic disease 127
Ipsilateral ILC 24
Ipsilateral DCIS 65
Ipsilateral 
Same quadrant
DCIS & LCIS 66
Contralateral Medullary 56
Contralateral DCIS 19
Contralateral IDC & DCIS 178
Table 46: Subsequent breast cancer events in tbe screen detected group.
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In the incidental group there was follow up information available on 132 women with a 
total of 558.72 years. 8 of the 10 subsequent events in the incidental group were invasive. 
This gives a crude rate of 17.9/1000 women years of follow up of all, and 14.3/1000 of 
invasive events. This is a relative risk of screen detected to incidental of 2.7 (Cl 1.0-6.9).
Some of the women in the incidental group were also treated with unilateral or bilateral 
mastectomy and taking this into account there were 128 unilateral breasts with 544.2 
years of follow up and 3 subsequent breast cancer events, giving a rate of 5.5 events/1000 
women years of follow up. There were 130 contralateral breasts with 548.3 women years 
of follow up giving a rate of 5.5 events/1000 women years of follow up.
The differences in disease free survival between the screen detected group and the 
incidental group is illustrated in the Kaplan Meier curve in Figure 26. The difference 
when adjusted for age did not reach statistical significance p=0.085 but showed a hazard 
ratio for the screen detected group compared to the incidental group of 3.05 (Cl 0.86- 
10.82).
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Figure 26: Difference in disease free survival between the screen detected group and the incidental group.
d) All Subsequent Events Related to Pathological Features
A comparison of the pathological features of those women who had a subsequent breast 
event to those who did not and this is shown in table 47 to investigate whether 
pathological features could predict which women would go on to have a subsequent breast 
cancer event. The pathological size was compared and adjusted for age and a relative risk 
of subsequent event was related to a group with <7mm of LCIS. 7-23mm was not 
statistically different to <7mm (p=0.96) however >24mm although not significant (p=0.2) 
showed a relative risk of a subsequent breast event of 2.72 (CI0.62-12.04).
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Pathological
feature
No subsequent event 
n=147
Subsequent event 
n=17
Statistical
significance
Type of LCIS Type A = 103 
Mixed = 9 
Type B = 35
Type A = 9 
Mixed = 2 
Type B = 6
NS
Multifocal 15 3 NS
Necrosis 10 3 NS
Lobules Unknown 9 
75 Expanded 
65 mildly expanded
12 expanded 
5 mildly expanded
NS
Duct involvement 81 
15 solid,
6 solid & pagetoid 
60 pagetoid only
15
10 pagetoid, 5 solid P=0.009
Margin
involvement
Unknown = 6 
> 5mm = 52 
1mm = 8 
2mm = 7 
3mm = 2 
4mm = 2 
Involved = 70
>5mm = 4 
2mm = 1 
Involved =12
NS
P=0.07
Table 47: A  comparison o f  pathological features o f women who had a subsequent event to those who did not.
There were no statistically significant differences between the two groups except duct 
involvement. There were 15/17 in the group that went on to have a subsequent breast 
cancer event that had ductal involvement compared to 81/147 in the group that did not 
(p=0.009).
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CHAPTER SIX
THE DISCUSSION:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Double Back - Francine Van Hove
D isc ussio n
The aim of the study was to ascertain if LCIS can be screen detected and if it can, to see if 
there was any difference between these cases and incidental LCIS. Screen detected 
disease was defined by mammographic/pathological correlation, where calcifications 
were visualised only in the LCIS and not in the surrounding tissue. We attempted to 
answer the questions that had arisen from the literature review. The results are 
summarized in Figure 27.
22 unable to 
make a 
diagnosis
164 confirmed as LCIS 
on review
reclassified as 
ADH or 
DCIS
366 women identified 
from the NHS screening
205 specimens available 
for pathological review
136 found to be incidental 
(10 of whom had a 
subsequent breast cancer
28 found to be screen detected 
(7 of whom had a subsequent 
breast cancer event)
Figure 27; Cases identified & classified as incidental or screen detected LCIS
166
K e y  F in ding s
This has been a study into a rare disease where there is much controversy regarding 
diagnosis and management, regarding whether it can be screen detected and whether it is 
a precursor lesion or a marker of risk. This is the largest study worldwide to date looking 
at whether LCIS can be screen detected. In the 366 women identified, we found a marked 
variation in current practice in England for initial surgical management, adjuvant 
treatment and follow up/surveillance of women diagnosed, reflecting the differences in 
beliefs of clinicians involved in their care pathway.
Pathology was available on 205 cases, which enabled us to confirm the diagnosis and 
build up an immunohistochemical profile to aid the diagnosis of this lesion, which at 
times can be difficult to distinguish from DCIS. We believe that we are the first 
investigators to show that by combining E-cadherin and Cytokeratin 34B E l2 with H&E 
staining it is possible to confirm a diagnosis of LCIS in 100% of cases. With pathological 
and mammographie correlation, rarely performed in other studies, we identified a small 
proportion of cases in our study that were truly screen detected and not incidental to an 
adjacent disease process. There were however, no mammographie features specific to 
these true screen detected lesions.
With the use of hospital notes and an excellent response from the General Practitioners, 
we were able to accrue a total of 701.32 women years of follow up on the 164 
pathologically confirmed cases of LCIS. We identified 17 subsequent breast cancers and 
calculated breast cancer rates of 24.2/1000 women years of follow up. Of these 17 events, 
7 were in the screen detected group (n=28) and 10 in the incidental group (n=136) giving 
a subsequent event rate of 49/1000 women years of follow up in the screen detected group
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compared to 17.9/1000 in the incidental group. This is a relative risk of screen detected to 
incidental disease of 2.7 (C.11-6.9).
This chapter will discuss these key findings in detail and relate them to previously 
published studies with a view to providing recommendations for clinicians involved in the 
management of women with LCIS as well as detailing further research that could be 
undertaken.
1) Generalisabilitv of the Study
a) Patient Selection Demographics
i) Age
By selecting patients from the NHSBSP we restricted the age range from 50 -70 years and 
therefore the women were more likely to be postmenopausal. They were also all 
diagnosed with LCIS because of mammographie changes. However, the mammographie 
‘prompt’ was not always associated with the LCIS on pathology review. This represents a 
specific pre-selected group of women and the findings cannot therefore be generalised to 
all cases of LCIS, which are usually thought to be detected incidentally.
ii) Mode of Detection
Historical studies by Rosen (1978) and Haagensen (1978) were based on incidental LCIS 
found at surgical biopsy, usually for benign breast disease in a younger group of women. 
However, as fewer benign biopsies are now being performed and more women worldwide 
are being screened for breast cancer, our study represents a truer reflection of current 
clinical practice of the group of women that are under going breast biopsies.
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Other cases of LCIS will be identified in England in women undergoing biopsy for benign 
breast disease such as fibrocystic change or sclerosing adenosis. We believe that these are 
comparable to our incidental group, as in our study these were the pathological processes 
that prompted the identification of LCIS. Although we appreciate that our women are 
likely to be older.
iiif Number of Women 
60 out of a total of 83 screening centres in England supplied data and the demographics of 
the screening centres that supplied information and those that did not were similar, as seen 
in Appendix X & Figures 28/29 (pages 169/170). There was an even distribution of 
centres across the country, with a combination of inner city and rural communities and 
ethnic groups. We did not ask the screening centres to provide information other than the 
names of the women diagnosed with LCIS in order to encourage as many centres as 
possible to participate. However, had we been in the position to offer financial 
recompense for the data collection we may have achieved a higher participation rate. The 
priorities of the staff within the screening centres are related to throughput of women 
requiring screening and not necessarily on external audits or studies. These factors may 
have reduced the response rate from the screening centres in our study.
iv) Pathologv
205 of the possible 366 pathological blocks were retrieved from the participating units 
distributed throughout England including rural and urban populations. There was no 
difference in patient demographics between the cases that underwent pathological review 
and those that did not. We do not anticipate that failure to obtain all blocks has caused any 
bias towards the cases with pathological and mammographical correlation.
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v) Clinical Outcomes
The response rate from the General Practitioners was exceptional and follow up was 
available on a high proportion of the cases (92%), revealing 17 subsequent breast cancer 
events. This information is likely to be generalisable to all cases of LCIS detected after 
mammographie screening. In addition there is no reason to believe that surgeons and 
oncologists would treat women with incidental LCIS found in the symptomatic setting 
any differently from those detected via a screening programme.
2) Strengths and Limitations of the Study
This is a unique and large study of 366 women with LCIS detected from a national 
Mammographie Screening Programme, comparing pathology and mammography. 
Previous studies looking at mammographie abnormalities associated with LCIS have been 
small and most have not provided this pathology and mammographical correlation. Those 
that did correlate the two found that the majority of calcifications were only found in 
surrounding benign changes. To our knowledge, no studies have looked at subsequent 
breast cancer events following mammographically detected LCIS.
In this study, two trained specialist radiologists reviewed the mammograms performed 
and two trained breast specialist pathologist reviewed all the pathology. Correlation of the 
two was made by these individuals. There was therefore, consistency of the definitions of 
LCIS, DCIS and ALH, and unlike other studies, subjectivity was limited.
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There was comprehensive data available on patient characteristics, pre-operative 
diagnosis and management. An average of 5 years of follow up information was available 
for the 164 confirmed cases of LCIS, which is not as long as the data firom the historical 
studies of the 1950 -  1970’s (Rosen 1978 & Haagensen 1978). However, although these 
studies quoted subsequent breast cancer events rates at 20 and 25 years there were in fact 
very few women with follow up of this length making the data less meaningful.
Our follow up was sufficient to allow us to calculate 5-year subsequent breast cancer rates 
per 1000 women years of follow up and compare these for screen detected LCIS 
(49/1000) and incidental LCIS (17.9/1000). As well as a combined 5-year disease free 
survival of 89%. As LCIS has a long natural history there is a need to continue to follow 
up this group of women with LCIS in the future to provide 10 and 15-year subsequent 
event rates.
We did not include cases where LCIS was associated with other pathology such as ADH 
or DCIS as this would have had an impact on risk of subsequent breast cancers rates and 
possibly survival. Nor did we review core biopsies initially diagnosed as DCIS where 
final pathology revealed only LCIS.
3) Data Collection
We had a good response rate from the screening centres 60/83 (72%). It is of great 
concern that a number of centres were unable or unwilling to extract data from their 
databases, especially as the NHSBSP is dedicated to audit, as is the ABS (Association of 
Breast Surgeons) at BASO. From correspondence, it was clear that many of the centres 
had no flexibility to mobilise manpower to retrieve data and participate in the study. This 
has been a problem in recruitment to other NHSBSP audit projects such as the Sloane
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project (Association of Breast Surgeons). The United Kingdom is in a unique position 
with a nationally run and audited screening programme to provide high quality data on 
large numbers of women. Inability to access NHSBSP data sets is a wasted opportunity to 
provide answers to important questions. It is also illustrates that it is easier to audit 
process and difficult to audit outcomes and that all databases must have good access and 
retrieval facilities.
The NHS Framework has documented the need for good quality audit and research as 
paramount in improving clinical outcome. There is little provision of manpower or 
finance in order to facilitate this within the Health service. This study also highlights the 
problem of retrospective data collection.
There was a very high response rate fi*om the General Practitioners (92%) who were 
contacted to provide additional information. Normally one would expect a response rate 
of 40 -  70%. In recognition of this we will be sending out an information leaflet 
summarising our results to all participating General Practitioners as well as thanking them 
for their help.
As far as data completeness, there was limited information within the screening packets 
regarding parity, age of first child, oral contraceptive and HRT use. This meant there were 
too small numbers for meaningful analysis. All of these are known to be risk factors for 
breast cancer but the potential impact on LCIS is unknown. It would be helpful for future 
studies if there was standardisation of the dataset collected within the screening 
programme.
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4) Incidence
The number of women diagnosed with LCIS in the screening programme has increased 
steadily since it began in 1988, (Figure 7). This increase could be real, reflecting an 
increase in the incidence of LCIS or reflect the overall increase in the cancer detection 
rate with mammographie screening in the NHSBSP, part of which is due to better 
pathological recognition of this condition. The data for 1988 was incomplete because not 
all screening centres had begun screening at that time. The drop off of numbers in 2003 
relates to the fact that screening centres were first contacted in 2003 and responded either 
in 2003 or 2004.
Each year the number of women screened in the NHSBSP has increased. From April 1995 
to March 1996 1,058,623 were screened compared to 1,419,241 from April 2003 to 
March 2004. Over the same time period the number of cases of LCIS diagnosed each 
year, from participating centres rose from 17 to over 40 per annum. This illustrates a 
gradual increase in the number of cases but also reflects the rarity of a diagnosis of LCIS 
after mammographie screening. It also implies that the increase in the number of cases is 
not only a reflection of the increase in the number of women screened but possibly an 
increase in the overall cancer incidence and detection rate of non-invasive breast disease. 
In Britain the age-standardized incidence of breast cancer per 100,000 women has 
increased from 75 in 1979 to 114 in 2000 and over the 20-year period 1981 to 2000 the 
incidence rate has increased by 46%. As the incidence of breast cancer is rising it is not 
unreasonable to assume that the incidence of LCIS may be rising. Over the last 14 years 
some screening centres have moved and the boundaries of the centres have changed 
making comparisons difficult between observed and expected cases.
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The population studies in the USA by Levi et al (1997) and Li (2002 & 2005) both 
showed an increase in the number of cases of LCIS identified over time, with rates of 
around 1.0 per 100,000 women in the late seventies to rates of 3.19 in 1996-1998. There 
are several postulated reasons why the number of cases of LCIS detected within the 
screening programme in England appears to be increasing.
l)This could be due to an increase in detection 
a. At the screening level
i. Advances in technology
ii. Increase in the number of biopsies
la) With the advancements in technology, mammogram machines have the ability to 
detect smaller lesions. This accompanied by the advances in biopsy techniques e.g. 
stereotaxis; mammotome has been associated with an increase in the number of biopsies 
performed because lesions are more visible and accessible.
b) At the pathology level
iii. More extensive sampling of specimens
iv. Better histological recognition 
V. Accurate reporting
lb) Since Foote and Stewart first described the pathology sixty years ago. LCIS has 
become better understood and more widely publicised. In addition specimens are being 
examined in more detail and reporting of all breast lesions has become more standardised, 
due to quality assurance and education promoted by NHSBSP.
2) Or a true increase in incidence
i. Associated with a general rise in all breast cancers
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2) The increasing incidence of breast cancer may be mirrored for LCIS. The reasons for 
this increase are likely to be complex and multifactorial. One of the theories that has been 
postulated is that as LCIS is usually oestrogen receptor positive (Ottesen 2000 & Etzell et 
al 2001). In the NSABP PI (Fisher et al 1998) study reported a huge reduction in 
subsequent breast cancers in women with LCIS treated with Tamoxifen, since LCIS is 
largely hormone dependant it maybe that the increasing use of exogenous hormone 
replacement could be related to the increase in incidence of LCIS.
It is however impossible to ascertain whether it is a true increase in incidence or an 
increase in the detection and it is likely to be a combination of the two.
51 Patient Characteristics/ Risk Factors
i) Age
Our population is older than those in other LCIS studies with an average age of 54.4 years 
(range 40-74) SD 4.97. This reflects the population studied, as screening in England is 
from 50 -  70 years. All previous studies have shown an average age of between 43 and 51 
years (Table 11). This however, may reflect selection bias as these studies were based on 
incidental LCIS found at surgical biopsy, usually for benign breast disease, which is more 
common in younger women. Fibrocystic change has a peak incidence at 31-40 years. 
Indeed, authors in these key studies suggested that as more biopsies were going to be 
performed in older women as a result of screening, more cases would be identified in this 
older age group.
These suggestions are supported by Li (2005) who found that the rates of LCIS increased 
more among women ages 50-69 than those aged 40-49 and rates had actually decreased in 
women 30-39 over the past 5 years. This is likely to be a reflection of the increase in
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biopsies in the older screened age group in conjunction with a decrease in biopsy rates in 
the younger age group. With the increase use of more sophisticated imaging and non­
operative biopsy it is likely we will see a continuing shift of diagnostic age for LCIS from 
the younger to older woman.
The average age of diagnosis, 54 years, reflects the fact that the majority of cases of 
LCIS, in this study, were identified on the first screening (prevalent) round, with a decline 
over subsequent (incident) rounds. Since 2004 screening in the UK has been increased to 
include women 65-70 years of age. With this extension we may see a small increase in the 
number of older women diagnosed with LCIS from the screening programme. Although, 
we have seen in the incidental group that the majority of cases were diagnosed due to an 
associated benign process, commoner in younger women.
ii) Menopausal Status
Menopausal status was known in 224 women, of who half were postmenopausal. This is a 
reflection on the age of women at diagnosis and the population studied. Other LCIS 
studies have only had small numbers of postmenopausal women.
Haagensen (1978) suggested that LCIS regressed after the menopause but there is no 
evidence to support this in our or other studies, nor has a plausible biological explanation 
been suggested. If this were the case there may be a rising incidence of LCIS in 
postmenopausal women, or as suggested above, due to screening and improved 
pathological assessment.
iiO HRT Usage
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In the 283 of the 366 (77.3%) women where our study of HRT usage had been 
documented, 131 (46%) had taken or were taking HRT compared to 153 (54%) who had 
never taken HRT. 102 (78%) were current users at the time of LCIS diagnosis and the 
average duration (known in 129 women) was 65.96 months (range 1-360 months) SD 
56.78. In the Million women study 50% of women screened had taken HRT at some 
point, supporting our findings, 
ivl Familv Historv
Family history information was available for 164 of 366 women. 84 (32%) had a positive 
family history. Claus (1993) and others found a positive family history ranging fi*om 9 -  
32% in women with LCIS and our study is at the higher end of this range. Other studies 
have shown that for LCIS, relation to family history is more than twice that of other breast 
cancer histological groups. Claus (1993) found that 15.6 % of women with LCIS had an 
affected mother and 10% had at least one affected sister. Unfortunately the information 
was limited in our study due to poor documentation within the hospital notes. However, 
information was known on 73 of the 84 women with a positive family history and 31 
women had an affected mother and 15 had at least one affected sister. One concern, in our 
study, regarding HRT usage and family history is that there may be positive 
documentation bias, in that healthcare professionals may be more likely to document a 
positive finding in these categories than a negative finding.
Some authors have suggested that LCIS arises from a genetic susceptibility (Lakhani 
1999) and the well-documented bilaterality of LCIS may also support this hypothesis. 
Any gene predisposing to LCIS must be of low penetrance as the risk of progressing to 
invasive disease is low compared to the known high risk seen in other oncogenes such as 
BRCA 1 and 2 genes.
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Other relevant breast cancer risk factors, suggested by other authors (Weiss 1996) such as 
parity, age at first child, OCP use and breast feeding, were very poorly documented in the 
screening and hospital notes and therefore we are unable to comment.
v) Mammogranhv
Most women in this study had PI or P2 classification of breast density on mammography, 
which fits in with their age and menopausal status, the equal distribution of LCIS between 
both breasts is also as expected in the general population. The preponderance of cases of 
LCIS located in the upper outer quadrant of the breast has also been documented in 
previous studies (Carson 1994). 99 of 164 of our cases presented with calcifications, 
Monsees (1995) stated that calcifications accounted for 50% of all biopsies of non- 
palpable lesions, in our study it is higher probably because we are dealing with an in situ 
lesion and invasive lesions are more likely to present with distortion.
6) Pathology Review & Diagnosis
In order to ascertain if any cases of LCIS were screen detected pathological review was 
essential to confirm the diagnosis and to correlate the pathology with the findings on 
mammography. LCIS is difficult to distinguish from low grade DCIS and other ductal 
proliferations and using immunohistochemistry and mucin we hoped to find ways of 
illustrating differences between these disease processes to improve accuracy of diagnosis.
After active encouragement 205 of the 366 (56%) detected cases had pathological 
material available for this review and correlation with mammography. Correspondence 
suggested this lower than anticipated return was due to lack of manpower, with the 
histopathology units unable to retrieve blocks and slides from archives and send them,
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which in turn was put down to financial restraints. Of these 205 cases with available 
material we were unable to classify 22 as there was either insufficient material in the 
blocks sent or because only benign changes were seen. It is impossible to comment if 
these were incorrectly classified or if the initial lesion was so small that it was ‘cut out’ at 
the sectioning of the blocks, or in a different block that was not sent, or completely 
removed by core biopsy.
All 205 cases underwent a standardised review process by two pathologist of H&E 
staining, mucin staining and immunohistochemistry. In this way we established a reliable 
diagnostic profile with internal validation. Those cases where we felt the H&E appearance 
was classical and diagnostic allowed us to establish the immunohistochemical profile of 
the lesion designated as LCIS and compare it to other changes. We were then able to 
extrapolate and classify equivocal lesions.
Of the 164 cases confirmed as LCIS, the majority 140 (85%) were done so on H&E 
staining alone. 30 equivocal cases on H&E were reliant on the immunohistochemistry for 
confirmation of the diagnosis.
Nineteen of the 205 (9.3%) cases were reclassified as DCIS or ADH or DCIS with 
invasion (after H&E stain and immunohistochemistry). These cases were distributed 
equally throughout the time frame and not as might have been expected in the initial study 
years. This implies that LCIS continues to pose diagnostic difficulties and in particular it 
can be hard to distinguish LCIS from certain types of ductal proliferation. There is, 
therefore, a need to improve and standardise diagnosis with the help of additional 
techniques, such as immunohistochemistry. In 13 of the 19 cases reclassified as a ductal
181
proliferation, this was made on H&E staining alone whereas the remaining six that were 
equivocal on H&E relied on immunohistochemistry for confident diagnosis.
E-cadherin staining for DCIS and LCIS has been previously reported (Jacobs 2001 & Vos 
1997). Patient numbers in these studies have been small, less than 50, and they have all 
shown that the majority of cases of LCIS failed to stain. This was confirmed in our study 
with 151 of the 158 (95.6%), where material was available, staining negative and the 
remaining 7 equivocal. In contrast 17 of the 19 cases of DCIS were positive and this 
confirms the literature that E-cadherin is an excellent tool for distinguishing between 
these two types of in situ breast disease. Of the 30 equivocal cases on H&E staining, 24 
could be classified after negative staining with E-cadherin, with a further 6 remaining 
equivocal.
There is little in the scientific literature regarding the use of cytokeratin 34B E l2 to aid in 
the diagnosis of LCIS. In our study it was usefiil in differentiating between LCIS and 
DCIS. 132 of the 158 (83.5%) LCIS cases stained positive with 34B E12, with 14/158 
staining negative and 12 equivocal. In comparison 14/19 of the DCIS cases stained 
negative, 2 positive and 3 equivocal. Cytokeratin 34B E l2 was not as sensitive a tool as 
E-cadherin but in combination they enabled confident diagnosis in all 158 cases. In the 30 
cases equivocal after H&E stain, 20 were classified as LCIS after negative E-cadherin 
staining and 4 as DCIS with positive staining. The remaining six were defined as LCIS 
(n=4) by a positive stain on 34B E12 or DCIS (n=2) by a negative stain.
In a previous study by Lacroix-Triki (2003) cytokeratin 5/6 was found to be good at 
distinguishing between ADH and in situ disease but not between DCIS and LCIS. There 
were however, only 11 cases of LCIS in their study. In our study, with its larger numbers.
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confirms that CK 5/6 was not helpful in the differentiation between LCIS and DCIS, with 
155/158 of the LCIS cases and 19/19 of the DCIS cases staining negative.
Previous work has shown that 60 -90% of cases are oestrogen receptor positive (Ottesen 
2000 & Sneige 2002). In this study 98% of the LCIS cases were oestrogen receptor 
positive as were 17/19 of the DCIS cases. The high proportion of positive DCIS cases 
reflects that the majority of cases were low grade DCIS, as high grade DCIS is less likely 
to be ER positive. This oestrogen sensitivity in LCIS explains the benefit of Tamoxifen 
seen in the reduction in subsequent events in the NSABP -  PI study (Fisher 1998).
The presence or absence of Mucin did help to differentiate between DCIS and LCIS with 
119/158 (75.3%) of the LCIS cases staining positive and 15/19 DCIS cases staining 
negative, but was less useful than E-cadherin and 34B E12. There is anecdotal evidence 
and one historical study (Breslow et al 1976) that suggested that intracytoplasmic mucin 
is more common in invasive lobular cancers and LCIS than invasive ductal cancer and 
DCIS.
Our study has shown that the majority of LCIS can be diagnosed on H&E staining, with 
only 15% requiring immunohistochemistry for confirmation of diagnosis. We have also 
shown, that in the 183 cases that we reviewed, 19 (10.4%) were reclassified as DCIS or 
ADH. This highlights that there is some subjective variability amongst pathologists as has 
been suggested by other authors (Hutter 1969 & Page 1991) and the difficulty in some 
instances of distinguishing LCIS from DCIS and other ductal proliferations.
Diagnostic accuracy is important because the management of LCIS and DCIS is different. 
The current guidelines for the management of DCIS include clear margins of excision.
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radiotherapy if at high risk of recurrence and consideration of Tamoxifen or Aromatase 
Inhibitors for hormone receptor positive cases. In contrast we have found most clinicians 
in England are managing LCIS by surveillance alone without attention to clear margins or 
preventative measures. Therefore cases of DCIS misclassified as LCIS and treated as 
such, are likely to have a high subsequent event rate due to sub-optimal treatment. We 
have demonstrated this in our study that 3 of the 19 women who really had DCIS had a 
subsequent breast cancer giving an event rate of 31/1000 women years of follow up (3.1% 
per year) in this group. Seven of these cases had involved margins.
This need for accurate diagnosis is even more relevant if clinicians move towards 
managing LCIS with core biopsy and surveillance alone without formal surgical excision.
Our study has shown that the use of E-cadherin in combination with cytokeratin 34B El 2 
provides a profile that will enable a confident diagnosis in all cases of LCIS. In view of 
these findings we would recommend that the additional stains of E-cadherin and 34B El 2 
stains be done in all cases considered to be LCIS. There are however often financial and 
logistical restraint, which may mean this is not always possible and therefore these two 
additional stains can be used in situations where the diagnosis is equivocal after H&E 
review or if LCIS is to be managed with only a core biopsy and surveillance. However, if 
these stains are used infrequently reproducibility and interpretation could be affected.
7) Can LCIS be Screen Detected?
The main remit of this study was to ascertain whether LCIS is ever truly screen detected, 
by correlating pathology with mammography. A review of the scientific literature 
revealed that studies, which have looked at the mammographie features of LCIS 
contained small numbers of patients and most of them did not relate mammographie
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features with pathology (Smith 2001 & Lanyi 1985). Most authors suggest LCIS has no 
mammographie features and that the mammographie calcifications are usually in the 
surrounding benign disease and not associated with the LCIS (Singletary 1994, 
Sonnenfield 1991). Those authors that did find calcifications associated solely with LCIS, 
noted that the calcifications were too fine to been seen on a pre-operative mammogram. 
Lanyi (1985) found 21 of 43 had calcifications solely in the LCIS but in all cases the 
calcium was too small to be visualised on mammography. Smith (2001) noted that the 
calcifications in his 7 cases were equal or smaller to 0.5mm but felt that they were large 
enough to be visible on mammography.
Based on these previous studies we defined LCIS as screen detected if the calcification 
was large enough to be seen on mammography and found only in the LCIS, not in the 
surrounding tissue. In our study 99/164 cases of LCIS were initially identified by 
calcifications on a screening mammogram, to our knowledge this is the largest study to 
date of LCIS detected in this way. On pathological review, 28 of these cases had 
calcifications solely within the LCIS lesion and were large enough to be detected without 
magnification (range 0.05 -  0.6mm). This means that in 1 in 6 cases of LCIS (28/164) 
detected via a mammographie abnormality were truly screen detected with the remaining 
136 being incidentally detected. Therefore, LCIS can be a screen-detected condition.
Unlike Pope (1988) who felt it was difficult to correlate precisely the calcifications in the 
specimen with the mammographie abnormality. We felt that by reviewing the slides firom 
the localisation biopsy for calcifications and reviewing their morphology we could be 
confident that the calcifications seen in the LCIS corresponded to those visualised on the 
mammogram.
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One reported theory is that the calcifications were present before the LCIS developed and 
have subsequently been engulfed by the LCIS (Sonnefield 1991). This is difficult to 
disprove. If all cases were incidental and the calcifications had in fact been present prior 
to the LCIS one would expect similar subsequent event rates in the two groups. However, 
we have shown a difference in subsequent breast cancer events between the incidental and 
screen detected groups this adds supporting evidence that the two are different. Herman 
(1993) suggested that LCIS is capable of producing the biochemical changes necessary 
for the development of calcifications.
8) Screen Detected and Incidental LCIS — Comparison of Mammographie Features
We reviewed the mammographie calcifications in the screen-detected group (n=28) and 
compared them with the calcifications in the incidental group (n=136) where the calcium 
was associated either solely with benign breast changes or both these changes and the 
LCIS. There were no statistical significant differences between the two, the extent of 
calcifications was similar, as was the morphology, with the majority being punctuate and 
rounded. Sapino (2000) described coarse microcalcifications associated with LCIS as 
rounded and suggested this feature was more suggestive of a lobular location. This is 
similar to the findings of Smith (2001). Based on our evidence we conclude that 
microcalcifications associated with LCIS have no specific predictive or distinguishing 
features to allow a confident pre-biopsy/operative diagnosis of LCIS.
9) Screen Detected and Incidental LCIS — Comparison of Pathological Features
We also compared the pathological features of the screen-detected cases with the 
incidental cases to ascertain if they were different. We compared type, the extent of the
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lesion, necrosis, duct involvement and lobular expansion as these features may be related 
to the difference in subsequent event rate between the two groups.
A) Type
Sapino (2000) described 10 cases of LCIS that were difficult to distinguish from DCIS on 
mammography and were pathologically different from the classical LCIS, with larger 
nuclei, more pleomorphism and central necrosis. She suggested this was a specific variant 
of LCIS that should be regarded as a more aggressive lesion. Unlike Sapino we had no 
statistically significant difference in the number of pleomorphic cases 7/28 in the screen 
detected group and in the incidental group 34/136.
B) Size
Although mammographie size was similar for the two groups, pathological size was 
significantly different with an average size of 15.9mm in the screen-detected group and of 
7.79mm in the incidental group (p= 0.038). This may be one of the determining factors 
for the higher rate of subsequent events in the screen-detected group. This is supported by 
the finding of a trend, although not statistically significant, towards larger size and 
subsequent event when we compared the women who had a further event to those that did 
not. Toker (1997) suggested that the risk of developing a subsequent invasive lesion was 
higher in larger lesions but in his study it did not reach statistical significance perhaps 
because the numbers in his study were small. The larger the size of the lesion the higher 
the likelihood of forming calcifications and therefore being screen detected. Size is also 
seen to matter when comparing ALH and LCIS. In ALH less of the lobule is involved by 
the disease process that in LCIS and we know from previous studies (Page et al 1989) that 
the risk of developing and invasive carcinoma after LCIS is twice that after ALH.
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C) Multifocalitv and Necrosis
There was no difference in multifocality between the two groups but there was a 
statistically significant difference (p<0.001) in the presence of necrosis with 9/28 in the 
screen detected group and 4/136 in the incidental group. This finding suggests that screen 
detected LCIS may have a more aggressive nature as necrosis carries a poorer prognosis, 
as is the case for DCIS. It may also be that the larger the area of LCIS the more likely 
necrosis is to occur.
D) Lobular Expansion
There was a trend seen in the degree of expansion of the lobules, with a higher proportion 
(18/28) in the screen-detected group compared to the incidental group (61/136) but this 
did not reach significance. Fisher (1996) showed a statistically significant hazard rate of 
developing invasive disease or LCIS if marked lobular distension was present. He 
classified lobular expansion into types 1, 2 and 3, with 3 being marked distension and he 
found this was the only statistically significant feature that was associated with an 
increased hazard rate of subsequent development of invasive disease.
E) Duct Involvement
Duct involvement was more common in the screen-detected group, with 22/28 in the 
screen-detected group compared to 72/136 in the incidental detected group but this was 
not statistically significant. It is possible that necrosis, duct involvement and lobular 
expansion are all related to the overall size of the lesion and that duct involvement is also 
related to necrosis. A lesion, which is larger, may reflect a later stage of the LCIS disease 
process and therefore closer to development of a precursor lesion, with necrosis, duct
188
involvement and lobular expansion. Size may also be related to the lesions ability to be 
screen detected. When small and in the early stages of the disease it can not be detected 
and as it gets bigger, in the later stages, it has higher rates of necrosis and therefore 
calcification on mammography, thus allowing LCIS to become screen detected This 
would be similar to DCIS, which is more easily detected if it is larger.
F) Margin Involvement
There was a significantly higher rate of potential margin involvement (p=0.001), 
classified in this series as less than 5mm, with 21/28 in the screen detected group 
compared to 63/136 in the incidental group and this may also have contributed to the 
higher subsequent event rate in this group. It may be that screen detected LCIS, which is 
larger and associated with more necrosis and duct involvement, behaves more like DCIS 
where these features are common. Supporting this, in our study, the screen-detected group 
contained one invasive lobular cancer in the subsequent events and had a higher 
subsequent event rate (49.0/1000 women years of follow up). In comparison to the 
incidental LCIS, with its lower rates of necrosis and duct involvement, where there was a 
lower subsequent event rate (17.9/1000 women years of follow up), and a high proportion 
of ILC in the ipsilateral breast subsequent events. Although we appreciate that the 
numbers in our study are small and did not reach statistical significance it is biologically 
plausible and with longer follow up this may be more striking.
10) Subsequent Breast Cancer Events Rates
Of the 164 cases that were confirmed on pathological review to be LCIS there were a total 
of 17 subsequent events, 1 of these was metastatic at presentation. Of the remaining 16, 
10 were ipsilateral and 6 were contralateral. This was with follow up of 701.32 years (for
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all women including those who had a bilateral mastectomy). This gives a crude event rate 
of 24.2/1000 women years of follow up for invasive and non-invasive disease and an 
invasive subsequent breast cancer event rate of 17.1/1000. There were no deaths from 
breast cancer following a diagnosis of LCIS, unlike other studies (Anderson 1974 & 
Fisher 2003). This may be related to our relatively short follow up of a disease with a long 
natural history, or due to improvements in diagnosis and treatment of these subsequent 
cancers.
Some of the women in our series were treated with unilateral or bilateral mastectomy and 
taking this into account, there was follow up on 143 ipsilateral breasts with a total of 
663.5 years of follow up, in which 10 breast cancers developed. Seven of these were 
invasive. This gives a total and invasive rate of 15.1/1000 and 10.6/1000 women years of 
follow up, respectively. Li 2006, found a rate of development of invasive cancer of 
12.5/1000 person years. In our study there were 151 contralateral breasts with 690.9 years 
of follow up and in these there were 6 subsequent breast cancers, 5 of which were 
invasive. This gives total and invasive rates of 8.7/1000 total and 7.2/1000 women years 
of follow up, respectively. This is similar to Page’s data (2003) with two thirds of the 
subsequent events occurring in the ipsilateral breast and one-third in the contralateral 
breast. Page suggested this observation is an indicator that LCIS could be a precursor 
lesion rather than a marker of risk.
From our Kaplain Meir disease free survival analysis we have shown a 5-year disease free 
survival of 89.7% and a crude subsequent event rate of invasive breast cancer of 
17.1/1000 women years. Rosen (1981), Haagensen (1978) and Habel (1997) published 
rates of 3.6%, 6% and 4.9% respectively at five years of follow up. Mcdivitt (1967) 
however showed an ipsilateral risk of 10% and a contralateral risk of 10% at 5 years. In
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the placebo arm of the NSABP PI (Fisher 2001) study they showed a risk of 13/1000 
women years of follow up and Chuba (2005) found that 7.1% of women developed an 
invasive breast cancer at 10 years of follow up. Comparing our rates with those from these 
and other studies listed in Table 14 page 65, it can be seen that they fall within the range 
of values. Many of these previous studies are historical and even the paper by Chuba 
published in 2005 contained a large number of patients diagnosed with LCIS in the 
1970’s. The follow up and subsequent detection of breast cancers is likely, therefore, to be 
very different from our group of women.
One of the ipsilateral non invasive events occurred at 10 months as LCIS and DCIS and 
we feel that this is likely to represent missed disease although it did not occur in the same 
quadrant as the initial diagnosis. It is biologically implausible that DCIS would occur after 
LCIS in such a short time frame.
i) Subsequent Event Rate in the Screen Detected Group
Within the screen-detected group, there were 7 of the 17 subsequent breast cancer events, 
4 of which were invasive. There was 142.6 years of follow up on the 28 women giving a 
total and invasive rate of 49/1000 and 28.1/1000 women years of follow up. One event 
was metastatic and three were ipsilateral and 3 were contralateral. Two women in this 
group had an ipsilateral mastectomy giving an ipsilateral follow up of 129.6 years and a 
contralateral follow up of 142.6 years. This gives an ipsilateral rate of subsequent events 
of 23.1/1000 women years and 21/1000 women years for contralateral events. The 
numbers are very small in this group and it is therefore hard to draw any conclusions to 
this. As no previous studies have identified a screen detected group of cases of LCIS there 
are no comparisons to make.
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ii) Time to Invasive Recurrence
Of the 12 invasive recurrences that occurred in the breast, the time to recurrence ranged 
from 14-178  months. There was no peak of events shortly after diagnosis, which could 
have been a reflection of missed disease at diagnosis. Like the studies of Rosen (1981) 
and Haagensen (1978) there are events after 10 years of follow up, showing that the risk 
persists for many years after diagnosis of LCIS. In invasive breast cancer there is a peak 
of recurrence at 5 years in oestrogen positive cancers at 5 years and at 2-3 years in 
oestrogen receptor negative cancers (EBCTCG 1998).
iii) Tvpe of Subsequent Event
We encountered subsequent events of an invasive lobular and ductal nature as well as 
special type (tubular and medullary) and DCIS. This is similar to previous studies as listed 
in the Table 17 page 72. Similarly to the debate regarding laterality of the event, the type 
of invasive event has also featured in previous studies of LCIS concerning the precursor, 
marker of risk discussion. Fisher (2001) found that all his ipsilateral recurrences were 
invasive lobular cancers and he felt that this was supporting evidence that LCIS may be a 
precursor lesion. Others Chuba (2005) found that there were equal numbers of invasive 
lobular and ductal cancers in the ipsilateral breast and therefore felt that this supported the 
‘marker of risk’ theory.
In our study there were 6 invasive lobular cancers and 2 invasive ductal cancers in the 
ipsilateral breast and no invasive lobular cancers in the contralateral breast. The invasive 
cancers in the contralateral breast were either invasive ductal or tubular or medullary. The 
reported incidence of invasive lobular cancer has varied from 1% to 15% of all invasive 
cancers (Wheeler & Enterline 1976, Martinez & Azzopardi 1979 & Ellis et al 1992).
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Compared to this we have shown an unexpectedly high proportion of ipsilateral invasive 
lobular subsequent events and this is more supportive of a precursor theory rather than a 
marker of risk theory. It is likely that it is a combination of the two as not all cases of 
LCIS go on to an invasive cancer. Recent studies looking at the clonality of LCIS and ILC 
support this (Aulmann 2008). This seems plausible as DCIS is a precursor lesion in the 
ipsilateral breast and both DCIS and IDC are markers of risk for the contralateral breast.
11) Subsequent Breast Cancer Events Related to Pathological Features
Many of the authors who have published work on LCIS previously have tried to identify 
pathological features that would predict a subsequent event in the hope that these women 
could be managed in a different way. Rosen (1978) failed to show any factors that 
predicted future breast cancer events. Ottesen (1993) suggested initially with 5 years of 
follow up that if there was a larger number of lobules involved there was a significantly 
increased risk of a subsequent breast cancer event although this significance was lost 
when these patients were followed up for 10 years (Ottesen 2000). Fisher (1996) found the 
degree of lobular expansion was suggestive but not significant and Toker (1997) 
suggested that larger lesions were more at risk. Overall therefore, no one has been able to 
predict who is more likely to have a subsequent breast cancer event. There have been 
anecdotal suggestions that pleomorphic LCIS or margin involvement would carry a higher 
risk for subsequent breast cancer events but there is no scientific evidence to support this.
We compared the pathological features of 147 patients who remained event free to 17 
patients who had a subsequent event. We found a trend, non significant, towards larger 
size of LCIS, when adjusted for age, and there was a relative risk of subsequent event of 
2.72 (Cl 0.62-12.04). There was no difference in the number of cases of pleomorphic
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LCIS, cases with necrosis or expanded lobules. There was a significant difference in duct 
involvement and a trend towards margin involvement p=0.07. The numbers in our study 
are small but with further follow up on these women we may find our values reaching 
significance.
LCIS A sso c ia ted  w it h  R a d ia l  Scars
It is well established that radial scars should be excised in view of their increased risk of 
association with breast cancer (Sloane 1993) and the difficulty in distinguishing them 
fi*om invasive cancers. There have been a few small descriptive studies of radial scars that 
have shown LCIS can be associated with such lesions. In our study we found 41 cases of 
LCIS associated with a radial scar or a complex sclerosing lesion, and in 27 of these the 
LCIS was contained within the lesion. There were 2 subsequent events in this group 
giving a rate of 11.1/1000 women years of follow up. In women with radial scars this was 
considerably lower than the overall rate for all women, which was 24.2/1000 women 
years.
The pathological features of both groups were similar except that in this group there was 
only one case found to have necrosis. Amongst the women in this category, for whom 
margins were assessable, 20 out of 40 had margins of less than 5mm; this is similar to the 
non-radial scar group. There was no pathological explanation as to why there would be a 
lower subsequent event rate in those women that had LCIS associated with a radial scar 
except the lower rate of necrosis. This is a small group but it may be that because the 
LCIS is associated with the radial scar it is detected at an earlier stage.
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LCIS A s s o c ia t e d  w i t h  F ib r o a d e n o m a s
Similarly there are a few case series in the literature of LCIS associated with 
fibroadenomas but most of these have not described the pathological relationship of the 
LCIS with the fibroadenoma. Pick (1984) found 40 of his 62 cases of carcinomas within a 
fibroadenoma were LCIS. Pick (1984) suggested that the apparently high association of 
LCIS and fibroadenomas was due to the common lobular origins of the two lesions. In our 
12 cases we found that 10 had LCIS either completely within the fibroadenoma or both 
within and around it. Within these 12 cases one woman developed a subsequent breast 
cancer. There was a total of 41.2 years of follow up giving a subsequent breast cancer rate 
of 24.3/1000 women years of follow up. This is identical to the rate in the overall group of 
164 women with LCIS, the numbers in the group however are small and it is difficult to 
draw conclusions fi*om this or make any suggestions on the clinical implications of these 
patients.
In c id e n t a l  LCIS
The cases of incidental LCIS in our study were associated with common benign lesions, 
which are known to have radiological features. One of these disease processes, columnar 
cell change, has been suggested by some investigators, to be a marker of increased risk 
(Tremblay et 1997) and also associated with LCIS (Sahoo 2005). Ottesen (1993) found 
that LCIS was most commonly associated with fibrocystic change and solitary cysts. In 
our study 41 of the 164 cases were associated with fibrocystic change and 7 with 
columnar cell change.
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M a n a g e m e n t
Al Pre-operative Diagnosis
The preoperative diagnosis of breast lesions is very important, in order to provide women 
with information on their disease and for clinicians to ensure that women have appropriate 
initial management of their condition. The preoperative diagnosis rate of cancer within the 
NHS breast screening programme has greatly improved since it began in 1988 and the 
guidelines suggest >90% of women should have a preoperative diagnosis and this is 
largely met in the screening programme today (ABS at BASO 2006).
i) Fine Needle Aspiration (TNAl
Of the 164 women with LCIS on pathological review 60 had an FNA preoperatively of 
whom 9/60 were classified as C5, with 11/60 found to be C2 or benign. This is of a 
similar proportion to the few papers published in the literature regarding FNA and LCIS 
(Ustun 2002) In the screening program, it is now widely accepted that core biopsy is a 
more appropriate way of sampling mammographically detected, impalpable lesions and 
there is therefore a move away from the use of FNA in this situation.
ii) Ultrasound
Of the 86 women with confirmed LCIS who had assessment by ultrasound, it only 
identified benign lesions that were adjacent to the LCIS such as fibrocystic change, 
masses caused by fibroadenomas or other benign processes or radial scars. We conclude 
that ultrasound did not prove to be helpful in the diagnosis of LCIS.
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iii) Needle Core Biopsy
Of the 99 women, with confirmed LCIS, who had a core biopsy 39 had a preoperative 
diagnosis of LCIS and 8 a diagnosis of lobular hyperplasia, which is less than half of the 
cases. A further 35 women had a diagnosis of atypia. This is a reflection on the difficulty 
of making a diagnosis of LCIS on small amounts of tissue and perhaps the lack of use of 
immunohistochemistry. With an improvement in pathological awareness, understanding 
and standardisation of LCIS diagnosis as well as an increase in the use of E-cadherin and 
34B E12, as discussed earlier, we anticipate that the preoperative diagnosis rate of LCIS 
on core biopsy could improve considerably. The NHSBSP has stated that all cases of 
LCIS should be classified as B3 on core biopsy. In our study, it was clear that there were 
still a large proportion of pathologists labelling LCIS as B5a.
M a n a g em en t
In this section we will discuss the management of all 366 women identified with LCIS. It 
is important to note that some of the initial management was decided after a core biopsy 
showing DCIS (n=27). However after surgical treatment, all cases were subsequently 
managed in the belief that the diagnosis was LCIS and this is irrespective of our 
pathological findings.
Almost all of the women had a form of localisation biopsy, usually a needle localization, 
which is to be expected as these were screen detected, impalpable lesions. Three women 
had a mastectomy in the first instance, one of which had 70mm of calcification on her 
mammogram and a core biopsy result of DCIS and it was not performed in the belief that 
this was LCIS, another one had a 25mm of calcification on her mammogram and a core 
biopsy diagnosis of LCIS, and the other had 10mm of calcification on her mammogram
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and a core biopsy result of ALH. From the documentation in the screening notes the last 
two women had a mastectomy driven by patient choice and the inability to accept any 
subsequent cancer risk. It was not documented what degree of risk had been 
communicated with the women in order for them to make an informed decision.
A) Management of LCIS with Core Biopsv and Surveillance Alone
There has been intense debate in the recent literature regarding a diagnosis of LCIS on 
core biopsy, with some authors (Cardenosa 2001, Liberman 1999 & Renshaw et al 2002) 
suggesting that as LCIS is a marker of risk and can managed by core biopsy alone plus 
surveillance. Others are strongly against this (Crisi 2003, Arpino 2004).
Nine women, in our study had a core biopsy or mammotome biopsy alone; these were all 
diagnosed after 2001 and in two centres only. Although at the end of the study period 
none of the women had developed a subsequent breast cancer, with the concern regarding 
accuracy of diagnosis of LCIS on core biopsy, we suggest that this group of patients 
should be observed very closely to ensure that there is not a higher rate of subsequent 
breast cancer events possibly reflecting missed disease at diagnosis.
There are no large studies indicating that core biopsy and surveillance is detrimental to the 
patient in terms of subsequent breast cancer events or survival compared to excision 
biopsy. To our knowledge, in the scientific literature there is also no data documenting the 
follow up or subsequent breast cancer incidence of women managed in this way. We 
believe that if these women do not have a subsequent excision biopsy there should be a 
definitive follow-up programme and inclusion into a database to document any 
subsequent breast cancer events. Until the evidence exists we feel that management of 
LCIS in this way is under treating such lesions and risking a misdiagnosis.
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Six of these 9 women in our study had yearly mammographie and clinical follow up, one 
had nine monthly mammograms and two were discharged back to three yearly 
mammograms in the NHSBSP. This shows the variability that exists in this small group of 
women who could be at higher risk of missed associated disease. There was, therefore, no 
evidence from our study that women managed in this way in England were being 
followed up more closely than those who had had a subsequent surgical excision and 
some were put back into the NHSBSP for three yearly mammograms.
The size of the lesion, in our data, has also been show to be relevant in predicting 
subsequent breast cancer events and core biopsy alone will give no indication of this 
measurement. There is also debate as to whether these women are being adequately 
informed regarding the high risk of a possible associated invasive component and the lack 
of evidence that this is an appropriate management.
Also relevant to this method of management of women with LCIS, is the accuracy of 
pathological diagnosis on core biopsy material. It is imperative that LCIS can be 
accurately diagnosed on core biopsy to prevent misdiagnosed DCIS being under treated. 
There have been several small studies that have looked at LCIS on core biopsy and 
compared this to the definitive histology at surgical biopsy. In almost all of these studies it 
has been shown that between one fifth and one third have associated invasive disease or 
DCIS found at definitive surgery that was not represented in the core biopsy specimen 
(Foster 2004). From our study we are able to add to this discussion by looking at this in a 
slightly different way. By identifying women with a definitive diagnosis of LCIS on 
surgical biopsy and working backwards to see who had a pre-operative diagnosis of LCIS. 
We have shown only a 47.5% pre-diagnosis of LCIS on core biopsy. Until we can show
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that core biopsy can accurately diagnose LCIS we find it hard to recognise core biopsy 
followed by surveillance as an acceptable management for LCIS.
B) Management of LCIS bv Mastectomv
24 women had a mastectomy following initial localisation biopsy of which nine were 
bilateral. In some instances the reason for this was documented in the notes as patient 
choice and 3 unilateral mastectomies were explained by the extensive positive margin 
involvement with LCIS. In others there was no documentation as to why this management 
was undertaken. The mastectomies were done on women between 1994 and 2002. This 
highlights the wide variation in treatment of LCIS from core biopsy only to bilateral 
mastectomy as well as the poor documentation in the hospital notes of decision processes 
made by multidisciplinary teams. This documentation is particularly important in the less 
common management of LCIS by mastectomy. In total 8% of the women we identified 
had either a unilateral or bilateral mastectomy, which is higher than we had anticipated. 
Claus 2003 found that women diagnosed with LCIS were 2.6 times more likely than 
women with DCIS to be diagnosed with a contralateral cancer within the first six months 
after initial diagnosis.
C) Margin Excision After WLE
After initial localisation biopsy margin excision was performed in 32 of 366 cases and 
further margins at a third operation in 2 cases. After positive margins 6 women went on to 
have a unilateral mastectomy. It is difficult to know if this reflects clinician’s beliefs or 
patient choice.
2 0 0
D) Precursor Verses Marker of Risk
There are two very different perspectives on LCIS, with one camp believing that LCIS is 
a marker of risk and the treatment offered by this group is likely to be biopsy only. The 
other believing that LCIS is, or can be a precursor lesion and these clinicians will be more 
inclined to advise excision to clear margins or mastectomy, as would be the case for 
DCIS. This was reflected nicely in the literature in a letter by Knapnick (2001). She was a 
nurse with LCIS who went to two different surgeons in the United States one of whom 
offered her core biopsy and surveillance and the other bilateral mastectomies. She 
eventually chose biopsy and surveillance. It is also reflected in our study in all aspect of 
management.
There is some scientific evidence emerging from the literature that LCIS can be a 
precursor lesion, with Lakhani (2001), Lu (1998), Berx (1996) and Hwang (2004) 
providing molecular evidence that the DNA of LCIS is very closely linked to ILC. There 
are, however, confounding facts for example we can see from the previous literature and 
our study that subsequent breast cancers occurring after LCIS are not always ILC but 
some are IDC and that these subsequent cancers can occur in the contralateral breast or in 
quadrants distant to the original disease. We have, however shown a high rate of invasive 
lobular cancer in the ipsilateral breast, which may indicate that in these instances the 
LCIS is a precursor lesion.
Looking at the management in the NHSBSP of patients with LCIS there is a wide 
variation in treatment based on this difference in belief and a lack of guidelines or 
protocols. Added to these differences in beliefs amongst the professions are the inherent 
difficulties with risk communication and differences in risk perceptions of the patients.
2 0 1
E) Adjuvant Treatment
The NSABP PI study (Fisher 2000) is the only randomised controlled study looking at 
adjuvant hormonal therapy in women with LCIS. It showed a significant reduction of 
subsequent breast cancer events in the LCIS arm treated with Tamoxifen compared to the 
placebo arm. In our study, adjuvant treatment was known in 324 women and amongst 
these 68 women received Tamoxifen. In a retrospective study like ours it is impossible to 
show whether women were offered Tamoxifen but failed to use it. However, there was no 
increase in usage after 2001 when the NSABP PI study was published and suggested this 
benefit. Tamoxifen has a substantial but well known side effect profile and there is no 
proven benefit on survival in cases of LCIS treated with Tamoxifen, these factors may be 
deterring clinicians and patients in England from its use after an LCIS diagnosis. In the 
United States Tchou (2004) showed that a diagnosis of LCIS was the commonest reason 
for women to use Tamoxifen as a preventative strategy.
Cutili (1998) described a series of women with LCIS treated with radiotherapy, none of 
whom developed an ipsilateral breast cancer event with a median follow up of 7.3 years. 
It was however, confounded by the fact that some of these women also received 
Tamoxifen. In our study 10 women received radiotherapy and all of these were treated 
before 2000. One of the women developed a subsequent breast cancer but this was in the 
contralateral breast. There is no scientific evidence to support the use of radiotherapy in 
LCIS management and in England clinicians, working in the screening programme, are 
not using it.
2 0 2
F) Follow up/Surveillance
There was much variation in the follow up provided for these 366 women with LCIS as 
there was variety in their surgical management. Clinical follow up ranged from no follow 
up at all, to clinical review every two years. 213 of the 319 where followed up was 
known, initially had annual review. Our study revealed that a third of the subsequent 
breast cancer events were detected clinically and this highlights the need for some form of 
clinical follow up for these patients.
Mammographie follow up was also varied; all patients who did not have a mastectomy 
were offered mammographie follow up but the time interval ranged from six monthly to 
three yearly. 251 of the 319, with information available, initially had annual 
mammograms.
The length of follow up was also very varied. The evidence from the historical studies 
with long follow up (Rosen 1978, Haagensen 1978 & Bodian 1996) suggests that an 
elevated risk of subsequent breast cancer persists beyond 20 years and there is little in the 
literature regarding the optimum frequency of follow up. There is increasing pressure in 
the NHS to discharge cancer patients early and recommendation from the NICE 
guidelines (NICE Guidelines 2002), to reduce follow up length. We have demonstrated a 
crude subsequent invasive breast cancer risk overall of 17.1/1000 women years and a 
DCIS and invasive rate combined of 24.4/1000 women years. This compares to the 5-year 
recurrence risk for DCIS of 8.2% as invasive cancer and 11.7% as DCIS, in women 
treated by conservation surgery (Kerlikowske et al 2003). In the DCIS studies 
approximately half of the recurrences are invasive disease and half are non-invasive 
cancers (Skinner et al 1988). In our study of LCIS three quarters of the subsequent events 
were invasive disease and a quarter non-invasive.
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In view of this and as there appears to be no national consensus, it would therefore seem 
logical to follow these women with LCIS up for at least the same amount of time as 
women with a diagnosis of DCIS. We suggest this follow up should consist of annual 
mammography and annual clinical review perhaps six months apart. In addition it would 
be better if there were a consensus across the screening programme of an appropriate time 
frame, although we understand that individual trusts may have policy and financial 
constraints.
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CHAPTER SEVEN
FURTHER WORK:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Study for the Nose in the Pillow - Franeine Van Hove
F u r t h e r  WORK
The follow up in this study is relatively short compared to the historical studies of Rosen 
(1978) and Haagensen (1978) in the scientific literature. To answer Anther questions and 
to provide stronger evidence into the nature of LCIS, we recommend the data that we 
have collected should be kept by the NHS BSP and that the risk of subsequent breast 
cancer events should be re evaluated in a Anther 5 years time. This should give an average 
follow up of 10 years. The General Practitioners were a valuable source of information 
with a response rate of over 90% and this would be an ideal way of collecting subsequent 
data, the cancer registries would also be a useful resource.
The Sloane Project (funded by the NHSBSP and PAzer Pharmaceuticals in collaboration 
with the ABS at BASO) is collecting prospective data on cases of DCIS and LCIS 
identiAed within the NHSBSP, Aom participating centres. However, it will take a long 
time to obtain the follow up that we have already achieved. Also the pathology is not 
being reviewed and we have shown that there was a signiAcant rate of misdiagnosis at a 
local level. We hope that as many centres as possible will enter their cases of LCIS into 
this important National audit.
We have shown that in LCIS, duct involvement and the ability to be screen detected 
carries a higher risk of subsequent breast cancer event. Like previous studies, we have 
failed to identify features either mammographie or other pathological features that help to 
predict which women go on to develop a subsequent breast cancer. However, we hope 
with the advance in molecular studies that future work into DNA abnormalities and the 
identiAcation of gene ampliAcations will help clinicians identify conAdently which 
women are at a higher risk than others, by adding prognostic factors to routine 
histological features.
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CHAPTER EIGHT
CONCLUSIONS:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Study for Karen at Rest - Franeine Van Hove
C o n c lu sio ns
1) LCIS can be screen detected as a mammographie abnormality, in a small proportion of 
cases.
2) Those cases that are truly screen detected may have a higher subsequent breast cancer 
event rate.
3) There is improvement in the accuracy of diagnosis of LCIS pathologically with the use 
of E-cadherin and cytokeratin 34B E12.
4) Historically accurate pre operative diagnosis of LCIS on core biopsy is low and can be 
much improved by the use of routine immunohistochemistry.
5) We have demonstrated a subsequent breast cancer rate of 24.4/1000 women years, 
which is comparable to DCIS.
6) We found a very high proportion of invasive lobular cancers in the ipsilateral 
subsequent breast events compared to what is seen in the general population.
7) The management and follow up of LCIS within the NHSBSP in England are very 
varied.
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CHAPTER NINE
RECOMMENDATIONS:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Celine Looking Out - Franeine Van Hove
R eco m m en d atio ns
1) Multidisciplinary teams must recognise the ability of LCIS to form calcifications 
and when they do there is a significantly higher risk of subsequent breast cancer 
events.
2) Women must be counselled appropriately regarding the risk of subsequent risk of 
breast cancer following a diagnosis of LCIS.
3) E-cadherin and cytokeratin 34B E12 should be used in all cases of LCIS both core 
biopsy and excision biopsy to ensure increased accuracy of pathological diagnosis.
4) There should be NHSBSP recommendations regarding management and follow up 
of women with a diagnosis of LCIS.
There was a huge variation and follow up should be offered as for DCIS, for the
management of LCIS it is essential that all options are discussed with women with
available supporting evidence.
5) Tamoxifen as prophylaxis against subsequent breast cancers should be discussed 
with all women with a diagnosis of LCIS in view of the findings of the NSABP PI 
study.
6) Further work needs to be done with long term follow up to provide more 
information on disease free survival of women with a diagnosis of LCIS.
7) Screen detected LCIS should be viewed as a more aggressive disease than 
incidental LCIS.
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Breast Unit
Egerton Road 
Guildford 
Surrey 
GU2 7XX
Tel: 01483 571122 
Direct Line: 01483 464093 
F f lv  n i4 R i anAAi?
Dear .
Re; AUDIT screen detected LCIS
Your QA office have supplied me with the names of the patients in your centre who 
qualify for the audit of screen detected cases of LCIS with in the f^SBSP. I have 
collected data on over 150 cases so far and am now planning a trip to Suffolk and Norfolk 
gather the cases identified that I have not yet reviewed.
I would like to come to your centre between 26 and 27th of February in order to review 
the mammogram packets and the hospital notes of these patients if possible (I have 
MREC approval for both of these). Would this be convenient, I have the names of the 
patients if the QA office has supplied me with these rather than yourselves.
Please write and confirm if this is acceptable or email (which is better and faster) 
mkhogben@niIdram.co.uk to let me know so that I can plan the logistics of this journey.
Thank you again for your help and please contact me if you have any queries. 
Yours Sincerely,
Katy Hogben MBBS BSc FRCS 
Specialist Registrar
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Breast Unit
Egerton Road 
Guildford 
Surrey 
GU2 7XX
Tel: 01483 571122 
Direct Line: 01483 464093 
F n v  ni4R1 anAAl?
Dear M r ,
We are writing to ask for your collaboration in a study into screen detected Lobular 
Carcinoma in situ of the breast.
My name is Katy Hogben and I am a specialist registrar on the South West training 
programme in general surgery and I am undertaking this as part of an MS degree.
The aim of this study is to provide Radiologists, Pathologists and Surgeons within the 
screening programme with information to aid diagnosis and management of this little 
known about disease. In order to do this, we wish to review all cases previously diagnosed 
within the screening programme. Throughout this study, patient confidentiality will be 
maintained as much as is possible in accordance with our ethical approval.
According to our information via the QA office your patient...
Patient name d.o.b
was diagnosed with LCIS on and referred to you by the St George’s screening centre.
We would like to ask for access to her hospital notes as well as pathology specimens. (I 
will also write to the pathologists). We are looking for the following information.
Potential risk factors 
Type of surgery performed 
Follow up data
Confirmation of calcification within the LCIS pathologically 
Margin status
Subsequent breast pathology and death
We have obtained MREC approval for this study Ref. 02/10/49 and your co-operation is 
crucial to its successful completion. We also have the fiill support of Julietta Patnick and 
the collaboration of the NHSBSP. We hope you are willing to help us.
One of us will contact you in the next few days to find out whether you agree and, if you 
do, to make an appointment to extract this data when it is convenient for you.
(We will pull the notes personally and require minimal manpower from your team.)
Thank you very much.
Yours Sincerely,
Katy Hogben MBBS BSc FRCS Mark Kissin Mchir FRCS
Specialist Registrar Consultant Breast Surgeon
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The Royal Surrey County Hospital
NHS Trust
G2za
NHS BREAST SCREENING PROGRAMME AUDIT
into
LOBULAR CARCINOMA IN SITU
Dear Dr
The aim of this study is to provide Radiologists, Pathologists and Surgeons within the 
screening programme with information to aid diagnosis and management of this little known 
about disease. In order to do this, we wish to review all cases previously diagnosed within 
the screening programme. Throughout this study, patient confidentiality will be maintained 
as much as is possible in accordance with our ethical approval. MREC Ref. 02/10/49. This 
allows us to write to you and ask for patient information without gaining patient consent.
We have collected 366 cases nationally, which is, by far the largest database in the world on 
this disease process and we have recently won a prize in the USA for our work.
According to our information your local screening and Quality Assurance office identified 
that your patient...
Patient name d.o.b
was diagnosed with screen detected LCIS.
Her mammograms and pathology have already been reviewed but we require some further 
follow up information from you. Please can you answer the questions on the following sheet 
and return them in the stamped addressed envelope. We hope you are willing to help us.
Please contact us if you have any queries regarding the project by telephone 01483 571122 
EXT 4555 or by email at mkhogben@nildram.co.uk. (this is the best way).
Thank you very much for your help.
Yours Sincerely,
Mrs Katy Hogben MBBS BSc FRCS 
Lead Investigator
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EDGEWARE 6
We know she had an NLB in August 1995 and we have reviewed the pathology specimens. 
Did she have further surgery?
Did she have adjuvant treatment?
Did she have mammographie follow up?
Did she have clinical follow up?
Is she well with no further breast problems. YES / NO
Thank You
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The Royal Surrey County Hospital
NHS Trust
NHS BREAST SCREENING PROGRAMME AUDIT
into
LOBULAR CARCINOMA IN SITU
Dear Dr
We are writing to ask for your collaboration in a study into Screen detected Lobular 
Carcinoma in situ of the breast.
My name is Katy Hogben and I am a specialist registrar on the South West training 
programme in general surgery and I am undertaking this as part of an MD degree.
The aim of this study is to provide Radiologists, Pathologists and Surgeons within 
the screening programme with information to aid diagnosis and management of this 
little known about disease. In order to do this, we wish to review all cases previously 
diagnosed within the screening programme. Throughout this study, patient 
confidentiality will be maintained as much as is possible in accordance with our 
ethical approval.
As you can imagine there are not many cases from each unit so we would much 
appreciate your assistance in this matter.
According to our information via the QA office patients...
were diagnosed with screen detected LCIS.
We would like to ask for you to send us the slides and one representative block in order 
for us to review the pathology. It is essential that we confirm that the mammographie 
abnormality, usually calcification is present within the LCIS. We would also like to 
perform further immunohistochemical studies for profiling of this condition. Please send 
them to Dr Peter Jackson Consultant Histopathologist, Royal Surrey County Hospital, 
Egerton Road, Guildford, SURREY.
We have obtained MREC approval for this study Ref. 02/10/49 .We also have the full 
support of Julietta Patnick and the collaboration of the NHSBSP. We hope you are 
willing to help us.
Please contact us if you have any queries regarding the project by telephone 01483 
571122 EXT 4555 or by email at mkhogben@mIdram.co.uk
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We have already reviewed the screening mammograms and obtained follow up 
information from the hospital notes and GP records.
Thank you very much for your help.
Yours Sincerely,
Katy Hogben MBBS BSc FRCS 
Specialist Registrar
Mark Kissin Mchir FRCS 
Consultant Breast Surgeon
Peter Jackson FRCPath
Consultant Pathologist & Deputy QA Pathologist
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D ata  Proform a
NAME
SCREENING NUMBER
D.O.B
Date of first stage Screen
Screening Centre
Age at Dx
Previous Screens 
(Outcome & retrospective)
RISKS
LMP
Children/preg
HRT OCP
PREVIOUS SURGERY 
PMHx/MEDS
SYMPTOMS (at first stage screen)
MAMMOGRAMS
FIRST STAGE VEIWS
FURTHER VEIWS
CLINICALLY
ULTRASOUND
FNA
CORES
WERE CORES XRAYED
Age at first 
FHx
FINDINGS 
EXTRA INFO
REPEATED
REFERRED TO
SURGEON
SURGERY PERFORMED
OTHER TREATMENT
PATH
HOSPITAL HOSPITAL NO.
COPY TAKEN
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M am m ogram  Proform a
NAME
SCREENING NUMBER Screening Centre
DENSITY OF MAMMOGRAMS
POSITION
MASS ASYMETRY DISTORTION CALCIFICATION
CALCIUM DISTRIBUTION (SEGMENT/SHAPE/PLEOMORPHIC)
SIZE CALCIUM (ON NON MAG VEIW)
TIGHT/LOOSE CLUSTER
FINE PARTICLES PRESENT ON MAG
VARIABILITY OF PARTICLES CC/45
DENSITY OF PARTICLES
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Pathology  Proform a  
NAME
SCREENING NUMBER Screening Centre
PURE LCIS 
SIZE
NUCLEAR GRADE A/B
MARGINS 
MULTIFOCALITY 
ER STATUS
CALCIFICATION ASSOC WITH LCIS & SIZE
DUCT INVOLVEMENT
NECROSIS
? CALCIFICATION DUCTAL 
LOBULAR SIZE
ASSOCIATED WITH BENIGN CONDITION +/- CALCIFICATION 
? RELATES TO MAMMOGRAPHIC CHANGES
NON-CALCIFIED LESIONS COMMENT
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Follow  up and  Survival  Proform a  
NAME
SCREENING NUMBER Screening Centre
SURGERY TYPE 
DATE
WEIGHT
ABNORMALITY REMOVED
FURTHER SURGERY NEC.
ADJUVENT TREATMENT
MAMMOGRAM F’UP
CLINICAL F’UP
LAST SEEN
DEVELOPED FURTHER CANCER
FURTHER TREATMENT
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S c r een in g  C en t r es  &  C a ses  C o n tr ibu ted
Screening Centres No. of 
Cases
Screening Centres No. of 
Cases
Acrington 0
Aylesbury 0
Barnsley 2
Basingstoke 0
Birmingham 0
Bolton 14
Boston 0
Brighton 6
Bristol 0
Bromsgrove 0
Bury St Edmonds 8
Cambridge 0
Cannock 6
Canterbury 5
Carlisle 5
Charing Cross 15
Cheltenham 7
Chester 0
Chesterfield 4
Cholchester & Chelmsford 5
Cottingham 0
Coventry 6
Crewe 4
Derby 4
Doncaster 3
Dorset 0
Dudley 3
Edgbaston 0
Edgware 21
Edmonton 0
Epping 0
Exeter 0
Gateshead 0
Great Yarmouth 1
Guildford 32
High Wycombe 2
Ipswich 0
Isle of Wight 0
Kettering 6
Kings Cross 9
Kings Lynn 5
Lancaster 5
Leeds 4
Leicester 6
Lincoln 0
Liverpool 0
Luton 17
Maccelsfield 3
Maidstone 5
Manchester 0
Medway 8
Milton Keynes 0
Newcastle-Upon-Tyne 0
Northampton 3
Norwich 10
Nottingham 3
Oxford 0
Peterborough 2
Plymouth 8
Portsmouth 1
Reading 4
Romford 0
Rotherham 8
Sheffield 5
Shewsbury 0
Sidcup 6
Southampton 21
Southend 15
St Bartholomews 6
St Georges 8
Stoke-on-Trent 6
Sutton 2
Swindon 0
Taunton 3
Truro 14
Walsall 2
Warrington 0
Whipps Cross 3
Wigan 1
Windsor 1
Wirral 4
Worthing 5
York 4
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Sc reenin g  C entr es  C o n t a c t ed  & R espo n se s  R ec e iv e d
Screening Centres Contacted Responded Yes/No Screening Centres Contacted Responded Yes/No
Acrington No Maccelsfield Yes
Aylesbury No Maidstone Yes
Barnsley Yes Manchester No
Basingstoke No Medway Yes
Birmingham No Milton Keynes Yes
Bolton Yes Newcastle-Upon-Tyne No
Boston No Northampton Yes
Brighton Yes Norwich Yes
Bristol No Nottingham Yes
Bromsgrove No Oxford No
Bury St Edmonds Yes Peterborough Yes
Cambridge No Plymouth Yes
Cannock Yes Portsmouth Yes
Canterbury Yes Reading Yes
Carlisle Yes Romford No
Charing Cross Yes Rotherham Yes
Cheltenham Yes Sheffield Yes
Chester No Shewsbury No
Chesterfield Yes Sidcup Yes
Cholchester & Chelmsford Yes Southampton Yes
Cottingham No Southend Yes
Coventry Yes St Bartholomews Yes
Crewe Yes St Georges Yes
Derby Yes Sutton Yes
Doncaster Yes Stoke-On-T rent Yes
Dorset No Swindon No
Dudley Yes Taunton Yes
Edgbaston Yes Truro Yes
Edgware Yes Walsall Yes
Edmonton Yes Warrington No
Epping No Whipps Cross Yes
Exeter No Wigan Yes
Gateshead No Windsor Yes
Great Yarmouth Yes Wirral Yes
Guildford Yes Worthing Yes
High Wycombe Yes York Yes
Ipswich No
Isle of Wight Yes
Kettering Yes
Kings Cross Yes
Kings Lynn Yes
Lancaster Yes
Leeds Yes
Leicester Yes
Lincoln Yes
Liverpool No
Luton Yes
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G lo ssa ry
Alcain Blue -  PAS - Enables the detection of glycoprotiens. Periodic acid-Schiff staining 
is used to demonstrate carbohydrates (glycogen, glycoprotein, proteoglycans). It is used to 
distinguish different types of glycogen storage diseases.
Atypia -  Not typical, not corresponding to the normal form or type.
Atypical Lobular Hyperplasia (ALH) - A proliferative lobular process that exhibits 
cytological features of lobular carcinoma in situ, but does not fulfil the requirements for 
extent of involvement. It is a possible precursor to lobular carcinoma in situ
Bilateral -  Relating to or affecting both sides of the body or of a tissue or organ or both 
of a pair of organs.
Body Mass Index (BMI) -  The weight of a person (in kilograms) divided by the square 
of the height of that person (in metres): used as an indicator of whether or not a person is 
over- or underweight.
BRCAl and BRCA2 - Genes associated with susceptibility to breast and ovarian cancer. 
Women with mutations in either of these genes have a 56-85% risk of developing beast 
cancer, and this form of the cancer tends to develop at a relatively young age.
Chemotherapy -  The prevention or treatment of disease by the use of chemical 
substances or drugs.
Complex Sclerosing Lesion - Is composed of a radial arrangement of ductular structures 
around a central fibroelastotic core. In early lesions the central connective tissue is 
cellular and includes numerous myofibroblasts. The entrapped ductular or tubular 
structures are lined by a two-layered epithelium although epithelial proliferation is 
commonly present. Atypical ductal Hyperplasia (ADH) or lobular neoplasia may also be 
seen.
Craniocaudal -  Mammographie view of the breast from above.
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Deep Vein Thrombosis (DVT) -  Obstruction of a vein by a blood clot, without 
preceding inflammation of its wall. It is most common within the deep veins of the calf of 
the leg.
Deoxyribonucleic Acid (DNA) -  The genetic material of nearly all living organisms, 
which controls heredity and is located in the cell nucleus. It is a long chain of nucleotides, 
which consist of Deoxyribose, Phosphoric Acid, Organic (nitrogenous) bases.
Ductal Carcinoma in Situ (DCIS) -  The earliest stage of breast cancer, which is 
confined to the milk ducts of the breast.
Fine Needle Aspiration (FNA) - A technique that allows a biopsy of various bumps and 
lumps to retrieve enough tissue for microscopic analysis and thus make an accurate 
diagnosis.
Human Epidermal growth factor Receptor 2 (HER2) -  A protein occurring in 
excessive amounts on the surface of tumour cells in highly malignant forms of breast 
cancer. It acts as an epidermal growth factor receptor, which influences the growth and 
proliferation of the tumour.
Hormone Replacement Therapy (HRT) -  The use of female hormones for the relief of 
symptoms resulting from cessation of ovarian function, either at the time of the natural 
menopause or following surgical removal of the ovaries.
Hyperplasia -  The increased production and growth of normal cells in a tissue or organ 
without an increase in the size of the cells. The affected part becomes larger but retains its 
normal form. Hyperplasia can be physiological, as in the breasts during pregnancy, or 
pathological.
Immunohistochemistry (IHC) - Refers to the process of localizing proteins in cells of a 
tissue section exploiting the principle of antibodies binding specifically to antigens in 
biological tissues.
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Invasive -  Denoting local spread of a malignant neoplasm by infiltration or destruction of 
adjacent tissue.
Invasive Ductal Carcinoma (IDC) - The spread of cancer into neighbouring normal 
structures; spread to the surrounding tissues. It is ductal because the cancer began in the 
milk ducts.
Invasive Lobular Carcinoma (ILC) -  The spread of cancer into neighbouring normal 
structures; spread to the surrounding tissues. It is lobular because the cancer arose in the 
lobules of the breast.
In Situ -  Confined to the site or origin; "in its original place" means that the cancer has 
not spread to any surrounding tissues.
Ipsilateral -  On or affecting the same side of the body.
Ischaemic Heart Disease (IHD) - Coronary artery disease is a condition in which fatty 
deposits (atheroma) accumulate in the cells lining the wall of the coronary arteries. These 
fatty deposits build up gradually and irregularly in the large branches of the two main 
coronary arteries, which encircle the heart and are the main source of its blood supply. 
This process is called atherosclerosis, which leads to narrowing or hardening of the blood 
vessels supplying blood to the heart muscle (the coronary arteries). This results in 
ischemia (inability to provide adequate oxygen) to heart muscle and this can cause 
damage to the heart muscle. Complete occlusion of the blood vessel leads to a heart attack 
(myocardial infarction).
Lobular Carcinoma in Situ (LCIS) - A lesion that arises in the lobules of the breast and 
is composed of neoplastic lobular cells without stromal invasion.
Lower Inner Quadrant (LIQ) -  Lower inner pole of breast
Lower Outer Quadrant (LOQ) -  Lower outer pole of breast
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Magnetic Resonance Imaging (MRI) -  A diagnostic technique that utilizes the 
phenomenon of nuclear magnetic resonance to obtain a biochemical profile of tissues by 
exciting elements other than hydrogen in water and other body components. There is no 
exposure to X-rays or any other damaging forms of radiation. It has been used since the 
beginning of the 1980s.
Mammogram -  The study of the breast by imaging techniques, most commonly X-rays. 
The breast is usually compressed between radiolucent plates before being exposed to 
relatively low-energy X-rays to emphasize differences in the soft tissues.
Mastectomy -  Surgical removal of a breast. Radical mastectomy; performed when the 
breast cancer has spread to involve the lymph nodes. This classically involves removal of 
the breast with the skin and underlying pectoral muscles together with all the lymphatic 
tissue of the armpit.
Menopause -  The time in a woman’s life when the ovaries cease to produce an egg cell 
every four weeks: menstruation ceases and the woman is no longer able to bear children.
Multifocal - Relating to or affecting a number of areas within the breast.
Needle Core Biopsy (NCB) -  The process of removing tissue from living patients for 
diagnostic examination. It is performed by inserting a small hollow needle to remove a 
sample or core. The sample is submitted for histological examination for diagnosis.
Needle Localised Biopsy (NLB) -  Excision of tissue marked by a small needle placed 
into the tumour or calcification.
Neoplasia -  A form of abnormal growth that is independent of the body’s normal 
homeostatic growth-regulating mechanisms, continues after the initiating stimulus has 
been removed, and is purposeless. Neoplasia is always pathological.
Oral Contraceptive Pill (OCP) -  A tablet, containing one or more synthetic female sex 
hormones, taken by women to prevent conception.
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Oestrogen Receptor Status (ER) -  A specific site on the surface of a cell that binds to 
oestrogen: the binding triggers responses of the cell to the hormone. Oestrogen-receptor- 
positive cancer cells rely on oestrogen to grow and are therefore susceptible to anti­
oestrogen therapy, which prevents oestrogen from binding to these receptors.
Progesterone Receptor Status (PR) - A specific site on the surface of a cell that binds to 
progesterone: the binding triggers responses of the cell to the hormone. Progesterone- 
receptor-positive cancer cells rely on progesterone to grow and are therefore susceptible 
to anti-progesterone therapy, which prevents progesterone from binding to these 
receptors.
Radiotherapy -  Therapeutic radiology: the treatment of disease with penetrating 
radiation, such as X-rays, beta rays, or gamma rays, which may be produced by machines 
or given off by radioactive isotopes. Beams of radiation may be directed at a diseased part 
from a distance, or radioactive material, in the form of needles, wires, or pellets, may be 
implanted in the body.
Ultrasound -  Sound waves of high frequency (above 20kHz), inaudible to the human ear. 
Used to produce images of the interior of the human body as the waves reflect off 
structures back to the probe. Ultrasound waves have the advantage over X-rays of not 
being ionising and are therefore much less harmful, particularly at energy levels used for 
diagnosis.
Upper Inner Quadrant (UIQ) -  Upper inner pole of the breast.
Upper Outer Quadrant (UOQ) -  Upper outer pole of the breast.
Unilateral -  Relating to or affecting one side of the body or one side of an organ or other 
part.
Wide local excision (WLE) -  Conservative form of surgery taking away just the cancer 
along with a border of healthy tissue all around it, and leaving behind as much healthy 
breast tissue as possible.
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A bbr e v ia t io n s
British Association of Surgical Oncology (BASO) -  Founded in 1971. Its mission 
statement is the furtherance of the art and science of cancer surgery within the UK and 
beyond and the interests of British cancer surgery patients.
The Breast Cancer Linkage Consortium (BCLC) - Is a worldwide cooperative 
network of scientists founded in 1989 in Lyon, France, who share a major interest in 
inherited breast and ovarian cancer. By means of annual workshop meetings and by 
collating information contributed by the participating centres, the BCLC has provided 
accurate estimates of the cancer risks conferred by the breast cancer susceptibility genes 
BRCAl and BRCA2, and on the type of families associated with either of them.
The Breast Imaging Reporting and Data System (BI-RADS) - Developed in 1993 by 
the American College of Radiology (ACR), provides a standardized classification for 
mammographie reporting, to improve communication, to reduce confusion regarding 
mammographie findings, to aid research, and to facilitate outcomes monitoring.
Early Breast Cancer Trials Collaborative Group (EBCTCG) -  Initiated in 1993 is part 
of the Clinical Trial Service Unit (CTSU) whose work chiefly involves studies of the 
causes and treatment of "chronic" diseases.
Multi-Centre Research Ethics Committee (MREC) -  Before a clinical trial can take 
place, it must be approved. First, the plan (protocol) should be approved by a group 
of researchers who are not involved in the trial. This is called 'independent scientific 
review' or 'peer review'. The trial protocol is then reviewed by the multicentre research 
ethics committee, or MREC. The committee decide if the trial is ethical to do and if it can 
go ahead or not. Once a trial has approval from the multicentre ethics committee, each 
hospital that wants to take part has a site specific assessment (SSA) done by their local 
research ethics committee, or LREC. The assessment makes sure that the hospital has the 
staff, equipment and expertise to carry out the trial. SSA's must be done for all trials of 
new treatments or procedures.
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National Health Service Breast Screening Program (NHS BSP) -  (est 1988) Provides 
free breast screening every three years for all Avomen in the UK aged 50 to 70. It is an 
effective part of the UK's efforts to reduce the death toll from breast cancer and is 
nationally coordinated. It sets national standards, which are monitored through a national 
quality assurance network.
The National Institute for Health and Clinical Excellence (NICE) -  Is the
independent organisation responsible for providing national guidance on the promotion of 
good health and the prevention and treatment of ill health. NICE guidance is developed 
using the expertise of the NHS and the wider healthcare community including NHS staff, 
healthcare professionals, patients and carers 
industry and the academic world.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) -  Is a clinical 
trials cooperative group supported since its inception by the National Cancer Institute 
(NCI). They have a 50-year history of designing and conducting clinical trials that have 
changed the way breast cancer is treated, and, more recently, prevented. The NSABP was 
one of the first organizations to undertake large-scale studies in the prevention of breast 
cancer.
The Patient Information Advisory Group (PIAG) -  Was established to provide advice 
on issues of national significance involving the use of patient information and to oversee 
arrangements created under Section 60 of the Health and Social Care Act 2001. Its 
membership is drawn from patient groups, healthcare professionals and regulatory bodies.
Quality Assurance Reference Centre (QARC) -  Is an NHS body organisationally 
located within Northumberland, Tyne & Wear ST A. Quality Assurance is a fundamental 
part of the NHS BSP. The aim of quality assurance in NHS Screening is to maintain 
minimum standards and to improve the performance of all aspects of screening. Each 
NHS Region has a Regional Quality Assurance Director (RQAD) for screening who is 
accountable directly to the Regional Director of Public Health. Each RQAD manages a 
regional QARC.
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The Sloane Project -  Is a UK wide prospective audit of screen detected non-invasive and 
atypical hyperplasia of the breast. It is a multi-disciplinary project involving radiologists, 
pathologists, surgeons and oncologists. The data for the project are being collected by 
way of specifically designed data collection forms for each professional group, which will 
provide full and detailed information about the patients' journey from diagnosis to 
treatment. The NHS Breast Screening Programme (NHSBSP) and Pfizer Pharmaceuticals 
are helping to fund and organise the audit, the latter through an unrestricted educational 
grant.
Surveillance, Epidemiology, and End Results (SEER) -  SEER began collecting data on 
cancer cases on January 1, 1973, in the US. It is the program of the National Cancer 
Institute (NCI) an authoritative source of information on cancer incidence and survival in 
the United States. SEER currently collects and publishes cancer incidence and survival 
data fi-om population-based cancer registries. The SEER Program registries routinely 
collect data on patient demographics, primary tumour site, tumour morphology and stage 
at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program 
is the only comprehensive source of population-based information in the United States. 
The SEER Program is considered the standard for quality among cancer registries around 
the world. Quality control has been an integral part of SEER since its inception. Every 
year, studies are conducted in SEER areas to evaluate the quality and completeness of the 
data being reported.
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